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Abstract
The antiphospholipid syndrome (APS) is characterised by the presence o f 
antiphospholipid antibodies (aPA) associated with thrombosis (arterial and venous) and 
pregnancy morbidity. This thesis has aimed to investigate the frequency o f  protein C 
pathway defects in patients with aPA and to study clinical correlates; exam ine the 
mechanisms o f antiphospholipid interference in the protein C pathway; and to assess 
activated protein C (APC) resistance in patients with aPA in terms o f throm bin 
generation. Although have I have discovered a high degree o f heterogeneity in the 
phenotype o f patients with APS, I have demonstrated APC resistance and increased 
thrombin generation in the majority o f patients with APS. While in some cases, APC 
resistance is clearly im munoglobulin mediated, it is a multifactorial phenom enon with 
many confounding variables. M y data suggest that immunoglobulin dependent APC 
resistance may occur through P2 glycoprotein-I dependent and independent 
mechanisms. In a detailed study o f women with a history o f pregnancy morbidity, I 
have found evidence for an underlying prothrombotic condition, which is due in part to 
a deficiency o f tissue factor pathway inhibitor. This is associated with resistance to APC 
and increased thrombin generation, both o f which may be attenuated through the 
restoration o f  normal TFPI levels by low molecular weight heparin.
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Chapter 1 Introduction
1.1 History of antiphospholipid antibodies
Antiphospholipid antibodies (aPA) were first recognised in the 1950s, w ith the 
description o f two unusual phenomena in patients with systemic lupus erythematosus 
(SLE). In 1952 Conley and Hartman (Conley 1952) described patients with 
haemorrhagic symptoms due to a non-specific coagulation inhibitor, which acted as an 
anticoagulant o f in vitro coagulation tests. In the same year, Moore and M ohr (Moore 
JE 1952) found that some SLE patients demonstrated persistent false positive 
serological tests for syphilis and five years later it was found that the ‘lupus inhibitor’ 
was frequently associated with false positive syphilis tests (Laurell & Nilsson 1957). 
Although several publications followed, at the end o f the ‘60s Ethel Bidwell commented 
“Elucidation o f the mode o f  action o f  this inhibitor has proved to be extremely difficult, 
and at the time o f writing its aetiology and mode o f  action remain obscure" (Bidwell 
1969).
This in vitro coagulation inhibitor was shown to have an association with thrombotic
events (Bowie et al. 1963) and was subsequently named the ‘lupus anticoagulant’ (LA)
(Feinstein & Rapaport 1972). Both persistent false positive syphilis tests and LA were
also found to be associated with recurrent obstetric problems and throm bocytopenia
(Feinstein et al 1972). It later became apparent that antibodies that appeared to bind
anionic phospholipids were responsible for both the false positive syphilis tests and LA
(Thiagarajan, Pengo, & Shapiro 1986). This allowed the development o f more specific
tests for anticardiolipin antibodies (aCL) (Harris et al. 1983) and LA (Exner, Rickard, &
Kronenberg 1978) (Thiagarajan et al 1986). Following the discovery that the clinically
relevant aPA actually recognise phospholipid binding proteins, rather than
phospholipids themselves, specific assays for anti P2 glycoprotein-I antibodies (anti-
P2GPI) antibodies were developed (McNeil et al. 1990). Since then, antiphospholipid
12
antibodies have been described that bind to a variety o f phospholipid binding proteins 
involved in haemostasis (de Groot & Derksen 2005).
1.2 Detection of antiphospholipid antibodies
Three types o f test are routinely used for the detection o f aPA: lupus anticoagulant tests 
(eg, dilute RusselTs viper venom time, dRVVT); anticardiolipin (aCL); and anti- p2GPI 
assays.
LA is defined as an immunoglobulin or a group o f immunoglobins that interfere with 
phospholipid (PL) dependent coagulation tests. Paradoxically, LA usually prolongs tests 
such as the activated partial thromboplastin time (APTT) but is rarely associated with 
haemorrhage. It is associated with an increased risk o f arterial or venous thrombosis, as 
well as recurrent fetal loss (Hughes, 1993; Triplett, 1995). At the time o f writing, the 
presence o f LA is considered to be the strongest risk factor o f the aPA tests for 
thrombosis in (Galli et al. 2003b), although anticardiolipin antibodies may be a stronger 
independent risk factor for pregnancy morbidity (Robertson et al. 2006)
The APTT is usually prolonged by LA, and fails to correct after patient and normal 
plasmas are mixed, demonstrating the presence o f an inhibitor. This inhibition is usually 
immediate, although some time dependent inhibitors have been reported. There is wide 
variation in the sensitivity o f different APTT reagents, and the test may be affected by 
increased levels o f fibrinogen and factor VIII, which have the effect o f  shortening the 
APTT and may mask weak LA. It is therefore important not to rely solely on the APTT 
for LA detection, and more sensitive and specific tests are required.
National and international guidelines (Brandt et al. 1995; Greaves et al. 2000) 
recommend that a sensitive screening test is used, and that a further test is performed for 
confirmation. A large number o f tests have been suggested for LA screening and 
confirmation (Figure 1), which detect interference with different parts o f the coagulation
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pathway. It is generally recommended that two tests should be selected which operate 
by different coagulation mechanisms or reactions. The tests used should demonstrate 
the presence o f an inhibitor and phospholipid dependence. The latter is usually achieved 
using either high concentrations o f phospholipid, or using washed normal platelets that 
have been activated or lysed, so that they express LA bypassing activity.
Figure 1. Detection of lupus anticoagulant antibodies by in vitro coagulation tests:
APTT activated partial thromboplastin time CSCT Colloidal silica clotting time, KCT kaolin 
clotting time, dPT dilute thromboplastin time (Levine, Branch, & Rauch 2002)
The most widely used test in the UK is the dRVVT. This test utilises the venom o f 
Russell’s Viper (Daboia russelii), which contains an enzyme that directly activates 
factor X (Thiagarajan et al 1986). In the presence o f  factor V, the resulting factor Xa 
cleaves prothrombin to thrombin in a reaction dependent on the presence o f  calcium
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ions and suitable concentrations o f coagulant active phospholipid (the prothrom binase 
complex). Fibrin is then formed, and clot detection is the end-point o f the test. The 
venom is diluted to make the test sensitive to any small prolongations o f  the clotting 
time, and the phospholipid is diluted to make the test sensitive to any interference with 
phospholipid dependent coagulation reactions. The dRVVT should be performed in 
conjunction with a confirmatory step to assure specificity. This may be achieved by 
substituting the dilute phospholipid reagent with a high concentration o f phospholipid, 
or by using washed, lysed platelets (the platelet neutralisation procedure). The 
mechanism by which the platelets neutralise or by-pass LA is unknown, but it is 
possible that they protect the prothrombinase complex from inhibition, either by causing 
steric hindrance o f the immunoglobulins, or because the reaction kinetics favour 
prothrombinase.
The kaolin clotting time (KCT) was previously widely used for the detection o f LA 
(Exner et al 1978), but suffers from poor sensitivity and specificity (Jennings et al.
1997) as it is more susceptible to variation due to poor sample quality.
Other tests such as the Textarin/Ecarin ratio (Triplett et al. 1993), the Taipan venom 
time (Rooney et al. 1994) and the dilute thromboplastin test (Schleider et al. 1976) are 
used principally as additional confirmatory tests or for use with plasma from patients 
receiving oral anticoagulants, and will not be discussed further.
Anticardiolipin and anti- P2 GPI antibodies (McNeil et al 1990) are both detected using 
solid phase enzyme linked immunosorbent assays (ELISA). In the aCL ELISA, 
microtitre plates are coated with cardiolipin and non-specific binding o f diluted sera is 
eliminated by blocking o f plates with 10% fetal calf serum (Loizou et al. 1985). Diluted 
patient sera are then added to the plates and antibody binding is detected through the use 
of enzyme-conjugated antisera. Galli et al. (1990) noted that highly purified antibodies 
did not bind cardiolipin in assay systems in which bovine serum was not added, and that
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a protein cofactor was required for antibody binding. This cofactor was subsequently 
confirmed as P2 GPI or apolipoprotein H (McNeil et al 1990). Consequently, anti- 
P2 GPI antibodies are now measured using an ELISA in which an ELISA plate is coated 
with P2 GPI, and binding o f antibodies to the immobilised protein in an antiphospholipid 
independent manner is measured (Martinuzzo, Forastiero, & Carreras 1995; M cNally et 
al. 1995a). This is made possible through the binding o f p2GPI to the charged surface o f 
an irradiated plate, which alters the confirmation o f the (32GPI molecule thus exposing 
the epitope to which the anti- p2GPI antibodies bind (Matsuura et al. 1994). It is thought 
that this process mimics the effect o f anti-phospholipid binding. Our group at UCL 
demonstrated that anti- P2GPI discriminated between anticardiolipin antibodies 
associated with infection and those associated with an increased risk o f thrombosis 
(McNally et al 1995a; McNally et al. 1995b).
Although in theory, the aCL and anti- P2GPI ELISA detect the same antibodies, it is not 
uncommon to encounter serum from patients with aPA that bind cardiolipin but not 
P2 GPI. and vice versa. This may be partly explained by the fact that some anti- P2 GPI 
recognise human P2 GPI. but not bovine p2GPI in aCL assays. The bovine serum in aCL 
assays provides antigenic targets other than P2 GPI. One would expect anti- P2GPI 
assays to show better agreement between centres, as only one well-defined antigen is 
measured, but collaborative studies have shown that inter-laboratory agreement remains 
poor Antigen density, protein damage through the use o f perchloric acid, proteolysis o f 
P2 GPI and P2 GPI isoforms may all contribute to poor standardisation (Reber et al.
2005). Therein lies the problem, in that we do not fully understand what solid phase 
antibody detection tests are measuring. The proponents o f anti- P2GPI point to the 
increased specificity o f these antibodies (de Groot et al 2005; Sheng, Kandiah, & Krilis
1998) others have suggested that their measurement adds no additional information to 
the diagnosis o f APS (Previtali. Barbui. & Galli 2002). At the scientific and
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standardisation committee (SSC) o f the International Society for Thrombosis and 
Haemostasis (ISTH) at Boston in 2002, it was suggested that the aCL test would be 
better replaced with a direct test o f anti- (32GPI. This has since been challenged by our 
group (Nash et al. 2004), who showed that omission o f aCL would lead to a failure to 
diagnose APS in over 25% of patients.
Clearly problems remain with the laboratory diagnosis o f the APS. The antibody 
specificity, concentration and avidity are extremely variable among APS patients and 
not all o f the known target antigens are represented by the antibodies detected by the 
routine tests. Indeed some authorities believe that antibodies measured in aPA 
laboratory tests are epiphenomenona, rather than pathogenic in their own right.
1.3 The antiphospholipid syndrome
The association o f aPA with thrombosis, stroke and/or fetal loss is termed 
‘Antiphospholipid Syndrome (APS) (Hughes 1983). It is now known that many o f 
patients with these clinical symptoms and laboratory findings do not suffer from SLE or 
related autoimmune diseases (e.g., Sjogren's and scleroderma) and these patients are 
said to have Primary Antiphospholipid Syndrome (PAPS). Other clinical associations 
include neurological disorders and immune mediated thrombocytopenia.
1.3.1 Thrombosis
Venous thrombosis occurs in the western world with a frequency o f approximately 1 per 
1000 individuals per year. It is associated with a high degree o f morbidity and, if  
pulmonary embolism develops, it may be fatal. Venous thrombosis is a multifactorial 
process, which is generally the result o f one or more inherited or acquired risk factors, 
eg increasing age, malignancy, orthopaedic surgery, obesity, immobilisation, 
puerperium, the use o f combined oral contraceptives (COC) and o f course 
antiphospholipid antibodies. In some instances, there appears to be a strong hereditary
17
tendency to thrombosis, and this is known as heritable throm bophilia (Greaves et al. 
2001). APS is considered by many to be the most important acquired throm bophilic 
condition, with strong associations between the presence o f aPA and throm bosis both in 
patients with SLE (Wahl et al. 1997) and without underlying autoimmune disorders 
(Wahl et al. 1998). In patients affected by thrombophilia, the first incidence o f 
thrombosis is commonly seen at a relatively early age and often without any obvious 
precipitating cause. It has been reported that at least one genetic defect predisposing to 
thrombophilia can be found in 70% of families with thrombophilia (Bertina 1997). 
Many o f these hereditary risk factors are quite common and, when found in isolation, 
are associated with only a slightly increased incidence o f thrombosis. However, when 
co-inherited with other defects, there is a synergistic effect, resulting in a much higher 
occurrence o f thrombotic disorders (Rosendaal 1997).
The association between aPA and thrombosis had long been recognised (Bowie et al 
1963). LA followed by medium/high titre IgG aCL are most strongly associated with 
venous thrombosis (Galli et al 2003b). Anti-prothrombin antibodies and anti- p2GPI 
also demonstrate an association with thrombosis, but there is little data and more studies 
are required (Galli et al. 2003a).
The aetiology o f arterial thrombosis is more complex than that o f venous thrombosis, 
but tends to associated with abnormalities of the vessel wall, disordered lipid 
metabolism and excessive platelet activation rather than the heritable thrombophilic 
defects associated with venous thrombosis. However, APS is an important contributing 
factor for arterial thrombosis, particularly in younger patients.
1.3.2 Pregnancy morbidity
The association o f a circulating anticoagulant and pregnancy loss was first described by
Nilsson (Nilsson et al. 1975), who reported the presence o f “antithrom boplastin” in a
woman who had three interuterine deaths characterised by placental infarction. It is
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known that in pregnant women with SLE, anticardiolipin is a predictor o f fetal loss 
(Lockshin et al. 1985) and that pregnancy losses tend to occur later than in SLE patients 
without anticardiolipin (Loizou et al. 1988).
There is considerable controversy over which tests are most useful in predicting 
pregnancy morbidity. Creagh et al (1991) reported that LA and IgG aCL are risk factors 
for recurrent pregnancy loss, while anti- P2 GPI antibodies have been shown by others to 
be most strongly associated with recurrent pregnancy loss (Falcon et al. 1997; 
Forastiero et al. 1997). Our group have shown that the presence o f anti-prothrombin 
antibodies are linked with fetal loss (Donohoe et al. 2001). but this has been disputed by 
others (Falcon et al 1997; Forastiero et al 1997) and may depend upon the 
methodology used as well as the selection o f the clinical cohort. Antibodies against 
factor XII (Jones et al. 2001) and annexin V (Rand et al. 1997) have also been 
implicated in the pathology o f aPA associated pregnancy morbidity
In one o f the few prospective studies performed. Rai et al (1995) reported a fetal loss 
rate of 90% in untreated pregnancies o f women with recurrent miscarriage and 
antiphospholipid antibodies. At present, the mainstay o f treatment for high-risk 
pregnancies is aspirin and/or low molecular weight heparin (LMWH) (Brenner et al. 
2005: Rai et al. 1997) which improves the live birth rate. However, even these treated 
pregnancies have a high rate o f complications (Backos et al. 1999; Brenner et al 2005; 
Lima et al. 1996) and the effectiveness o f LMWH has been disputed (Farquharson, 
Quenby, & Greaves 2002).
1.3.3 Other conditions associated with antiphospholipid antibodies
The antiphospholipid syndrome is frequently associated with other autoimmune
conditions, and although the differentiation between primary and secondary APS may
not be useful in the treatment o f the thrombotic or obstetric complications, it may aid
the diagnosis. Thrombocytopenia, livedo reticularis, migraine, valvar heart disease and
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cognitive dysfunction are all commonly reported, although the causal link with aPA is 
often tentative at best.
A rare, but severe complication is catastrophic antiphospholipid syndrome, which is an 
acute condition cause by intravascular thrombosis at multiple sites, affecting several 
organs. It is frequently associated with disseminated intravascular coagulation, which is 
not seen in APS, and is often fatal.
1.4 Normal haemostasis
The haemostatic system has two principal functions: To keep blood fluid in normal 
circulation; and to limit the loss o f blood when blood vessels become damaged. Normal 
haemostasis involves complex interactions between procoagulant, anticoagulant and 
fibrinolytic plasma proteins, platelets, leukocytes and the vascular endothelium.
The generation o f thrombin is the central event in blood coagulation: Insufficient 
thrombin leads to an increased risk o f bleeding, while unregulated thrombin generation 
predisposes to thrombosis. While the prothrombin time and activated partial 
thromboplastin time may be useful tests in identifying bleeding risk, they are o f little 
value in predicting thrombotic risk, as they do not reflect the overall thrombin 
generation. In order for blood to clot, it is only necessary for a small proportion o f the 
available prothrombin to be converted to thrombin, with >95% of thrombin formation 
occurring after this point (Brummel et al. 2002). The endogenous thrombin potential 
(ETP), i.e. the area under the thrombin generation curve, better represents this.
The laboratory investigation o f thrombophilia, in particular, has become increasingly 
reductionist in approach over the last three decades, i.e. the amount, the activity and 
mutations or polymorphisms o f individual haemostatic factors are measured in order to 
predict thrombotic risk. The clinical utility o f some o f these measurements, however, is 
questionable in predicting thrombotic risk and many now feel that a global assessment
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of the capacity o f a patient’s blood to generate thrombin (ETP) may be more useful in 
this setting (Baglin 2005).
Thrombin generation is now a widely used research tool, with applications in the 
investigation o f bleeding and thrombotic disorders. A method for throm bin generation 
was first described by MacFarlane and Biggs (1953), who observed, “'Experimental 
procedures have become increasingly complex and artificial. These techniques have 
yielded information o f great importance, but they must have a limited application, since 
they are far removed from the natural process of clotting”. It was not until 1993 when 
Hemker et al (1993) described a method for the continuous registration o f thrombin 
generation, that it became a practical technique even for dedicated research laboratories. 
This technique, while useful for small numbers o f samples, was technically demanding 
and time consuming. The development o f slow acting thrombin substrates (W ielders et 
al. 1997) allowed the semi-automated measurement o f ETP in defibrinated plasma using 
a centrifugal analyser.
Although the components o f the haemostatic system are intertwined, for practical 
reasons it is more convenient to describe them separately, although we should never 
forget how closely the various components are linked.
1.4.1 Primary haemostasis
Primary haemostasis is characterized by vascular contraction, platelet adhesion and
formation o f a soft aggregate plug. Immediately after a blood vessel has been cut or
ruptured, the trauma to the vessel wall itself causes the vessel to contract
(vasoconstriction, vascular spasm), instantaneously reducing blood flow from the vessel
rupture. The local vascular spasm can last for many minutes or even hours, during
which time the process o f platelet plug formation and blood coagulation can take place.
This is followed by platelet adhesion to von Willebrand factor(vWf) secreted from the
subendothelium into the subendothelial matrix. Glycoproteins on the platelet surface
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adhere to the von Willebrand factor(vWf) forming an unstable platelet plug that is 
strengthened by contact with collagen. Collagen-activated platelets form pseudopods, 
which stretch out to cover the exposed subendothelium and bridge exposed collagen 
fibres. The collagen-activated platelet exposes receptors that bind circulating fibrinogen 
to their surfaces and the fibrinogen recruits more platelets. The activated platelets play a 
major role in thrombin generation, which consolidates the platelet plug to form a clot.
1.4.2 The role of the endothelium
Endothelial integrity is essential for the function o f blood vessels and maintenance o f a 
non-thrombotic state. Under normal conditions, blood flows unimpeded through the 
circulatory system. However, following injury, local vasoconstriction occurs 
instantaneously in order to reduce loss o f blood from the damaged vessel. Thrombin 
acts as a pivot in the maintenance o f  the haemostatic balance; the vascular endothelial 
cell in particular limits the generation o f thrombin by localisation o f anticoagulant 
processes on its luminal membrane. The endothelial cell synthesises key molecules in 
this process and also binds exogenously derived molecules, as well as releasing proteins 
o f the fibrinolysis cascade. The thrombo-resistance o f the luminal surface is further 
regulated by lipoxygenase and cyclo-oxygenase metabolites o f unsaturated fatty acids 
synthesised by the endothelial cell. In response to trauma, inflammatory reactions, 
normal wound healing and in association with a variety o f disease states, the 
anticoagulant and fibrinolytic mechanisms are down-regulated and the procoagulant and 
thrombotic mechanisms predominate with resultant generation o f thrombin, fibrin clot 
formation and subsequent platelet adhesion and aggregation. Pro-inflammatory 
cytokines down-regulate the fibrinolytic and activated protein C pathways as well as 
inducing synthesis o f specific procoagulant and prothrombotic mediators by platelets 
and leukocytes as well as endothelium
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1.4.3 Coagulation
The cascade or waterfall hypothesis o f coagulation, developed in the 1950s and 1960s, 
depicts the coagulation system as a series o f proteolytic reactions (Figure 2). It helped 
us to understand the interactions between the various coagulation factors and also 
explained the importance o f anionic phospholipids and calcium. The cascade model 
correlates very well with the PT and APTT screening tests, and for this reason, it is still 
widely taught today. However, it has several serious limitations, in that it cannot be 
used to explain why factors VIII and IX deficiencies cause haemophilia, yet deficiencies 
in the contact factors are not associated with a bleeding diathesis. W hen Osterud 
(Osterud & Rapaport 1977) demonstrated that factor IX could be directly activated by 
the factor Vila/tissue factor complex, it became clear that the cascade model was an 
over simplification o f the coagulation process.
Central to coagulation are the vitamin K dependent proteins which include the 
coagulation factors II. VII. IX, X and the anticoagulant proteins C, S and Z. These 
proteins all contain a glutamic acid-rich y-carboxyglutamic acid or “gla domain" which 
is the result o f gamma carboxylation, and is required for the proteins to bind to 
phospholipid and calcium. Gamma carboxylation is a vitamin K dependent process and 
the inhibition o f this process is the basis o f oral anticoagulants such as warfarin. 
Without gamma carboxylation these proteins are largely inactive and this is the basis o f 
vitamin K antagonist anticoagulants such as warfarin. The gla domain allows the 
correct orientation and alignment o f  procoagulant and anticoagulant proteins on 
negatively charged antiphospholipid surfaces.
23
Figure 2 The ca sca d e  model of coagulation
(from Hoffman and Monroe (Hoffman & Monroe, III 2001)
The realisation that cells play a central role in haemostasis, rather than simply providing 
an anionic phospholipid surface (Hoffman et al 2001; Roberts, Hoffman, & Monroe
2006) has revolutionised the field. The prevailing view for many years was that 
thrombosis was simply haemostasis occurring in the wrong place, whereas it is now 
generally accepted that normal haemostasis and thrombosis are very different processes. 
Key to the cellular theory o f haemostasis is the idea that different stages o f coagulation 
occur in different sites. The three stages are, initiation, propagation and amplification.
Initiation o f thrombin generation occurs on tissue factor bearing cells. These may be 
extravascular cells, which constitutively express TF. Alternatively, in some pathological 
states, monocytes and endothelial cells, may express inducible TF due to stimulation by 
endotoxin, inflammatory cytokines or aPA. Factor VIIa/TF dependent generation of 
factors IXa. FXa and FVa are generally held in check by tissue factor pathway inhibitor 
(TFPI) and to a lesser extent, protein Z-protein Z-dependent protease inhibitor complex
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(PZ/PZI). It has been suggested that formation o f the prothrom binase complex is a 
threshold event that only occurs when there is sufficient TF, and hence extrinsic tenase 
complex, to overcome TFPI inhibition (v an 't Veer & M ann 1997b).
The propagation stage occurs on the surface o f  activated platelets, and generates factors 
IXa, Xa, Va and trace amounts o f thrombin. Antithrombin readily inhibits free factor Xa 
and throm bin, but factor IXa less so. Factor IXa is thus able to move to other sites.
The am plification phase occurs on several activated platelets. Feedback through 
throm bin activation o f factor XI leads to an amplification loop, hence the im portance o f 
factors VIII and IX. The protein C pathway does not function well on the surface o f 
activated platelets, but when the throm bin leaves the vicinity o f the haem ostatic plug 
and reaches an area o f  intact endothelium  it is bound to thrombomodulin w ith high 
affinity. The throm bin-throm bom odulin complex has no procoagulant activity, but 
activates protein C to activated protein C. This in turn inactivates factors Va and V illa  
in a protein S catalysed reaction, thus limiting coagulation to the site o f  injury.
Such is the complexity o f the coagulation system, that it may be best understood as a 
series o f key complexes.
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The extrinsic tenase complex forms on the 
tissue factor-bearing cell (Figure 3). Factor Xa 
is generated, and small amounts o f  thrombin 
are produced, which activate platelets and 
release active factor VIII from vWf. It also 
generates factor IXa which is able to move to 
other sites where the propagation phase 
occurs. This complex is controlled by TFPI.
Factor IXa forms a complex with factor V illa  and 
factor Xa (Figure 4). This complex is many times 
more efficient than the extrinsic tenase complex, 
and generates many molecules o f Xa on activated 
platelets. This is the propagation phase.
Figure 3 Extrinsic tenase com plex 
from Mann et al (2006)
Figure 4 intrinsic tenase Mann et al
(2006)
The prothrombinase complex also forms on the 
activated platelet (Figure 5). Factor Va acts as a 
cofactor for factor Xa and generates large amounts 
o f  thrombin. This thrombin may feed back through 
factor XI to cause further amplification.
When thrombin reaches in tact endothelium, it is 
tightly bound by throm bomodulin and alters it 
substrate specificity to protein C (Figure 6). The 
APC formed controls the formation o f  thrombin 
through the inactivation o f factors Va and V illa.
Figure 5 prothrombinase com plex 
Mann et al (2006)
Figure 6 Protein C-ase Mann et al
(2006)
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1.4.4 Inhibitors of coagulation
Most cases o f thrombophilia, involving venous disease, appear to involve either 
inappropriate thrombin generation or decreased thrombin inhibition. There are four 
levels o f control o f throm bin generation:
• proteins such as P2 glycoprotein-I and annexin V limit the availability o f 
negatively charged phospholipid surfaces, which support most coagulation 
reactions
• tissue factor pathway inhibitor (TFPI) controls the availability o f the active 
tissue factor/factor V ila complex, major determinants o f the amount o f throm bin 
generated
• the protein C system inactivates the activated cofactors FVIIIa and FVa, which 
amplify factor Xa and throm bin generation.
• a range o f serine protease inhibitors, o f which antithrombin is the most 
important, limit the activity o f activated clotting factors (eg thrombin, factor Xa)
As with most aspects o f haemostasis, this is an over-simplification. It is now known that 
TFPI and the protein C pathway act in synergy (v a n 't  Veer et al. 1997a). In purified 
systems, the presence o f normal plasma levels o f TFPI, protein C and protein S, and 
InM  thrombomodulin, is sufficient to eliminate all prothrombinase activity initiated by 
1.25 pM factor VIIa.TF. Thus, TFPI and the protein C pathway combine to create a 
minimal inhibitory potential required to shut down tissue factor-initiated thrombin 
generation. Defects in these control mechanisms may result in predisposition to venous 
thrombosis proportional to the severity o f the deficiency and the importance o f  the 
control mechanism involved. Hence, a homozygous deficiency o f antithrombin, which 
is the major plasma inhibitor o f thrombin, is thought to be incompatible with life,
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whereas homozygous p 2-glycoprotein-1 deficiency does not appear to be associated 
with an increased risk of thrombosis.
1.4.5 The protein C system
The protein C anticoagulant pathway serves as a major system for controlling 
haemostasis and limiting inflammatory responses. The pathway involves thrombin, 
thrombomodulin, endothelial cell protein C receptor (EPCR), protein C, and protein S, 
but, so far as haemostasis is concerned, APC is the main effector molecule (Figure 7). 
Homozygous deficiencies of protein S and C cause purpura fulminans and require 
treatment from birth. Thrombomodulin and EPCR gene knockouts are lethal in mice, 
and the homozygous deficient state has not been reported in humans, underlying the 
importance o f the protein C system. Disturbances in the protein C pathway are strongly 
implicated in the aetiology o f thrombosis, stroke and recurrent miscarriage. The 
majority of familial thrombophilia defects discovered so far reside in the protein C 
pathway (Rosendaal et al, 1997); genetic defects linked to thrombophilic states have 
now been described in protein C, protein S, EPCR. thrombomodulin and factor V.
Figure 7 The role of protein C in regulating coagulation From Esmon (Esmon 2003)
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Current laboratory diagnosis o f  defects in the protein C system relies on the following 
types o f specific assay.
• Clotting tests based on the prolongation o f a clotting time by APC, w hich may
be formed by the activation o f endogenous protein C using Protac™  (an extract
from Agkistrodon Contortrix venom) or the addition o f exogenous APC.
• Amidolytic assays that utilise the ability o f  APC to cleave synthetic peptide
substrates, producing p-Nitroaniline, which can be, measured
photocolorimetrically.
• Immunological assays that use specific monoclonal antibodies to recognise 
proteins. The most commonly used assays are ELISA, although automated latex 
agglutination assays for free protein S are now widely available.
1.4.5.1 Protein C
Protein C is a vitamin K-dependent glycoprotein first described in 1976 (Esmon, 
Stenflo, & Suttie 1976). Unlike the other vitamin K dependent zymogens known at that 
time, protein C is not required for blood coagulation, and was subsequently found to 
inhibit thrombin formation (Comp & Esmon 1979; Dahlback & Stenflo 1980). We now 
know that this occurs through the inactivation o f factor Va (Walker 1980) and factor 
V illa. Hereditary protein C deficiency was first described in a three Dutch families with 
a high incidence o f venous thromboembolism (Broekmans, Veltkamp, & Bertina 1983). 
It has been estimated that approximately 3% o f patients presenting with their first 
episode o f deep vein thrombosis (DVT) and 6 % of individuals with familial 
thrombophilia are protein C deficient. Large studies o f blood donors show that the 
prevalence o f heterozygous protein C deficiency is approximately 1 in 400, yet most o f 
these subjects are asymptomatic, suggesting that an additional risk factor for thrombosis 
is required in heterozygous deficiency (Rosendaal et al, 1997). However, homozygous
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protein C deficiency is a severe disease, which usually presents in the neonate as 
purpura fulminans or disseminated intravascular coagulation. Using qualitative and 
quantitative assays it is possible to identify two main types o f  protein C deficiency. 
Type I is the most common and refers to a decrease in antigen with a concom itant 
decrease in activity; whereas in type II, antigenic levels are normal but a dysfunctional 
protein results in reduced activity.
The activated form o f protein C (APC) has both anticoagulant and anti-inflammatory 
functions and has been shown to reduce mortality in patients with sepsis (Bernard et al. 
2001). The recombinant human form (rhAPC, Drotrecogin Alfa, Eli Lilly) is now 
widely used in the treatment o f systemic inflammatory response syndrome in sepsis.
1.4.5.2 Protein S
Protein S is a vitamin K-dependent plasm a glycoprotein and was discovered three years 
after protein C (DiScipio & Davie 1979). In the circulation, Protein S exists in two 
forms: a free form and a complex form bound to C4b binding protein. It is rare amongst 
vitamin K dependent glycoproteins, in that it has no serine protease activity, but acts as 
a cofactor for other enzymes. Protein S has several functions, and it is convenient to 
divide these into APC-dependent and independent functions.
Protein S forms a complex with APC on negatively charged phospholipid and 
potentiates the anticoagulant effect o f APC on factor Va and factor V illa  (W alker 
1980). C4b-binding protein inhibits the factor V-dependent but not the factor V- 
independent cofactor activity o f  protein S in the activated protein C-mediated 
inactivation o f factor V illa  (van de Poel, Meijers, & Bouma 2001).
It is known that protein S has an inhibitor effect o f factor Xa (Heeb et al. 1994), 
independent o f APC. Protein S also recognises apoptotic cells and this allows the C4b-
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binding protein-protein S complex to prevent secondary necrosis through com plement 
activation (Rezende, Simmonds, & Lane 2004).
A strong association between protein S deficiency and familial throm bophilia exists 
with a similar clinical presentation to that o f protein C deficiency. There are no reliable 
estimates for the prevalence o f  protein S deficiency in a normal population, but 
estimates for patients presenting with first DVT and familial throm bophilia are 
approximately 1.4% and 7.2% respectively (Rosendaal 1997). Free and total protein S 
levels are known to fluctuate over time, and to be strongly influenced by acute phase 
reactions, age, sex and hormonal status (Liberti, Bertina, & Rosendaal 1999).
1.4.5.3 Thrombomodulin
Thrombomodulin, an integral membrane protein, is expressed on the surface o f vascular 
endothelial cells and the syncytiotrophoblast. It binds thrombin in a high affintyl :1 
stoichiometric non-covalent complex, which alters the specificity o f thrombin so that it 
preferentially cleaves a small peptide bond in the protein C heavy chain, to form the 
active serine protease: APC. Once bound to thrombomodulin, the substrate specificity 
o f thrombin is redirected from procoagulant to anticoagulant reactions. The 
thrombomodulin-bound thrombin activates protein C and thrombin-activatable 
fibrinolysis inhibitor (TAFI) at a rate -1000  greater than thrombin alone (Lane, 
Philippou, & Huntington 2005). Although thrombomodulin polymorphisms and defects 
are rare in patients with thrombosis, antibodies to thrombomodulin have been described 
in APS and may inhibit protein C activation (Carson et al. 2000; Oosting et al. 1993b). 
Mutations in the thrombomodulin gene are associated with an increased risk o f late fetal 
loss (Franchi et al. 2001) and mouse knockout models have shown that thrombomodulin 
is essential for fetal development (Isermann et al. 2003).
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1.4.5.4 Endothelial protein C receptor
The endothelial protein C receptor (ECPR) is also a transmembrane protein, found 
primarily on the endothelium o f large vessels and trophoblasts (Esmon 2006). EPCR 
binds protein C and facilitates activation by the throm bin-throm bomodulin complex, 
increasing the rate o f APC formation twenty fold (Steam s-Kurosawa et al. 1996)
EPCR also binds activated protein C (APC) and inhibits the anticoagulant activity o f 
APC, but not its anti-inflammatory functions (Regan et al. 1996). ECPR is essential for 
embryonic viability (Li et al. 2005) (Gu et al. 2002). Furthermore, a polym orphism in 
the ECPR resulting in increased shedding o f the receptor is associated with increased 
risk o f  thrombosis (Medina et al. 2004) and pregnancy loss in humans (Lavigne- 
Lissalde et al. 2005). Antibodies against EPCR in APS have been reported to be a risk 
factor for fetal death (Hurtado et al. 2004).
1.4.5.5 Tissue Factor Pathway Inhibitor
Tissue factor pathway inhibitor (TFPI) is a Kunitz-type serine proteinase inhibitor that 
down-regulates tissue factor/factor Vila-initiated blood coagulation via a two-step 
negative feedback mechanism, through formation o f a bimolecular FXa/TFPI complex. 
This complex subsequently interacts with TF/FVIIa, yielding an inactive quaternary 
complex o f Xa, TFPI, and factor V ila and tissue factor, thus terminating TF/FVIIa- 
catalysed FX activation. TFPI contributes significantly to the inhibition o f Xa in vitro 
(v an 't Veer et al 1997b), despite being present at concentrations o f only 2.5nM. The 
association o f low levels o f plasma TFPI with venous thrombosis (Dahm et al. 2003), 
suggests that TFPI is also important in vivo and indeed, homozygous TFPI deficiency 
causes a lethal phenotype.
Although not considered a part o f the protein C system, TFPI may act in synergy with 
APC, in purified systems (v a n 't  Veer et al 1997a). TFPI is associated with vascular
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endothelium and is released into the bloodstream by heparin (Sandset, Abildgaard, & 
Larsen 1988). Both TFPI (M ast et al. 2002) and a related molecule tissue factor 
pathway inhibitor type-2 (TFPI-2 also known as placental protein 5) are associated with 
placenta (Udagawa et al. 2002).
1.4.5.5 Resistance to activated protein C
The most common inherited cause o f throm bophilia is activated protein C resistance 
(APCR). This defect is usually associated (>80%) with a point mutation in the factor V 
gene resulting in an Arg506Gln substitution which renders the mutant protein, factor V 
Leiden (FVL or R506Q), resistant to cleavage by APC (Bertina 1997). The factor V 
Leiden defect occurs in approximately 2 -  16 % o f Caucasian populations although it is 
extremely rare in Asians, Arabs and Africans. Factor V Leiden is a fairly com mon 
defect, which may be readily confirmed by the identification o f a single polymorphism. 
These features have allowed studies involving large numbers o f affected individuals, 
previously impossible with rarer mutations. Consequently, much more is known about 
the increased risk o f thrombosis associated with factor V Leiden and interactions with 
other thrombogenic risk factors, than for other defects. Heterozygous factor V Leiden is 
associated with a 3 to 7 fold increased risk o f thrombosis, whereas the homozygous 
form has an 80-fold increase. When factor V Leiden is co-inherited with other defects, 
such as protein C, deficiency, protein S deficiency or the prothrombin gene m utation 
20210A, there is a synergistic effect resulting in an increased risk greatly exceeding the 
sum o f the individual risk factors. Recent work has identified three other 
polymorphisms in the factor V gene that may be thrombotic risk factors. Factor V 
Cambridge (Arg306Thr) and homozygosity for the HR2 haplotype for the factor V gene 
both cause APCR (de Visser et al. 2000), whereas the Arg306Gly mutation first 
discovered in Hong Kong Chinese does not appear to be associated with APCR 
(Norstrom, Thorelli, & Dahlback 2002). Several conditions are associated with acquired
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APCR that may also be a risk factors for thrombosis including lupus anticoagulant, 
pregnancy, combined oral contraceptive use and elevated factor VIII (Rosendaal 1997).
1.4.5.6 Antithrombin
Antithrombin, previously known as antithrombin III, is a serpin that inactivates a 
number o f enzymes from the coagulation system, namely thrombin, factor Xa, factor 
IXa, Factor XIa, and Factor Xlla. The rate o f its reaction with these molecules is greatly 
enhanced by the presence of heparin. This is achieved through two functional domains, 
a heparin binding site and a reactive centre, that complexes and inactivates the 
proteinase (Lane et al. 1996). The heterozygous inherited state and acquired deficiencies 
o f antithrombin result in a hypercoagulable state. The homozygous deficient state has 
not been described and is thought to be incompatible with life.
1.4.5.6 Fibrinolysis
Plasmin is the major fibrinolytic protease. Plasminogen, a circulating plasm a zymogen, 
can be converted to plasmin by both tissue plasminogen activator (tPA) and urokinase 
(uPA). Fibrin, the major plasmin substrate, regulates its own degradation by binding 
both plasminogen and tPA on its surface, thereby localizing and enhancing plasm in 
generation. While tPA is a weak activator o f plasminogen in the absence o f fibrin, its 
catalytic efficiency for plasminogen activation is enhanced in the presence o f fibrin. 
Plasmin cleaves fibrin, generating soluble degradation products (Cesarman-M aus & 
Hajjar 2005).
tPA and urokinase are themselves inhibited by plasminogen activator inhibitor - 1 and 
plasminogen activator inhibitor-2 (PAI-1 and PAI-2). Plasmin stimulates its own 
production through the cleavage o f single chain tPA and urokinase to more
active two-chain polypeptides. Alpha 2-antiplasmin and alpha 2-macroglobulin 
inactivate plasmin. Plasmin activity is also reduced by thrombin-activatable fibrinolysis
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inhibitor (TAFI), which removes the carboxy-terminal Lys residues o f fibrin, which 
modifies fibrin to make a less potent cofactor for the tPA-mediated plasm inogen 
activation. This has the effect o f  stabilising the fibrin thrombus and represents a 
regulatory connection between coagulation and fibrinolytic pathways.
Defective fibrinolysis has been described in APS and several mechanisms have been 
proposed (Keeling et al. 1991; Patterson et al. 2006; Takeuchi et al. 2002; Yang et al. 
2004).
1.4.6. The role of phospholipids in haemostasis
The central role o f the membrane surface in the reactions o f the coagulation cascade has 
been well known for many years (Mann et al. 1990). A negative charge on the 
membrane is recognized as necessary for the binding o f the vitamin K-dependent 
enzymes and substrates through their N-terminal Gla domains. Through this binding, the 
local concentrations o f the proteins are markedly increased, augmenting activation rates. 
Binding may also induce conformational changes in the proteins, aligning substrate 
cleavage sites with the active site o f the enzyme (M utucumarana et al. 1992). The nature 
o f the phospholipid head group was known to play a role, and phosphatidylserine (PS) 
has been considered the most important (Pei, Powers, & Lentz 1993). For many years, it 
was believed the reactions o f the coagulation cascade shared similar requirements for the 
membrane surface. However, most experiments were performed with the prothrombin- 
activating complex, prothrombinase, with a tendency to generalise to the other 
complexes. More recently, it has become apparent that the presence o f 
phosphatidylethanolamine (PE) potently enhanced the rate o f inactivation o f  factor Va 
by the activated protein C (APC) complex (Smirnov & Esmon 1994) and the 
anticoagulant activity in plasma while having little to no effect on the prothrom binase 
reaction when the PS concentration was optimal. (Pecheniuk 2003)
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The role o f oxidation in disease has gained considerable attention in the last few years. 
Oxidation is believed to play a key role in the pathogenesis o f  many inflammatory 
diseases including atherosclerosis, reperfusion injury, and autoimmune diseases. 
Oxidized LDL plays a major role in the initiation and propagation o f  the atherosclerotic 
plaque (Ross 1999). It can also lead to the activation o f endothelium and platelets. 
Endothelial cell activation can then lead to the elaboration o f other inflammatory 
mediators which themselves exacerbate coagulation. Oxidized LDL can also be 
immunogenic and lead to the development o f  antibodies that cross-react with cardiolipin 
or the surface o f endothelial cells. In addition, apoptotic cells with negatively charged 
surfaces can be immunogenic and lead to the development o f aPA. These observations 
led Horrko et al{ 1996) to determine that many aPA are directed toward epitopes o f 
oxidized phospholipids and or adducts o f oxidized phospholipid and (32-glycoprotein I.
More recently, Safa et al (2001) have shown that oxidation o f natural phospholipids 
increases the ability o f  the membranes to support the function o f APC, and potentiated 
the APC cofactor activity in o f protein S in factor Va inactivation, without significantly 
altering the ability to support thrombin generation. Cardiolipin also enhances the protein 
C pathway anticoagulant activity (Fernandez et al. 2000) and has been shown to be a 
normal component o f low density lipoprotein in human plasma (Deguchi et al. 2000)
Oxidation has long been recognized as having an effect in the in vitro coagulation 
assays (Barrowcliffe, Stocks, & Gray 1982), usually observed as a change in clotting 
time with the age o f the phospholipid preparation. It is also known that oxidised lipid 
have a profound effect on the protein C pathway (Safa et al. 2001; Safa, Esmon, & 
Esmon 2005).
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1.5 Proposed mechanisms for pathogenesis of antiphospholipid 
antibodies
Many of the autoantibodies associated with APS are directed against phospholipid- 
binding plasma proteins, such as beta2-GPI and prothrombin, or phospholipid-protein 
complexes. The mechanisms by which aPL cause thrombosis are not completely 
understood. There is no unique mechanism able to explain all symptoms associated with 
the presence o f aPL. A variety o f mechanisms have been proposed to explain the 
clinical phenomena, including abnormal activation and function o f protein C, activated 
platelets, reduced prostacyclin production, disordered fibrinolysis, and inhibition or 
potentiation o f the actions of p2-Glycoprotein I. As with other thrombotic disorders, the 
pathogenesis o f APS is likely to be multifactorial.
1.5.1 Endothelial activation
Several different theories have been proposed for the ability o f  aPA to induce 
endothelial activation. It has been shown that aPA react with directly with endothelium 
(Hill et al. 1995; Hill et al. 1998) and that this interferes with fibrinolysis on the cell 
surface. (Patterson et al 2006). aPA have been shown to induce tissue factor on 
endothelial cells (Branch & Rodgers 1993). It has been proposed that this occurs 
through p38 MAPK in the up-regulation o f  tissue factor NF-kappa B (Vega-Ostertag et 
al. 2005) and that this process may be P2 GPI dependent (Komberg et al. 2000). 
Furthermore, endothelial activation may also lead to the release o f tissue factor bearing 
endothelial microparticles (Combes et al. 1999). Inhibition o f prostacyclin release by 
endothelial binding aPA has also been reported (Lindsey et al. 1994). Aspirin has been 
shown to inhibit aPA dependent endothelial activation (Dunoyer-Geindre et al. 2004).
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1.5.2 Monocyte activation
Over-expression o f TF has been also shown in monocytes in vitro and ex vivo. TF is the 
major initiator o f coagulation in vivo; thus, its dysregulation may be one o f the most 
important contributors to thrombosis. It has been reported that some aPA may induce 
tissue factor on monocytes (Cuadrado et al. 1997) enhance throm bin generation on 
tissue factor binding cells (Hoffman, M onroe, & Roubey 2000).It has recently been 
shown that aPA induce tissue factor expression through the simultaneous activation o f 
NF-kappa B/Rel proteins (Lopez-Pedrera et al. 2006)
1.5.3 Platelet activation
Effects o f aPL upon platelets are not completely elucidated. aPL bind anionic 
phospholipid but they are normally in the inner side o f cell membranes. W hen platelets 
are activated, anionic phospholipids are exposed. There is evidence showing that 
activated platelets are present in aPL-positive patients (Joseph et al. 1998; Joseph et al. 
2001). This was supported by Nojima et al (Nojima et al. 2004) who reported that aPA 
enhance ADP induced platelet activation and may predispose to stroke. A role for anti- 
p2-GP I antibodies has been suggested, in which anti-p2-GP 1/ p2-GP I complexes 
activate platelets in a dysregulated manner via glycoprotein Ib-IX-V.
1.5.4 The role of anti p2 Glycoprotein-I antibodies
In recent years there has been a great deal o f interest in the role o f  anti-p2-GP I 
antibodies. At first sight, it is difficult to see why antibodies against p2-GP I should be 
pathogenic at all. Although, p2-GP I knockout mice are reported to have impaired 
thrombin generation (Sheng et al. 2001b), two human siblings, wholly deficient in p2- 
GP I had normal markers for thrombin generation and fibrin turnover (Takeuchi et al. 
2000). It is known that p2-GP I is expressed on normal placentas, (Donohoe et al. 2000) 
and that its placental expression is reduced in APS. However, the knockout mouse
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model has shown that, P2 -GP I is not essential for successful pregnancy in mice, 
although it is required for optimal placental development and fetal growth (Robertson et 
al. 2004). It therefore seemed unlikely that an antibody induced deficiency o f  P2 -GP I 
was responsible for the pathogenic effect o f the antibody. Indeed, the levels o f  P2 -GP I 
antigen are actually increased in APS (McNally et al 1995a).
Galli et al (1995) suggested that prothrombin and P2 GPI dependent antibodies could be 
differentiated by means o f the KCT and dRVVT tests. However, this was based on the 
ability o f cardiolipin vesicles to adsorb aPA, rather than a genuine demonstration o f  anti 
prothrombin and or anti-p2 GPI activity.
Binding o f anti- P2 GPI to P2 GPI is intrinsically o f low affinity and the binding is 
dependent on the density o f the antigen rather than neo-epitope formation (Sheng et al 
1998). Anti-P2 GPI has been shown to enhance the binding o f P2 GPI to phospholipids 
(Takeya et al. 1997). It was thought that this was due to the ability o f anti- P2 GPI to 
form divalent complexes o f P2 GPI on the phospholipid surface (Sheng et al 1998; 
Willems et al. 1996). Due to the increased affinity, P2 GPI is then able to compete with 
clotting factors for the phospholipid surface, resulting in the in vitro prolongation o f 
coagulation (Takeya et al 1997). This was substantiated by the finding that covalently 
bound dimers o f P2 GPI mimic the in vitro effects o f P2 GPI anti- P2 GPI antibody 
complexes (Lutters et al. 2001).
1.5.5 anti-prothrombin
It was initially thought that anti-prothrombin antibodies were not associated with 
venous thromboembolism (VTE) or recurrent pregnancy loss (Forastiero et al 1997) 
(Donohoe et al 2001). However, complexes o f anti-prothrombin antibodies and 
prothrombin cause lupus anticoagulant activity by competing with the binding o f
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clotting factors for catalytic phospholipid surfaces (Simmelink et al. 2001) in a 
mechanism similar to that o f anti- P2 GPI. Anti-prothrombin antibodies appear to be 
heterogeneous (Atsumi et al. 2000) (Horbach et al. 1998a) and their detection is highly 
dependent upon the assay system used (Donohoe et al 2001). At present, the 
standardisation o f anti-prothrombin antibody assays is poorly standardised and this may 
be hindering progress in this area (Galli et al 2003a).
1.5.6 inhibition of activated protein C
It has been proposed that aPA dependent inhibition o f the protein C pathway may have 
a role in the pathogenesis o f antiphospholipid syndrome and several mechanisms have 
been suggested:
• Some aPA may directly inhibit protein C and/or protein S (Malia et al 1990).
• P2 GPI is known to bind to protein C and modulate its activation (Keeling et al 
1993).
• It has been claimed that aPA may inhibit the thrombomodulin-dependent 
activation o f protein C (Cariou et al. 1988; Keeling et al. 1993; Oosting et al 
1993b) but this has been disputed by others (Potzsch et al. 1995)
• It has been proposed that some P2 GPI dependent antibodies bind to protein 
C/APC possibly stabilising a p 2 GPI- APC complex preventing its action 
(Atsumi et al. 1998).
• Anti-P2 GPI but not anti-prothrombin antibodies has been reported to inhibit the 
inactivation o f factor V by activated protein C (Galli et al 1998).
Galli et al (1998) suggested that only P2GPI dependent aPA, and not anti-prothrombin 
antibodies, were responsible for the inhibition o f APC, and this view has been supported 
by others were (M artinuzzo et al. 1996; M ercier et al. 1998; Viveros et al. 2005).
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Another group has reported that ‘anticardiolipin’ antibodies from patients w ith APS 
may cross-react with prothrom bin and thrombin (Hwang et al. 2001), APC (Hwang et 
al. 2003), factor Xa (Yang et al. 2006) and plasmin (Yang et al 2004) and have 
suggested that these antibodies prevent APC, antithrombin and plasmin from binding to 
their substrates through direct binding to the inhibitor or its substrate. However, the 
work hinges on the results obtained using seven monoclonal antibodies, which show 
remarkable cross-reactivity with many coagulation molecules.
It was against this background o f poor standardisation o f assays for aPA and the lack o f 
agreement over their pathological mechanisms, that I hypothesised that the 
measurement o f the haemostatic phenotype rather than the traditional immunological 
markers may be more informative in these patients.
1.6 Antiphospholipid antibody interference in laboratory screening tests
As the definition o f a lupus anticoagulants (LA) is an antibody that interferes with 
phospholipid dependent coagulation reactions in vitro (Brandt et al 1995), it is not 
surprising that aPA are associated with falsely abnormal results in other diagnostic tests. 
Interference in the APTT was first described by Okpara et al (1977) who reported that 
plasmas from patients with lupus anticoagulants prolonged both the APTT and the 
tissue throm boplastin inhibition test, and that this was not corrected by mixing with 
normal plasma. They also showed that the maximum rate o f change o f optical density 
during clotting was reduced when compared to normal plasma. APTT reagents differ 
widely in sensitivity to LA (Jennings et al. 2002), and this is largely dependent on the 
lipid composition, both in terms o f  the amount and the type o f phospholipid present.
While we have been aware o f the sensitivity o f the dilute thromboplastin test to lupus 
anticoagulant for many years (Schleider et al 1976), the susceptibility o f  the
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prothrombin time, and hence the International Normalised Ratio, to LA is more 
controversial. Moll et al (1997) showed interference with some reagents, while Lawrie 
et al (1997) reported that aPA had no effect. It is now generally accepted that antibodies 
from some patients with LA can cause a false elevation in INR with certain reagents 
(Della et al. 1999; Robert et al. 1998). Tripodi et al, (2001) recom mended that new 
thromboplastins, especially those made o f relipidated tissue factor, should be checked 
for their responsiveness to LA before they are used to monitor oral anticoagulant 
treatment in patients with APS.
1.7 Aims of this thesis
The central hypothesis o f this thesis was that acquired resistance to APC could be 
important in the pathogenesis o f  APS and that the global assessment o f the coagulation 
and protein C anticoagulant pathways might be more informative than the traditional 
immunological markers.
The aims o f this study were to:
• Investigate the frequency o f protein C pathway defects in patients with aPA and 
to study clinical correlates.
• Investigate the mechanisms o f antiphospholipid interference in the protein C 
pathway, with particular respect to phospholipid composition and P2 -GPI 
dependency.
• Assess the APC resistance in patients with aPA in terms o f thrombin generation.
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Chapter 2 Methods
2.1 Blood collection
Blood collection and plasma preparation were performed in the same manner 
throughout this study. Venous blood was collected into 5 ml tubes containing a one- 
tenth volume 0.105 M tri-sodium citrate (e.g. Vacutainer®, Becton Dickinson, 
RPlymouth, UK) using 19 or 21 gauge needles and minimal stasis. Platelet poor plasma 
was prepared by double centrifugation at room temperature at 2 0 0 0 g for 15 minutes, 
and frozen in aliquots at -80°C until assayed. A buffy coat sample was also collected for 
PC confirmation o f factor V Leiden status. Ethical consent was obtained and all patients 
and controls gave informed consent.
2.2 Protein C pathway screening tests
The following four screening tests were used:
a) ACTICLOT® V-OUT (American Diagnostica, Greenwich, CT, USA)
b) PCA test (Diagnostic Reagents Ltd, Thame, UK)
c) GradiThrom PCP (Gradipore, North Ryde, Australia)
d) ProC® Global (Dade Behring GmbH, Marburg, Germany)
a) V-OUT uses two snake venoms, the first o f which activates endogenous protein C 
while the second initiates clotting. The manufacturer declined to identify the snake 
venoms used, but as they stated that one activated protein C, and the other activated 
factor X, it was most likely that the venoms were an extract from Agkistrodon contortrix 
contortrix (Southern Copperhead, also known as Protac® or protein C activator) and 
Vipera russelii (Russell’s viper venom). Unlike the other three tests, exogenous APC is 
also utilized in this test. Briefly, equal volumes o f plasma and the APC reagent 
(containing both protein C activator and exogenous APC) or distilled water were
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incubated at 37°C for 2 minutes prior to the addition o f the clotting reagent. A ratio o f 
clotting time for patient plasma with APC reagent/clotting time o f  patient plasm a with 
water was calculated.
b) In the PCA test, a ratio o f clotting times obtained using an activated partial 
thromboplastin time (aPTT) reagent and the same aPTT reagent containing Protac® is 
calculated. Briefly, equal volumes o f plasma and aPTT or aPTT/PCA are incubated at 
37°C for 5 min prior to the initiation o f clotting by CaCb diluted in saline. Predilution 
o f plasma 1:5 in factor V-deficient plasma (Diagnostic Reagents) was performed for 
confirmation o f factor V Leiden.
c) The PCP test uses Protac® to prolong clotting initiated by a phospholipid-rich dilute 
Russell's viper venom reagent containing CaCb (PRVV). The test is simultaneously 
performed with the substitution o f saline for Protac®, and a ratio o f the two 
measurements is reported. Equal volumes o f  plasma and Protac® or saline were 
incubated at 37°C for 5 minutes prior to the initiation o f clotting by PRVV. Ratios o f  <
1.5 are usually due to factor V Leiden, and ratios between 1.5 and 2.5 are suggestive o f 
protein C or protein S deficiency.
d) ProC Global also measures the degree o f prolongation o f the aPTT caused by the 
activation o f  endogenous APC by a protein C activator (venom from Agkistrodon 
contortix). The CA-6000 coagulometer (Sysmex) incubates equal volumes o f plasma 
with aPTT reagent and buffer or protein C activator at 37°C for 3 min. Clotting is then 
initiated by the addition o f CaClj. Clotting times with and without protein C activator 
were measured in parallel. Standard Human Plasma (Dade Behring) was used to 
calculate a Normalised Ratio (NR) using a lot specific calibration factor.
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PCAT
PCAT/O sampleNormalised Ratio (NR) = 7 ------------7 ----------  x sensitivity o f SHP
PCAT SHP
PCAT/O^
Where PCAT = clotting time with activator, PCAT/O = clotting time with buffer, SHP = 
standard human plasma, and sensitivity = calibration factor for standard human plasma. 
For factor V Leiden screening, a 1:5 predilution o f plasma in factor V-deficient plasma 
(Dade Behring) was performed to minimize the influence o f factors other than factor V 
Leiden on the clotting times. NR < 0.8 was given as the decision limit for detecting 
factor V Leiden or protein C and protein S deficiencies.
Quality control was achieved by analysing the following lyophilised plasm a samples:; 
locally prepared pooled normal plasm a (double centrifuged and prepared from at least 
2 0  healthy normal subjects); a frozen pool o f plasmas from donors confirmed as 
heterozygous factor V Leiden (Precision Biologicals, Dartmouth, Nova Scotia, Canada).
2.3 Protein C assay
Protein C was assayed by an amidolytic method using Protac® and protein C substrate 
(Unitrate™ PC, Technoclone) and calibrated against a standard plasma (Technoclone).
2.4 Protein S assay
Free protein S was assayed by ELISA using a capture monoclonal antibody specific for 
free protein S and a polyclonal peroxidase conjugated detection antibody (Corgenix, 
Westminster, Co, USA) and calibrated against the international standard plasm a 93/590 
(NIBSC, UK).
2.5 Factor V Leiden mutation analysis
DNA extracted from whole blood buffy coats was analysed for the factor V Leiden 
mutation by polymerase chain reaction (PCR) and restriction fragment length 
polymorphism analysis (Bertina et al. 1994). A 267-basepair segment o f  the factor V
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gene was amplified using specific primers and the PCR products were digested with a 
specific restriction enzyme M nll, separated electrophoretically and visualised using 
ethidium bromide.
2.6 Activated protein C resistance test (Commercial clotting test)
APCR was determined using the Coatest® Activated Protein C Resistance m ethod with 
predilution in FV deficient plasma (Chromogenix, Molndal, Sweden). Briefly, APTT 
was measured using an ACL 3000 coagulometer (Instrumentation Laboratory) in the 
presence and absence o f  APC and the results were expressed as a ratio o f the two 
clotting times. Unless otherwise stated, APCR was performed without prediluting the 
patient plasma in factor V deficient plasma, i.e., the unmodified APCR test.
2.7 Antiphospholipid antibody detection
Lupus anticoagulant activity was assessed by the dilute Russell's viper venom time 
dRVVT method (Thiagarajan et al 1986) using the UNITEST LA -  dRVVT/PNR kit 
(Technoclone). In accordance with the BCSH guidelines (Greaves et al 2000), mixing 
studies using pooled normal plasma, and a platelet neutralisation procedure were 
performed on all samples giving a dRVVT ratio above the local normal reference range. 
A prolongation o f the 50:50 mix, and a correction o f the ratio by >10% or to w ithin the 
normal range was considered positive for LA (Gardiner et al. 2000)
Anti-cardiolipin antibodies were measured by ELISA using a method based on that o f 
(Loizou et al 1985). M icrotitre plates were coated with cardiolipin, and non-specific 
binding was eliminated by blocking the wells with 10% adult bovine serum. Sera 
diluted 1:50 were incubated in the wells and, after washing to remove unbound 
immunoglobulin, IgG and IgM were detected using enzyme conjugated antisera.
Both IgG and IgM anti-p2 -glycoprotein I antibodies were assayed using a commercially 
available ELISA (DIASTAT™ , Euro-Diagnostica, Arnhem, Netherlands) according to
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the method o f McNally et al (1995b). Briefly, diluted serum or plasma are added to 
microtitre plates coated with purified human P2 -GPI. Bound im munoglobulin is 
detected by means o f an enzyme labelled monoclonal antibody specific for IgG or IgM.
2.8 Endogenous APC ratio (EAPCR)
Acquired resistance to APC was assessed by the degree o f prolongation o f  the clotting 
time, produced by activated endogenous protein C in a modified dRVVT with dilute 
phospholipid. RVV and 0.2 U/ml Protac® (Technoclone). Two phospholipid
preparations were used: Bell and Alton platelet substitute (Diagnostic Reagents Ltd), a 
phospholipid source known to be rich in the zwitterionic phospholipids 
phosphatidylethanolamine and sphingomyelin; and Actin FS (Dade Behring), which is 
‘lupus insensitive’(Brancaccio et al. 1997; Lawrie et al. 1998). The Bell and Alton was 
diluted 1/2 and Actin FS was diluted in imidazole buffer prior to use. At these dilutions, 
the final total phospholipid concentrations were approximately the same. The 
phospholipid content o f a single lot o f both reagents is shown inTablel. These were not 
the reagent lots used in this thesis, so I have assumed that there is reasonable 
consistency between batches.
Table 1: Phospholipid content of preparations used pg/ml. 
From K itchen et al (1999)
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Testing was performed on the CA-6000 coagulometer (Sysmex), which uses light 
scatter at 660 nm to detect clot formation. The phospholipid was titrated to give the 
optimal prolongation of clotting time by activated protein C, yet retain sensitivity to 
antiphospholipid antibodies. Two aliquots of plasma were pre-incubated with dilute 
phospholipid, prior to the addition of Protac to one aliquot, and imidazole buffer 
(0.05M, pH 7.30) to the other. Following a 5 minute incubation, dilute RVV containing 
0.025M CaCb was added and the clotting times were recorded. The method is shown in 
figure 8. Results were expressed as a normalised ratio (EAPCR) against pooled normal 
plasma (PNP).
EAPCR = test with Protac*/PNP with ProtacK 
test with buffer/PNP with buffer
D ouble  spun p lasm a
38 pi i
38 p i phospho lip id  
+ 38 pi PC activato r
5 M inu tes 
at 37°C i
38 p i 
R V V /C aC l-
i
i 38 pi
38 p i phospho lip id  
+ 38 p i b u ffer
i 5 M inutes at 37°C
38 pi 
R V V /C aC T
i
C lot fo rm ation  is de tected  at 660 nm  and the 
resu lts repo rted  as a ratio  no rm alised  against 
poo led  norm al p lasm a
Figure 8 Endogenous APC resistance method
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2.8 Phospholipid vesicle preparation
Di-oleyl-phosphatidylethanolamine (DOPE), di-oleyl-phosphatidylserine (DOPS) and 
di-oleyl-phosphatidylcholine (DOPC) were purchased from Avanti Polar Lipids 
(Birmingham AL, USA), dissolved in chloroform.
The following chloroform dissolved lipids were dispensed into a clean dry 25 ml 
volumetric flask;
5.0 ml o f lOmg/ml DOPE
5.0 ml o f lOmg/ml DOPS
15.0 ml o f lOmg/ml) DOPC
After thorough mixing, 300 pi aliquots were pipetted into Pyrex™  culture tubes 
(Coming). In a fume cupboard, the phospholipids were dried under flowing nitrogen. 
When no chloroform remained the tubes were sealed the with Teflon™ screw tops. The 
tubes were stored at -80°C until required.
Prior to use, one aliquot o f phospholipid was removed from the freezer and brought to 
room temperature. It was then reconstituted in 20ml o f  buffer A. The tube was vortex 
mixed thoroughly for 60 seconds to ensure complete suspension o f phospholipids. The 
emulsion was sonicated for 30 seconds every minute for 40 minutes at 27°C at an 
amplitude o f  6 pm using an MSE Soniprep 1500. This forms unilamellar vesicles o f 
approximately 210 nm (Huang & Thompson 1974). Vesicles were prepared fresh daily 
and kept at room temperature before use. The suspension had to be entirely colourless 
and clear, as a milky appearance indicated that the preparation had deteriorated
In the later section o f this work, I used an alternative stable phospholipid emulsion, 
containing purified phosphatidyl choline, phosphatidyl serine and sphingomyelin 
(kindly provided by Steffen Rosen, Rossix, Molndal, Sweden). Due to the relatively
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noisy signal produced, this was not suitable for studying the kinetics o f  throm bin 
formation, but was perfectly acceptable for measuring the total throm bin generation.
2.9 Sub-sampling thrombin generation method
Reagents
The following reagents were used:
Buffer A, 20 mM Tris buffered saline containing 0.5% bovine serum albumen pH 7.35, 
Buffer B, 20 mM EDTA in buffer A pH 7.9
Buffer C, 20mM Tris buffered saline pH 7.35
Thrombin substrate (Unitrate THR 2AcOH.H-D-CHG-Gly-Arg-pNa, Technoclone) was 
reconstituted in 1 ml o f distilled water and further diluted in buffer A to give a 5 mM 
concentration.
Ancrod (Sigma Aldrich, product number A5042) was reconstituted in distilled water 
and diluted to 5U/ml and frozen in 0.5 ml aliquots at -80°C.
Activated protein C (Eli Lilly, lot: RS0289). Frozen at 500 nM at -80°C. W orking 
strength o f 108 nM was achieved by diluting 1/5 in buffer A.
Calcium Chloride (VWR) was diluted to 100 mM in buffer A (1/10).
Innovin; relipidated human recombinant tissue factor (Dade Behring) was diluted 1/32 
in lOOmM CaCC immediately prior to use.
Plasma preparation
Plasma was treated using Ancrod, an enzyme isolated from the venom o f the M alaysian
pit viper (Agkistrodon rhodostoma), which causes defibrination by the limited
proteolysis o f  fibrinogen. 20 pi o f 5 U/ml Ancrod were added to 600 pi o f plasma in a
1.5 ml microcentrifuge tube. The mixture was mixed with a wooden applicator and
incubated in a 37° water batch for 10 minutes, then placed on ice for a further 10
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minutes. The fibrin clot was removed by winding onto the applicator and excess plasm a 
was squeezed onto the side o f the tube. The defibrinated plasma was microcentrifuged 
at 10,000 g  for 3 minutes and placed on ice until assayed.
Measurement
The reagents were used at the following concentrations
Final reaction mixture Working concentrations
Final Concentration Working concentration
10 nM APC 500nM stock diluted 200pl in 1 ml o f buffer A
1/192 Tissue factor Innovin diluted to 1/32 in 100 mM CaCb
16mM CaCl2 100 mM
25 pM  phospholipid vesicles 400 pM  DOPE, DOPS, DOPC 20:20:60
240 pi o f defibrinated platelet poor plasma and 20 pi o f the phospholipid vesicle 
suspension were pipetted into a siliconised glass cuvette with constant stirring at 37°C 
(1000 rpm using the PAP4 platelet aggregometer, Biodata Corp, Philadelphia, USA). 
After 2 minutes incubation, 10 pi o f the reaction mixture was pipetted into 300 pi o f 
buffer B and mixed by gentle vortex mixing. The presence o f EDTA prevented any 
further reaction. This was the time zero sample. The reaction was started by the addition 
o f 60 pi o f the calcium/tissue factor mixture. 1 0  pi o f this reaction mixture was 
subsampled into 300 buffer B as described above, at the following times intervals: 30, 
40, 50, 60, 70, 80, 90, 100, 110, 120 and 600 seconds
The subsampled aliquots in buffer B were transferred into a micro-cuvette and 
processed using an ACL 300 in ‘Research m ode’. Thrombin activity was assessed by 
measuring the change in optical density at 405 nm, due to cleavage o f 5mM thrombin 
substrate, using the following instrument protocol:
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100 pi sample, 25 pi buffer B and 25 pi substrate, inter-ramp 1 s, time delay 0 s and 
acquisition time 120 s. The data were transferred to a computer and the changes in 
optical density over time were calculated (using the Chromo.dat path in the research 
software).
Two methods o f  assessing thrombin generation were used:
Thrombin activity was plotted against time and the lag phase prior to the start o f 
throm bin formation, the time o f peak thrombin formation and the relative size o f the 
thrombin peak were calculated.
As the endogenous thrombin potential o f a given sample is known to be directly 
proportional to the residual amidolytic activity o f 0 C2 macroglobulin-bound thrombin 
(oc2 M-IIa) (Nicolaes et al 1997) (Tans et al. 2000), the degree o f APCR was measured 
by comparing the ot2 M-IIa levels in the presence and absence o f rhAPC. Resistance to 
APC was expressed as a normalised APC resistance ratio (nAPCsr) which was 
calculated as follows:
nAPCsr — (oi2M “IIa + A P c /^ 2 M - I I a - A P c ) s a m p le /  (ot2 M-IIa + A P c /o ^ 2 M -I I a -A P c )n o r m a l plasma
2.10 Automated thrombin generation method
Reagents
The following reagents were used for this method:
Innovin; lyophilised recombinant human tissue factor (Dade Behring)
Pefachrom® TG, a slow acting thrombin specific substrate; H-p-Ala-Gly-Arg-pNA 
(Pentapharm, Basel, Switzerland)
Human recombinant activated protein C (rhAPC) (Eli Lilly, Indianapolis, IN, USA);
The phospholipids (DOPS:DOPE:DOPC) were prepared as for the subsampling method
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An alternative stable phospholipid emulsion, containing purified phosphatidyl choline, 
phosphatidyl serine and sphingomyelin (Rossix, Molndal, Sweden) was also used.
Automated thrombin generation method
Three reagents are prepared for this method:
• Innovin used at a final dilution o f 1/600 (approximately 7pM, as measured using 
the IMUBIND® Tissue Factor ELISA [American Diagnostica Inc, Stamford, 
CT] was mixed with CaCL (final concentration 15mM) and phospholipid (final 
concentration 20 pM).
• Innovin, CaCL, phospholipid and rhAPC (final concentration 5nM)
• Pefachrome TG diluted to 3.3 nM
Thrombin generation was measured with and without exogenous rhAPC, using the 
ACL9000 (Instrumentation Laboratory, Milan, Italy). This is an automated centrifugal 
analyser, which can measure changes in optical density (OD) at 405 nm. Plasma was 
defibrinated by the addition o f 0.2 U/ml Ancrod at 37°C for 10 minutes, followed by a 
further 10 minutes on ice and manual removal o f  fibrin, prior to analysis. Two start 
reagents were prepared, containing dilute tissue factor, CaCL (final concentration 16 
pM ) and phospholipid (final concentration 20pM). rhAPC in tris buffered saline, pH 
7.35 (final concentration 5nM) was added to one start reagent, while only buffer was 
added to the other. A fter warming the plasma, start reagent and thrombin substrate to 
37°C, the coagulometer mixed the reactants together and measured the optical density at 
405nm at 2-second intervals over a period o f  1000 seconds. The short time interval 
between measurements results in a ‘noisy’ signal, which was overcome by using a 
moving average algorithm to smooth the signal. The raw data was transferred to a 
personal computer, imported into Microsoft® Excel®, and, following curve smoothing, 
using a simple moving average (the unweighted mean o f the last 8  data points), the ETP
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was calculated from the area under the curve as described by Hemker and Beguin 
(Hemker & Beguin 1999). This allowed the data to be displayed cumulatively or as the 
rate o f thrombin generation against time, and the calculation o f total throm bin 
generation, lag phase to the start o f thrombin generation and peak throm bin generation. 
This provided important information about the kinetics o f thrombin formation. Total 
thrombin formed, with and without 5nM rhAPC, were expressed as ratios relative to 
pooled normal plasma (PNP) as suggested by Rosing et al (2004)
ETP = thrombin formed in patient plasma/thrombin formed in PNP, with no APC 
ETP+APC = thrombin formed in patient plasma /thrombin formed in PNP, with 5nM APC
2.11 Prothrombin assay
Plasma prothrombin levels were measured in a one-stage clotting assay using factor II 
immunodepleted plasma (Technoclone) and Thromborel S (Dade-Behring, Germany).
2.12 Factor V Leiden and prothrombin gene mutation analysis
Factor V Leiden and prothrombin gene mutation (G20210A) were assessed by PCR and 
electrophoresis (Poort et al 1996, Bertina 1997).
2.13 TFPI antigen ELISA
Total TFPI antigen was assayed using the IMUBIND® Total Tissue Factor Pathway 
Inhibitor ELISA kit (American Diagnostica). This is a quantitative sandwich ELISA 
employing a rabbit anti-human TFPI polyclonal capture antibody and a biotinylated 
monoclonal antibody, specific for the Kunitz domain 1 o f TFPI. This assay recognises 
native, truncated and conjugated forms o f TFPI
2.14 Automated TFPI sensitivity index
In order to assess TFPI function, I adapted a method from (Dahm et al. 2005). The 
method was in essence a dilute thromboplastin time, in which the plasmas were
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incubated in the absence and the presence o f saturating amounts o f a rabbit polyclonal 
antibody, that blocked TFPI function (American Diagnostica Inc). It was found that a 
concentration o f 250 mg/ml and an incubation time o f 15 minutes gave optimal 
inhibition o f TFPI function (Table 2). This is much longer than the original method with 
this antibody, perhaps reflecting differences in the avidity o f the antibodies used. 
Testing was performed on the ACL7000 by incubating the treated plasma with human 
recombinant tissue factor (Innovin, Dade Behring) diluted at 1:300 in tris buffered 
saline for 5 minutes. Coagulation was triggered by the addition 35mM CaC12. Results 
were expressed as a ratio with the clotting time in the presence o f anti-TFPI as the 
denominator. The ratio was normalized against a ratio obtained with pooled normal 
plasma. Due to the exceptionally low phospholipid concentration used, this test is 
exquisitely sensitive to residual platelet contamination, so double centrifugation o f 
plasma was essential. Acceptable within run and between run imprecision was obtained 
for the dilute thromboplastin clotting times with and without anti-TFPI antibody; 
percentage coefficient o f variation 1.86% and 1.39% (within run); 2.20% and 2.48% 
(between run) respectively.
Table 2: Titration o f anti-TFPI antibody
Ab
dilution
Stock
250
mg/ml
1 / 2 1/4 1 / 8 1/16 1/32 1/64 1/128 1/256 Plasma
only
Run l 64.2 70.7 72.4 69.9 72.2 71.7 71.4 72.7 71.7 74.4
Run 2 65.4 66.2 67.4 68.9 70.2 70.7 70.9 71.4 71.4 75.2
Mean 64.8 68.45 69.9 69.4 71.2 71.2 71.15 72.05 71.55 74.8
2.15 Anti-TFPI antibody detection by ELISA
Anti-TFPI antibodies were measured by ELISA using the following method based on 
that o f Wolberg et al (2004) . Polystyrene microtitre plates (Nunc Maxisorp, Nalge 
Europe Ltd. Hereford, UK) were coated with full-length recombinant TFPI (Chiron 
Corporation, Emeryville, CA, USA) at 5 mg/mL in 0.1M carbonate/bicarbonate buffer,
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overnight at 4°C. The wells were washed in phosphate buffered saline (PBS - pH 9.6) 
containing 0.05% Tween-20. The wells were blocked with PBS/tween buffer 
containing 1% bovine serum albumin for 1 hour at room temperature. Samples, diluted 
1 : 1 0 0  in the blocking buffer, were added to the wells and incubated at room temperature 
for 2 hours. After washing in PBS/Tween, bound IgG or IgM were detected by the 
addition o f  alkaline phosphatase-conjugated goat anti-human IgG or IgM (Sigma 
Aldrich, Poole, UK), diluted 1:2000 in blocking buffer. After 2 hours incubation, the 
plates were washed and 1 mg/mL disodium hexahydrate phosphatase (Sigma) diluted in 
1M diethanolamine buffer (pH 9.8, Sigma) was added to the wells. After 20 minutes, 
the reaction was stopped by the addition o f 3M sodium hydroxide and absorbance was 
measured at 405nm. Normality was defined as the 99th percentile o f 25 normal healthy 
subjects.
2.16 Factor VIII assay
Plasma factor VIII concentration was measured by a one-stage APTT based clotting 
assay, using Pathromtin SL (Dade Behring) and immunodepleted factor VIII deficient 
plasma (Technoclone). All assays were performed at three dilutions to ensure linearity 
using the multi dilution analysis function o f the CA-1500 coagulometer (Sysmex).
2.17 Affinity purification of immunoglobulin IgG
IgG fractions from patients with APS and from normal healthy individuals were 
purified using a protein G sepharose column (Amersham Biosciences, Little Chalfont, 
UK). Briefly, following equilibration with PBS, defibrinated plasma or serum was 
applied to the column, which was then washed with PBS. Immunoglobulin was eluted 
using 0.1 M glycine at pH 2.8, and immunoglobulin fractions were detected by 
measuring absorbance at 280nm. IgG was quantitated assuming an extinction 
coefficient o f 13.6 at 280nm.The fractions were dialysed using an Amicon Mini-
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Ultrafiltration Cell across a PM30 membrane into PBS, or desalted using Sephadex G25 
gel filtration (Amersham Biosciences) and freeze-dried in 16 m g/m l mannitol. The 
freeze-dried preparations were dissolved directly into defibrinated PNP for the IgG 
spiking experiments.
2.18 Affinity purification of immunoglobulin IgM
Purification o f IgM can be problematical as there is no single step procedure available, 
which does not result in low yield or a high degree o f impurity. Initial experiments were 
performed using the method Roodbari et al (2003). Briefly, an IgM-rich fraction was 
prepared by precipitating with polyethylene glycol 6000 (PEG-6000). This employed a 
two-step procedure to eliminate unwanted proteins and prepare an IgM -rich fraction. 
First, serum or defibrinated plasm a was diluted 2.5-fold in 20 mM potassium phosphate 
buffer, pH 7.4, and was placed in a magnetic stirrer. Then 40% PEG solution was added 
dropwise to achieve a final concentration o f 3% PEG in the mixture. After 1/2 h o f 
gentle stirring, the mixture was centrifuged at 3,000g for 15 m inand the supernatant was 
collected. In the second step, a 40% PEG solution was added as in step 1 to reach a final 
concentration o f 8 %. The solution was incubated overnight in a refrigerator, and IgM- 
rich precipitants were separated by centrifugation and kept at 4°C. This was then 
purified using a sephacryl column (see next section). However, preliminary experiments 
produced a poor yield and this approach was abandoned.
Sephacryl Column separation
A Sephacryl™ S-300 HR was prepared by suspending in 20:80 ethanol/PBS and 
allowing the column to slowly settle in order to eliminate air bubbles. The column was 
then equilibrated with 1% Sodium azide/PBS. 10 ml o f plasma was defibrinated with 
Ancrod, introduced to the column and eluted at a rate o f 1.5ml/minute. 7 ml fractions 
were collected and protein content was assessed by measuring OD at 280nm using an 
ultraviolet spectrophotometer. The relative IgM content was measured using an IgM
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enzyme linked immunosorbent assay (ELISA). Further purification was achieved using 
a thiophilic adsorption medium (2-mercaptopyridine coupled to Sepharose, Amersham 
Hi-Trap IgM column, GE Healthcare Life Sciences, Amersham, UK). D esalting was 
achieved using a Sepaphdex™  G-25 column (PD-10 desalting column GE Healthcare 
Life Sciences) equilibrated in 16mM mannitol. The purified IgM fractions were eluted 
in 16nM mannitol by gravity. Protein concentration was quantitated assuming an 
extinction coefficient o f 14 at 280nm. 5ml aliquots o f purified IgM were freeze-dried in 
16 mg/ml mannitol. The freeze-dried preparations were dissolved directly into 
defibrinated PNP for the IgM spiking experiments.
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Chapter 3. Factors influencing commercial protein C pathway 
screening tests
3 .11ntroduction
Routine thrombophilia screening generally requires the assay o f protein C, protein S and 
APC resistance/factor V Leiden. Accurate diagnosis may require the use o f antigenic, 
chromogenic and clotting assays in order to exclude or confirm a defect. These assays 
are frequently technically difficult, time consuming and expensive. At the inception o f 
my thesis, several manufacturers had developed methods for the global assessment o f 
the protein C pathway. These tests therefore appeared to provide a simple way o f 
identifying aPA patients with defects in the protein C pathway for further investigation.
When first muted in the literature, the idea o f  a single global screening test for defects in 
the natural anticoagulant pathways seemed an appealing idea. However, the validity o f 
the claims made regarding the sensitivity and specificity o f these assays, had not been 
independently verified and the issue o f aPA interference had not been addressed. As 
aPA are known to affect so many other phospholipid dependent coagulation tests, at the 
very least, one would expect the baseline clotting test to be prolonged by LA activity in 
some instances. It has been known for some time that functional protein S assays can 
give falsely low results compared to antigenic assays in the presence o f LA (Lawrie et 
al. 1995). It was reported at the time that the results could not be explained by activated 
protein C resistance, and that lupus anticoagulant caused prolongation o f the baseline 
clotting time within the protein S activity assay. However, Malia et al (1990) reported 
that some antiphospholipid antibodies inhibited the activated protein C/protein S 
complex in vitro.
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In order to establish the best way to study aPA interference in the protein C pathway, I 
decided that it made sense to first study the tests already available for assessing the 
protein C pathway, and determine the factors affecting these assays.
3.2 Materials and methods
Samples for this study were collected from both UCLH and the Royal Hallamshire 
Hospital, Sheffield, in order to obtain sufficient samples from patients with congenital 
defects in protein C and S (which are relatively rare), who were not receiving oral 
anticoagulants.
3.2.1 Patients and samples
Reference ranges, from 40 healthy normal volunteers (pregnant women were excluded) 
for each method. In addition, reference ranges for the ProC Global (Dade Behring) and 
Diagen PCA (Diagnostic Reagents Ltd.) tests were determined with factor V deficient 
plasma correction. PT and APTT were also performed on all samples to exclude 
underlying coagulation abnormalities. As many o f the clinical groups included patients 
receiving combined oral contraceptives (COC), it was thought inappropriate (at the 
time) to exclude women taking COCs from the control group. None o f the patients were 
receiving heparin or warfarin, nor were they suffering from an acute thrombotic event at 
the time o f testing.
Plasma samples from the following patients were tested
• 11 patients with congenital protein C deficiency
• 19 patients with congenital protein S deficiency
• 23 patients with the factor V Leiden mutation
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• 20 patients investigated for thrombophilia as defined by the BCSH guidelines 
(Greaves et al 2001), but with no known anti-phospholipid antibodies or defects 
in the protein C system
• 16 samples from patients with LA as defined by the BCSH guidelines (Greaves 
et al 2 0 0 0 ).
3.2.2 Global protein C pathway screening tests
The four screening tests studied were:
a) ACTICLOT® V-OUT (American Diagnostica)
b) PCA test (Diagnostic Reagents Ltd)
c) GradiThrom PCP (Gradipore)
d) ProC® Global (Dade Behring)
These were performed as described in the methods chapter
3.2.3 Statistical analysis
Instrument-specific reference ranges were used and, since most o f the data groups in 
this study were skewed and this was not always corrected by log conversion, the 2.5th 
percentile was used to define normality. Non-parametric tests were employed 
throughout and the level o f significance was taken as P<0.05.
3.3 Results
Acceptable within-run im precision was obtained, with a coefficient o f variation o f <7% 
for all tests using a range o f normal and abnormal controls. Between run imprecision 
was <10%. Reference ranges were established in forty healthy normal subjects. Plasma 
from two women believed to be using the oral contraceptive pill, and from another
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subject with an acute phase reaction, gave values that were clear outliers (below the 
2 .5 th percentile) by all methods and these results were subsequently excluded from the 
statistical analysis (table 3).
Table 3: R eference ranges from normal subjects (n = 37)
V-OUT PCA PCP ProC ProC NR
M ean 5 .5 6 13.51 7 .47 3 .34 1 .05
SD 1.17 3 .79 2 .2 7 0 .48 0 .1 5
M ean - 2 S D 3.22 5 .93 2 .9 4 2 .3 8 0 .7 5
M edian 5.27 13.16 7.30 3.31 1 .04
5th percentile 4 .2 0 7.01 4.31 2 .7 0 0 .8 5
NR =N orm alised ratio
The characteristics o f  the patients with protein C deficiency, protein S deficiency, factor 
V Leiden and LA are presented inTable4. The dilute Russell’s viper venom time 
(dRVVT) ratios reported were those obtained with the dilute phospholipid screening 
reagent. All patients selected because o f  a history o f  LA proved to positive again on this 
occasion. Protein S values are free protein S antigen levels determined by ELISA and 
protein C values are functional (chromogenic) levels. All factor V Leiden cases were 
detected using the Coatest APC resistance test, then were confirmed by RFLP and PCR.
Table 4: Characteristics of patients studied.
Results
Clinical group Sex Mean
(standard
deviation)
Range Reference range
Congenital protein C deficiency [protein C 
(lU /m l)]
Congenital protein S deficiency [free protein S 
(IU/ml)]
Lupus anticoagulant [dRVVT ratio]
Male (n = 5)
Female (n = 6) 
Male (n = 5)
Female (n = 14) 
Male {n = 6) 
Female (n = 10)
0.60 (0.02)
0.56 (0.06) 
0.65 (0.05)
0 .4 0 (0 .1 5 )
1.38 (0.25)
1.38 (0.22)
0 .5 7 - 0 .6 3
0 .4 6 - 0 .6 2
0 .5 8 - 0 .6 9
0 .1 7 - 0 .5 7
1 .1 4 - 1 .8 0
1 .1 5 -  1.75
0 . 7 0 -  1.30
0.73 - 1.76
0 . 5 8 -  1.14 
< 1.13
Factor V Leiden [factor V Leiden phenoty pe] Heterozygous H om ozygous
Male (n = 7) 5 2
Female (n = 16) 15 1
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a) No sex specificic differences in normal subjects were found with the V-OUT 
method so a single 2.5th percentile normal cut-off was used. Using this value, all 
factor V Leiden were correctly identified by the V-OUT method (figure 9). The V- 
OUT method was relatively insensitive to protein C deficiency [27% (3/11) 
identified. Only 35% (6/17) of protein S deficiencies gave results below the 2.5th 
percentile. 5% (1/20) of the thrombophilia samples and 30% (6/20) o f the LAC 
samples gave abnormal results.
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Figure 9: Plot o f A cticlot V -O U T  ratios.
Norm al su b je c ts , factor V  L eiden  (FVL), protein C d e fic ien cy  (PC  def), protein S  
d efic ien cy  (P S  def), L upus a n ticoagu lan t (LA) and throm bophilia . T h e broken line  
in d icates th e  2 .5 th  p ercen tile  of norm al.
63
b) All cases of factor V Leiden were correctly identified by the PCA method, with 
excellent discrimination between the normals and factor V Leiden samples 
observed (Figure 10). Abnormal PCA results were obtained in 55% (6/11) and 
47% (8/17) of the protein C and protein S deficiencies, respectively, whereas 
unexpected abnormal results were obtained in 5% (1/20) and 35% (6/17) o f the 
thrombophilia and LA positive samples, respectively.
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Figure 10: Plot of Diagen PCA test ratios.
Normal subjects, factor V  Leiden (FVL), protein C deficiency (PC def), protein S defic iency (PS 
def), Lupus anticoagulant (LA) and thrombophilia. The upper broken line indicates the 2.5th 
percentile o f normal males. The lower broken line indicates the 2.5th percentile o f normal 
females.
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c) All samples from patients with factor V Leiden fell below the 2.5th percentile of 
normal when tested with the PCP method (Figure 11). Seventy-three percent 
(8/11) of protein C deficiencies and 53% (9/17) of protein S deficiencies gave 
ratios below the 2.5th percentile. Ratios below the 2.5th percentile were 
obtained in 5% (1/20) of the thrombophilia samples and 29% (5/17) of the LAC- 
positive samples.
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Figure 11: Plot of G radipore P C P  te s t  ratios.
Normal subjects, factor V Leiden (FVL), protein C deficiency (PC def), protein S 
deficiency (PS def). Lupus anticoagulant (LAC) and thrombophilia (Thromb). The 
upper broken line indicates the 2.5th percentile of normal males. The lower broken line 
indicates the 2.5th percentile of normal females.
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d) All ProC values were reported as normalised ratios (NRs). No sex specific 
differences were observed in the normal subjects, so a single 2.5th percentile 
value was used. All factor V Leiden samples were correctly identified (Figure 
12). NR values less than the 2.5th percentile were observed in 55% (6/11) o f 
protein C-deficient samples and 35% (6/17) o f protein S-deficient samples. Low 
NR were observed in 10% (1/20) o f thrombophilia sample and 35% (6/17) LA- 
positive samples.
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Figure 12: Plot o f ProC Global normalised ratios.
Normal subjects, factor V  Leiden (FVL), protein C defic iency (PC def), protein S defic iency (PS 
def), Lupus anticoagulant (LAC) and throm bophilia. The broken line indicates the 2.5th 
percentile o f normal.
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As expected, predilution with factor V-deficient plasma gave much tighter reference 
ranges when used with the PCA and ProC methods (Figure 13). All factor V Leiden 
plasmas were correctly identified by both methods, using the 2.5th percentile cut-off 
value. Furthermore, the three samples from homozygous factor V Leiden patients were 
clearly discriminated using predilution.
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Figure 13: Diagen PCA test and ProC Global tests with predilution in factor V depleted plasma.
Upper broken lines indicate the 2.5th percentiles for normal fem ales and the lower broken lines 
show the 2.5th percentile for normal males. Open circles represent fem ales and closed circle 
represent males.
Plasma samples from seventeen patients with lupus anticoagulant, but no evidence o f
specific defects in the protein C system, were studied. Ten patients had abnormal APTT
results, and all had abnormal dRVVT. All four methods gave low ratios with 29 - 35%
o f samples (Table 5). There was considerable variation, between both the methods with
different samples giving abnormal results with different methods. In many cases the
abnormal ratio was due to prolongation o f the baseline clotting time, i.e., the APTT or
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venom clotting time without Protac® or exogenous APC. Not surprisingly, abnormal 
baseline clotting times for the PCA and ProC tests were found in those patients with 
abnormal APTT results (Table 6 ). However, some low ratios were caused by a reduced 
response to APC or Protac® resulting in only a mild prolongation in the clotting time by 
APC. Furthermore, in samples from three patients this finding was consistent with all 
four methods.
Table 5: Plasm a from patients with Lupus anticoagulant (n = 17)
V-OUT PCA PCP ProC ProC NR
Mean ratio 5.09 9.38 6.04 3.44 1.04
SD 1.73 4.25 2.49 2.08 0.66
2.44 2.29 2.09 2.01 0.57
Maximum 8.65 15.79 10.15 11.14 3.50
Below 5th 6 6 5 6 6
percentile (35%) (35%) (29%) (35%) (35%)
NR =Normalised ratios
A similar picture was obtained with the ProC Global test when the plasm as were
prediluted with factor V deficient plasma (Table 6 ). Surprisingly, a higher proportion o f
patients gave abnormal results with the PCA test when the plasm a was prediluted in
factor V depleted plasma, than when untreated plasm a was used, although this may be
due in part to narrower normal reference ranges when predilution was employed.
Table 6: Plasm a from patients with Lupus anticoagulant - factor V deficient plasm a added  
(" = 17)_______________________________________________
PCA test ProC Global
Mean ratio 4.84 2.76
SD 0.85 0.44
Minimum 2.92 2.18
Maximum 5.91 3.52
Below 5th percentile 10(59% ) 5 (29%)
In order to ascertain whether these abnormal ratios were as a result o f LA activity or 
the inhibition o f the APC pathway, I studied the individual clotting times and compared 
them to the reference ranges (Figures 14 and 15).
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Figure 14: Raw clotting times for normal (blue) and LA positive (red) plasmas in the absence of 
protein C activation.
(The so lid  horizontal lin es rep resen t th e  9 7 .5 th p ercen tile  for each  m ethod)
550 r
50
V-OUT PCA PCA ProC PCA+Vdef ProC +Vdef
Figure 15: Raw clotting times fo r normal (blue) and LA positive (red) plasmas with protein C 
activation.
(The solid horizontal lines represent the 97.5th percentile for each method).
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The rate o f abnormal results was highly variable, with between 0 and 9 o f the LA 
positive plasmas giving an abnormal result, in the absence o f protein C activation, and 
between 3 and 10 o f the LA positive plasmas showing a reduced response to protein C 
activation. Agreement between methods was also variable with kappa coefficients 
ranging from -0.08 to 0.90, the best agreement being found between the two APTT 
based methods without protein C activation (Table 7). There was more consistent 
agreement between samples dem onstrating a poor response to protein C activation, with 
samples LA4 and L A I5 giving abnormal results by all methods. The association 
between LA positivity and a poor response to activated protein C was more variable 
still, with the PCP method showing strong association (kappa = 0.82), the V-OUT and 
PCA test showing little or no association and the ProC test demonstrating a negative 
association with and without predilution in factor V deficient plasma (kappa = -0.42).
Table 7: Abnormal results for protein C pathway tests in LA positive plasmas (Positive dRVVT). 
Samples LA1, LA3, LA5, LA6, LA9, LA10, LA11, LA12, LA14 and LA17 had prolonged APTTs
No protein C activation Protein C activator add ed
ID V-OUT PCP PCA
PCA
+Vdef ProC
ProC
+Vdef V-OUT PCP PCA
PCA
+Vdef ProC
ProC
+Vdef
LA1 - - + + + - - - - - - -
LA2 - - - - - - - - - - + -
LA3 - - + + + - + - + + - -
LA4 - + + - - - + + + + + +
LA5 - - + - + + - - - - - -
LA6 - - + - - + - - - + - -
LA7 - - - - - - - - - + + +
LA8 - - - - - - - - - + - +
LA9 - - - + - + - - - + - -
LA10 - - + - - - - - - - - -
LA11 - - + + + + - - - + - -
LA12 - - - - - - - - - - + -
LA13 - - - - - - - - - - - -
LA14 - - + - + - + - - - - -
LA15 - + + - - - + + + + + +
LA16 - + - + + - - + - + + -
LA17 - + + + + - + - + + - +
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3.4 Discussion
Four methods, designed to screen for defects in the protein C pathway were studied. 
2.5th and 97.5th percentiles o f  the normal samples were used to determine normality. 
Three samples, which gave values well below the 2.5th percentile by all methods, were 
excluded from the normal reference range. Two were from women using com bined oral 
contraceptives, while the other had an acute phase response. High factor VIII:c levels 
(Chitolie et al. 2001), characteristic o f an acute-phase reaction, and/or low protein S 
levels, associated with pregnancy, horm one replacement therapy and certain combined 
oral contraceptives (Rosing et al. 1997), are known to affect APC ratios, possibly 
leading to misdiagnosis.
One method used both exogenous APC and activation o f endogenous protein C (V- 
OUT), while the other methods rely exclusively on the activation o f endogenous protein 
C. The V-OUT and ProC methods showed no significant differences between results for 
male and female normal subjects, whereas the PCA and PCP methods, males gave 
significantly higher values than females and, consequently, sex-specific cut-off ratios 
were employed. The two APTT based methods were also performed following 
predilution o f plasmas with factor V-deficient plasma, and this produced a narrower 
spread o f  results. The addition o f  factor V-deficient plasma did not eliminate the sex- 
specific differences as may have been expected.
Detection o f APCR due to the factor V Leiden mutation is prerequisite for any method 
intended to assess the protein C pathway, and all factor V Leiden positive samples were 
correctly identified by all methods. However, the degree o f separation between normal 
subjects and samples from patients with factor V Leiden was variable. Predilution o f the 
test samples in factor V-deficient plasma produced clearer separation between normals, 
heterozygotes and homozygotes, but as would be expected, massively reduced the
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sensitivity to protein C and S. The three methods relying on the activation o f 
endogenous protein C alone achieved 55-73%  sensitivity to protein C deficiency, 
whereas the method using additional exogenous APC detected protein C deficiency in 
less than 30% of the plasmas tested. None o f  the methods were able to consistently 
identify protein S deficiencies, with sensitivities ranging from 11 to 47%.
Some plasmas from patients with thrombophilia, as defined by BCSH guidelines 
(Greaves et al 2001), but no evidence o f protein C deficiency, protein S deficiency, 
lupus anticoagulant or factor V Leiden, gave low ratios with different methods. It was 
o f interest that one patient, who had no known defect associated with throm bophilia, 
had low ratios by all three Protac®-based methods. This was in line with recent reports 
suggesting that ‘Global tests’ for throm bophilia may identify patients with yet 
undefined risk factors for thrombosis (Grand'M aison et al. 2005; Robert et al. 1999). As 
my work progressed, I discovered several possible mechanisms for acquired APC 
resistance, and, during this time the scientific community started to regard acquired 
resistance to APC as more than an ‘artefact’ or ‘false positive’ result (Koenen et al. 
2003; Liestol et al. 2007; Robertson et al 2006; Tans et al. 2003). The mechanisms 
responsible came to dominate my thesis and are discussed in detail in the later chapters.
All four methods demonstrated excellent sensitivity for factor V Leiden when suitable 
cut-off values for normality were applied. However, all methods showed poor 
sensitivity for protein S deficiency, and only moderate sensitivity for protein C 
deficiency. Previous studies o f some o f these tests have demonstrated poor sensitivity to 
protein S deficiency, but have reported better detection rates for protein C deficiency 
(Haas, Sterkenburg-Kamp, & Scheepers 1998; Ruzicka et al. 1997; Toulon et al. 2000; 
Tripodi et al. 1998). There are several possible causes for the differences between this 
study and previous reports. I employed sex-specific protein S reference ranges (using 
healthy males and females, not known to be receiving drugs or hormones thought to
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affect coagulation tests), which in several cases have resulted in a diagnosis o f  protein S 
deficiency at levels in excess o f  the 0.70 IU/ml cut-off used in many o f these studies. 
Pre-analytical variables are also o f  prime importance in APCR testing; in our present 
study, all samples were double centrifuged at room temperature and stored at < 70°C for 
no longer than 12 months. Frozen plasm a samples were thawed in a waterbath at 37°C 
immediately prior to use and were not refrozen. It has been shown that A PCR testing is 
exquisitely sensitive to residual platelet contam ination o f plasma (Taube et al. 1999) 
and that clotting tests are affected by cold activation (Czendlik, Lammle, & Duckert 
1985; Palmer & Gralnick 1982) yet, in several o f the previous studies, plasm a was 
prepared by a single cold centrifugation step. Furthermore, it has recently been reported 
that protein S is unstable in plasma stored at -24°C (W oodhams et al. 2001) and that 
storage below -70°C is advisable, yet in the largest o f the published studies some 
samples were stored at -30°C. It was clear that these methods lacked sensitivity to 
protein C and protein S deficiencies, and although, they were suitable for the exclusion 
o f factor V Leiden, providing that predilution in factor V-deficient plasm a was used, 
they lacked specificity for factor V Leiden and could not replace the need for 
confirmation by PCR
In most o f the published studies o f methods for the assessment o f  the protein C 
pathway, testing for aPA was not performed, yet these antibodies are known to interfere 
with global clotting tests and protein C/protein S activity assays and are an important 
cause of the APCR phenotype in the absence o f factor V Leiden (Bokarewa et al. 1994; 
Malia et al. 1990; M arciniak & Romond 1989). Consequently, it came as no surprise 
when I found low ratios in 18-35%  o f LA-positive plasmas. As would be expected, in 
some cases abnormal ratios were due to prolongation o f the basal clotting time without 
protein C activation, due to lupus anticoagulant activity. However, there were striking 
differences between methods, with one (V-OUT) producing no abnormal basal clotting
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times at all, and between four and ten prolonged clotting times using the other three 
methods. There was some agreement between the two APTT based methods, but it was 
abundantly clear that different plasm as caused prolongation o f different methods. This 
is in keeping with previous studies at this centre, which confirmed that no single test is 
capable o f detecting all LA (Gardiner et al 2000; Lawrie et al. 1999). Predilution in 
factor V deficient plasma failed to correct the prolonged clotting times in 10/17 cases, 
indicating that a potent inhibitor o f in vitro coagulation was present.
However, it was clear that prolongation o f  the basal clotting times was not enough to 
explain the abnormally low ratios observed. A failure o f the endogenous and/or 
exogenous APC to prolong the clotting time was observed in 13/17 plasm a samples. 
Again, this finding was not consistent between methods, but good agreement was 
observed between the two viper venom based assays. Somewhat surprisingly, this effect 
was more apparent when the plasmas were prediluted in factor V deficient plasma. I 
looked for an association between the LA activity apparent in the screening test and the 
poor anticoagulant response to APC, but while this was apparent using one o f  the viper 
venom tests (PCP), there was no association for the other tests. Indeed, the converse 
appeared to be true for the ProC Global assay.
While it was clear that APC resistance was associated with LA in some patients, this 
was not a consistent finding. Although I knew little about the specific com position o f 
the individual reagents, it was clear that the V-OUT method used either a high 
concentration o f phospholipid, a Tupus insensitive’ phospholipid, or a com bination o f 
the two, as the basal clotting time was not prolonged by any o f the seventeen LA 
positive plasmas tested. Yet, six o f these plasmas demonstrated resistance to APC. 
While I had not demonstrated that aPA were responsible, the fact that predilution 
increased the resistance to APC strongly suggested that an inhibitor was responsible for
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this phenomenon. As the plasmas were all from patients with APS, it seemed reasonable 
to attribute the inhibition o f APC to an aPA; at least as a working hypothesis.
In the development o f these ‘protein C pathw ay’ screening tests, the m anufacturers’ 
attempted to attenuate the “artefacts” caused by aPA, by using high concentrations o f 
phospholipid, ‘lupus insensitive’ phospholipid and mixing with factor V depleted 
plasma. During the course o f this investigation it occurred to me that, rather than 
viewing acquired APC resistance as an inconvenient artefact, I should investigate this 
phenomenon as a possible marker for the throm botic disease in APS and the potential 
role of aPA interference in the protein C pathway in the pathogenesis o f APS. The 
paradoxical association between the prolonged clotting time caused by LA and 
thrombosis has puzzled me, and others, for many years. If  aPA were somehow 
responsible for acquired APC resistance, then this seemed to me a much more plausible 
explanation for their mode o f action than prolonging clotting times.
In order to investigate this further, I devised methods for measuring the anticoagulant 
response to APC, which were sensitive to aPA so I aimed to investigate whether this 
phenomenon was antibody dependent and, if  so, study the specificity o f  the antibodies 
responsible.
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Chapter 4. The Detection of Acquired APC Resistance using a 
novel clotting test
4 .1 1ntroduction
There is a great deal o f heterogeneity o f  antibody populations, concentration and avidity 
amongst patients with aPA and not all o f  the target antigens are represented by the 
antibodies detected by the typical clinical laboratory. As discussed in the previous 
chapter, plasma from some patients with APS interferes with the protein C pathway and 
this may manifest as APC resistance in the absence o f  the factor V Leiden m utation 
(Aznar et al. 1997; Malia et al 1990; M arciniak et al 1989; Rosing et al. 2004; Sarig et 
al. 2002; Tans et al 2003). Consequently, a num ber o f approaches have been used in 
attempts to attenuate this effect and to improve the specificity for factor V Leiden, 
including dilution in FV deficient plasma (Ivey et al. 2000; Le et al. 1995), use o f 
reagents containing concentrated phospholipid (Haas et al 1998) or mixing patient 
plasma with normal plasma prior to testing (Jacobsen & W isloff 1997).
It is known that APCR, even in the absence o f  factor V Leiden, is a risk factor for 
venous thromboembolic disease (VTE), both with (Male et al. 2001) and without aPA 
(de Visser, Rosendaal, & Bertina 1999). As most coagulation reactions require anionic 
phospholipids, in particular phosphatidyl serine (PS), and interference with anionic 
phospholipids is associated with LA, the importance o f other phospholipids is 
frequently overlooked in this setting. However, the inactivation o f factor Va is greatly 
enhanced by the presence o f zwitterionic phospholipids, including 
phosphatidylethanolamine (PE) (Smirnov et al 1994), glucosylceramide (Yegneswaran, 
Deguchi, & Griffin 2003) and sphingomyelin (SM) (Deguchi, Fernandez, & Griffin 
2002; Pecheniuk 2003). Cardiolipin, which is a component o f the normal plasma 
lipoprotein fraction (Deguchi et al 2000), also enhances the anticoagulant function o f 
the protein C pathway at physiological levels o f cardiolipin (Fernandez et al 2000).
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There have been several reports o f “antibodies to phosphatidylethanolam ine” as the 
only antiphospholipid antibodies, in patients with unexplained thrombosis (Sanmarco et 
al. 2001) (Berard et al. 1996) and vascular cutaneous diseases (Karmochkine et al. 
1992), although it is now known that these antibodies are directed against 
phosphatidylethanolamine bound proteins o f  the kallikrein/kinin system (Sugi & 
McIntyre 1996); (Katsunuma et al. 2003; Sugi et al 1996). Furthermore, it has been 
shown that some lupus anticoagulant activity can be inhibited by hexagonal phase 
phosphatidylethanolamine in the presence o f prothrom bin (Rauch et al. 1998).
I used these phenomena to develop a highly sensitive test for aPA-associated APCR, 
with the intention o f investigating the incidence o f  acquired APC resistance. As 
previously mentioned, currently available APCR tests are designed to be insensitive to 
aPA and so I used a dilute phospholipid preparation, o f known formulation, containing 
both phosphatidylethanolamine and phosphatidylserine, which I predicted would be 
sensitive to aPA interference in the protein C pathway. The test was, in essence, a 
modified R ussell’s viper venom time performed with and without endogenous protein C 
activation in the presence o f rate limiting amounts o f phospholipid. I hoped in this way, 
that I could get a better indication o f the prevalence o f acquired APC resistance and 
possible contributing mechanisms responsible. As no exogenous protein S was added to 
the assay, the effect o f free protein S antigen was studied, as I suspected that this might 
be a confounding variable.
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4.2 Methods
4.2.1. Patients and blood samples
Blood was collected and plasma prepared as described in the M ethods chapter. Forty- 
four patients with aPA referred to the UCLH thrombosis outpatient clinic were included 
in the present study (eight men and 36 women, mean age 41.7 years, age range 17-74 
years). All had LA, anti-p2GPI, and/or aCL on two or more occasions at least 6  weeks 
apart. None o f the patients had an acute thrombotic event, were receiving anticoagulants 
or were known to be pregnant at the time o f  testing. Their laboratory data are 
summarized inTable8 . 32% of patients were positive for lupus anticoagulant alone, 36% 
had raised aCL titres alone, while 33% dem onstrated both lupus anticoagulant and aCL 
positivity. 28% displayed positivity for anti- (32GPI, o f  which half also had LA activity. 
Forty-two o f the aPA positive patients had no underlying autoimmune disease, while 
two patients had aPA that were secondary to systemic lupus erythematosus (SLE). 
Twenty-four had a history of thrombosis (twelve patients had venous 
thromboembolism, seven had arterial stroke, three had cerebral ischaemia secondary to 
arterial disease, and two had transient ischaemic attacks). Ten women had a history o f  
aPA-associated pregnancy morbidity; three had early fetal loss (< 20 weeks) and 
seven had late obstetric complications (intrauterine fetal death, placental insufficiency, 
or premature birth due to preeclampsia). The remaining 10 aPA-positive patients had 
immune thrombocytopenic purpura (n = 3), migraine (n = 3), SLE (<n = 2) or were 
asymptomatic with aPA found coincidentally following routine coagulation testing (n = 
2).
A control group o f 20 patients attending the haematology outpatient clinic (three men 
and 17 women, mean age 41.1 years, age range 14-68 years), who were negative for 
aPA or protein C pathway defects but with a similar clinical history were also studied. 
Nine o f these patients had venous thromboembolism, seven had arterial stroke, four
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suffered recurrent early foetal loss and one had an intrauterine death. An additional 
control group (factor V Leiden controls) o f ten patients recruited from the haematology 
outpatient clinic (four men and six women Mean age 43.2 range 23 -  63 years), 
negative for aPA, but heterozygous for the factor V Leiden mutation were studied for 
comparison purposes. The normal reference range was established in 28 healthy normal 
volunteers (fourteen males and fourteen females, mean age 35.8 years, range 1 9 -51 ).
Table 8: Characteristics of the antiphospholipid positive patients studied:
Median value and ranges shown. dR W T  shown w as with dilute phospholipid in the screening  
part of the test. ‘According to the modified Sapporo criteria (Miyakis et al. 2006)
d R W T
ratio
ACL IgG 
(GPLu)
ACL IgM 
(MPLu)
Anti-p2 GPI 
IgG (GPLu)
Protein S 
lU/ml
Protein C 
lU/ml
APTT
APCR
All aPA (n=44) 1.21(0.88-2.39)
2.35
(0.0-92.2)
2.95 
(0 -48.6)
1.1
(0.0-120.0)
1.00
(0.57-1.43)
1.12
(0.78-1.55)
2.28
(1.75-2.98)
APA pos
thrombosis
(n=24)
1.21
(0.88-2.39)
1.3
(0.0-92.2)
4.10 
(0 -48.6)
1.2
(0.0-120.0)
1.05
(0.62-1.43)
1.23
(0.81-1.55)
2.28
(2.05-2.98)
APA pos 
pregnancy 
morbidity 
(n=10)
1.22
(1.01-1.55)
9.3
(0-86.1)
4.2
(0-38.8)
1.2
(0.7-19.2)
0.86
(0.43-1.14)
0.96
(0.57-1.19)
2.31
(1.75-2.65)
Definite APS* 
(n=23)
1.25
(0.63-2.39)
8.0
(0.0-92.2)
2.4
(0-48.6)
1.3
(0.0-75.0)
1.00
(0.43-1.24)
1.11
(0.57-1.55)
2.31
(1.75-2.76)
Reference
range < 1.13 < 5.0 <5.0 < 3.0
Male
0 .7 3 -1 .7 6
Female
0 .5 8 -1 .14
0 .7 0 -1 .30 > 2.0
4.2.2 Endogenous APC ratio (EAPCR)
Acquired resistance to APC was assessed by the degree o f prolongation o f the clotting 
time, produced by activated endogenous protein C in a modified d R W T  with dilute
iLphospholipid using RVV and Protac^ as described in the methods chapter. Two 
phospholipid preparations were used: Bell and Alton platelet substitute (Diagnostic 
Reagents Ltd), and Actin FS (Dade Behring), which is Tupus insensitive’ (Brancaccio 
et al 1997; Lawrie et al 1998).
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4.2.3 Statistical analysis
Due to the skewed nature o f the data, non-parametric tests were used throughout. 
Normality was defined by the 2.5th and 97.5th percentiles o f the 28 normal subjects and 
statistical significance was determined by the Wilcoxon signed rank test or Wilcoxon- 
Mann-Whitney U test, as p <0.05.
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4.3 Results
4.3.1 The effect of phospholipid concentration
The effect o f phospholipid concentration on clotting times with and without endogenous 
protein C activation was studied. Normal pooled plasm a was tested at a range o f  
phospholipid reagent concentrations (doubling dilutions from 5 -  11,000 ng/mL). In 
order for the test to be sensitive to aPA interference in the procoagulant and protein C 
pathways, the phospholipid concentration had to be the rate-limiting step. 1375 ng/mL 
o f the antiphospholipid was required to produce a demonstrable prolongation o f  the 
baseline clotting time. However, at this phospholipid concentration, the anticoagulant 
response to APC action was severely impaired (Figure 16). It was found that 5.5 pg/mL 
o f the Bell and Alton platelet substitute gave optimum conditions, i.e., Protac 
significantly prolonged the clotting time while all plasm a samples clotted within 300 
seconds, thus allowing automated detection. This dilution was subsequently used 
throughout this study.
1000
100
0
11000 5500 2750 1375 688 344 172 86 43 21 11 5
Final p h osp h o lip id  con cen tra tion  (ng/m l)
Figure 16 Effect o f phospholipid concentration on R W  clotting time.
Normal plasma with Protac® ■, w ithout Protac® O, and the endogenous APC ratio (EAPCR) • .
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4.3.2 The effect of phospholipid composition
A reference range for the normalised endogenous activated protein C ratio (EAPCR) o f 
0.81-1.21 (95% confidence interval) was established in 28 normal subjects (median 
1.04) with no significant difference between the sexes using the Bell and Alton reagent. 
Similar values were observed using the lupus insensitive reagent, (Actin FS; 0.72-1.27, 
median 0.97). However, the response to APC was much greater with the Bell and Alton 
reagent than the lupus insensitive reagent (Figure 17, Table 9) with mean Protac clotting 
time: clotting time (without Protac) ratios o f  5.2 (SD = 0.6) and 2.7 (SD = 0.5) 
respectively. Forty o f the 44 aPA-positive patients (91%) produced a high EAPCR, and 
this was predominantly due to a poor response to APC (33/40) rather than prolonged 
basal RVV clotting times alone (5/38) (Table 10, Figure 17). The same tests performed 
using the ‘lupus-insensitive’ phospholipid gave an abnormal result in only 16/44 (36%) 
o f the aPA-positive patients. The second reagent was relatively insensitive to 
endogenous APC as judged by the poor anticoagulant response obtained by the action o f 
Protac (Table 10). Furthermore, both limbs o f the test appeared to be only mildly 
affected by aPA, i.e., the baseline clotting time was only slightly prolonged by aPA and 
the response to endogenous activated APC was hardly affected at all. Consequently, all 
further work was performed using the Bell and Alton reagent.
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N o rm a l aPA p o s it iv e  N orm al a P A  p o s it iv e
L u p u s  s e n s it iv e  PL L u p u s  in s e n s i t iv e  PL
Figure 17 Effect of aPA on R W  clotting times
Clotting tim es with ♦  and without the addition of Protac® O, using a lupus anticoagulant 
sensitive, and a lupus anticoagulant insensitive phospholipid. The broken line is the 97.5th  
percentile of R W  clotting times without Protac® for the normal subjects. The unbroken line is 
the 2.5th percentile of R W  clotting times with Protac® for the normal subjects.
Table 9: Summary of statistical analysis of clotting tim es in normal plasm a and phospholipid 
preparation (n = 28)
BA = lupus anticoagulant sensitive reagent (Bell & Alton). AFS = Lupus anticoagulant insensitive reagents (Actin FS). 
IQR = inter quartile range_____________________________________________________________
BA BA + Protac AFS AFS Protac
M edian 80.0 413.0 46.4 127.7
IQR 74.9 -82.9 355.3 -459.8 4 2 .7 -4 9 .3 1 1 2 .6 -1 4 1 .2
Minimum 59.5 297.0 39.4 89.2
M aximum 88.8 543.0 59.5 180
Table 10: Summary of statistical analysis of clotting tim es in patients with aPA and phospholipid 
preparation (n = 44)
BA = lupus anticoagulant sensitive reagent (Bell & Alton). AFS = Lupus anticoagulant insensitive reagents (Actin FS). 
IQR = inter quartile range_______________________________________________________________
BA BA + Protac AFS AFS + Protac
M edian 46.4 127.7 51.8 103.4
IQR 42.7-49 .3 112.6-141.2 48.7 -58.0 90 .5- 124.2
Minimum 39.4 89.2 35.6 73.1
M aximum 59.5 180.0 110.6 162.0
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4.3.3 Endogenous APC ratio (EAPCR) measurement
Using the lupus sensitive phospholipid preparation, a reduced sensitivity to endogenous 
APC was observed in: aPA-positive patients with previous thrombosis or pregnancy 
morbidity, the aPA negative controls and factor V Leiden patients. However, due to 
variability in APC sensitivity o f  the assay, the differences between the aPA positive 
patients and aPA negative control group were not easily discem able (Figure 18). 
Consequently, normalisation against pooled normal plasm a was used to reduce the 
effect o f  between day imprecision and all results were reported as EAPCR. This 
normalised ratio is obtained by dividing the clotting time ratio (without Protac/with 
Protac) o f pooled normal plasma by the clotting time ratio o f the test sample, so that 
increasing EAPCR indicates increased resistance to APC.
The EAPCR in the 44 aPA-positive patients was significantly higher than the normal 
individuals (median 1.87 v 1.04; P  < 0.0001) or the aPA-negative control group 
(median 1.14; SD, 0.19) (Figure 19). aPA-positive patients with previous throm bosis and 
pregnancy m orbidity groups had similar EAPCR values, with slightly higher values in 
the factor V Leiden group (Table 11). Both o f  the SLE patients, 2/3 ITP patients, 2/3 
migraine patients and 1/2 coincidental aPA patients had a high EAPCR. W hen only 
patients fulfilling the criteria for definite APS (M iyakis et al 2006) were studied (n = 
23), all had a high EAPCR (median 2.15; range 1.46 -  3.17).
Table 11: Summary of statistical analysis of EAPCR by patient group
Normal aPA +ve aPA +ve aPA Factor V
(n = 28)
thrombosis 
(n = 26)
pregnancy 
morbidity 
(n = 24)
negative 
control 
(n = 20)
Leiden 
(n = 10)
M edian 1.04 1.80 2.27 1.08 2.64
IQR
0 .9 0 - 1 .4 8 - 1 .6 4 - 1 .0 5 - 2 .5 3 -
1.06 2.38 2.70 1.26 2.91
Minimum 0.83 1.18 1.29 0.79 2.14
M aximum 1.26 3.11 3.26 1.63 3.83
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Figure 18: Effect of clinical group on R W  clotting tim es
with ♦  and without the addition of Protac® O, using a lupus anticoagulant sensitive  
phospholipid. The broken line is the 97.5th percentile of R W  clotting times without Protac® for 
the normal subjects. The unbroken line is the 2 .5th percentile of R W  clotting times with Protac® 
for the normal subjects.
85
4.00
3.50
3.00
2.50
O'
0
01 2 .00  <
L U
1.50
1.00 
0.50  
0.00
p < 0.00001
p < 0.00001
o
O
O
O
Normal aP A + ve a P A + v e  aP A -ve  
T h r o m b o s is  P reg  m orb id  C on tro ls
FVL
Figure 19: Endogenous APC ratio by clinical group.
Normal subjects (O), aPA positive patients ( • )  aPA negative control patients ( ♦ )  and patients 
with factor V  Leiden (O ). The broken line represents the normal cut-off value (97.5th percentile).
Abnormal EAPCR showed significant association with LA, IgG aCL and IgM aCL, but 
no association with high IgG a n t i^ G P I  or APTT based APC resistance (Table 12). 
This is due to the low incidence o f abnormal IgG anti-p 2 GPI levels or low APTT-based 
APC ratios, and the high incidence o f abnormal EAPCR. The EAPCR value showed 
significant negative correlation with the APTT-based APC resistance method (Figure 
20) (r = -0.61, P = 0.001). However, only three aPA-positive patients demonstrated 
APCR using the APTT-based method, com pared with 41/44 for the EAPCR method. 
Predilution o f plasma in factor V deficient plasm a was not used in the determination o f 
APTT-based APC resistance.
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Table 12: Agreem ent betw een EPCR, antiphospholipid antibody tests  and APTT-based APC 
resistance
EAPCR EAPCR Kappa F ish er’s
norm al abnorm al sta tis tic ex a c t te s t
LA p ositiv e 3 24
0.36 P = 0.002LA n egative 19 19
IgG aCL p ositive  
IgG aCL n egative
1
21
18
25
0.29 P = 0.002
IgM aCL p o sitiv e  
IgM aCL n egative
2
20
18
25
0.26 P = 0.01
IgG anti-(32 GPI positive 1 9
0.12 NS
IgG anti-p2 GPI negative 21 34
APCR norm al 
APCR abnorm al
17
0
32
3
0.06 NS
4.00
r = -0 .61
p = 0 .0 0 13.50
3.00
2.50
O
Q- 2.00 <
LU
1.50
• • •
• • •
1.00
0.50
0.00  L -  
1.50 2.00 2.50 3.00
APTT based APCR ratio
Figure 20: Endogenous APC ratio (EAPCR) v APTT based APC resistance ratio.
The broken lines represent the upper limits of normal for EAPCR and for the APTT based APC 
resistance method.
A significant correlation was observed between the EAPCR and d R W T  (Figure 21), 
and this remained when only LA positive patients were analysed (rs = 0.56, P = 0.0009). 
IgG anticardiolipin (Figure 22) but not IgM anticardiolipin (Figure 23) were 
significantly correlated with EAPCR. Although all but one o f the patients with raised
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IgG anti-f^GPI levels also had a high EAPCR, the converse was not true, in that 
majority o f patients with a high EAPCR did not have increased levels o f IgG an ti-^G P I 
and no significant correlation was observed (Figure 24). Free protein S antigen 
demonstrated a significant negative correlation with EAPCR (Figure 25), despite the 
exclusion o f patients with protein S deficiency or those receiving vitamin K antagonists 
from this cohort. No relationship between the EAPCR value and protein C activity was 
observed.
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Figure 21: Endogenous APC ratio (EAPCR) v dR W T  ratio (using the dilute phospholipid in 
screening test).
The broken lines represent the upper limit of normal for EAPCR and the dR W T  ratio.
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Figure 22 EAPCR v IgG anticardiolipin antibody concentration.
The broken lines represent the upper limit of normal for EAPCR and anticardiolipin. The 
regression line w as performed on p lasm as with IgG cardiolipin values of >5.0 GPU only.
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Figure 23 EAPCR v IgM anticardiolipin antibody concentration.
The broken lines represent the upper limit of normal for EAPCR and anticardiolipin. The 
regression line w as performed on plasm as with IgG cardiolipin values of >5.0 MPU only.
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Figure 24. EAPCR v IgG anti-(32 glycoprotein-l antibody concentration.
The broken lines represent the upper limit of normal for EAPCR and anti-(32 glycoprotein-l. The 
regression line w as performed on plasm as with IgG cardiolipin values of >5.0 U/ml only.
90
4.00
r = -0 .4 6
p = 0 .0 2
3.50
3.00
K 2.50 
O
5-  2.00 <
LU
1.50
1.00
0.50
0 .0 0   1---------- 1------LJ------------1---------- 1---------- 1---------- 1-----------1
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60
free protein S (lU/mL)
Figure 25 EAPCR v IgG free protein S concentration.
The broken lines represent the upper limit of normal for EAPCR and the lower limit for free 
protein S.
4.3.4 Effect of IgG fractions from patients with antiphospholipid antibodies
In order to ascertain whether the observed resistance to APC was due to the 
antiphospholipid antibodies rather than some other perturbation o f the protein C 
pathway, IgG fractions were prepared from four healthy normal individuals and six 
patients with APS with a range o f symptoms and antiphospholipid antibody types 
(Table 13).
Table 13: Characteristics of donors used for the IgG fractions
IgG fraction
Lupus
anticoagu lant A nticardiolip in
Anti-02
G lycoprotein-l C linical h istory
N1 - - - None
N2 - - - None
N2 - - - None
N4 - - - None
aPA1 - + - Stroke SLE
aPA2 + +++ +++ VTE
aPA3 + + - VTE
aPA4 ++ +++ +++ Stroke LPP
aPA5 +++ - - Stroke SLE
aPA6 + + + VTE
VTE = venous throm boem bolism ; SLE = system ic lupus erythem atosus; LPP = late pregnancy problem s, 
i.e. preeclam psia and intrauterine growth retardation
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When the four normal IgG fractions at approximately 6  mg/ml were added to pooled 
normal pooled plasma (PNP), an increase o f up to 5 seconds was observed in the R W  
clotting time (Figure 26), causing a slight increase in the EAPCR (0-8% ). The six IgG 
fractions from aPA patients showed a variable effect on the R W  clotting times at the 
same concentrations, with two o f the six demonstrating LA activity by this method. 
However, all except one caused significant reductions in the R W  + Protac clotting time 
(Figure 26), and EAPCR (Figure 27), indicating that antibodies from patients with APS 
caused resistance to APC to varying degrees. It was notable that the IgG fraction 
causing the greatest amount o f APC resistance (aPA5) was isolated from a patient 
without detectable anti-p2 GPI. When one o f these IgG preparations (aPA 6 ) was added 
to normal plasma at several dilutions, the increase in the EAPCR occurred in a dose- 
dependent manner (Figure 28).
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Figure 26 Effect of the addition of purified immunoglobulin
Immunoglobulin from normal subjects (N1 - N4) and patients with the antiphospholipid 
syndrome (aPA1 -aPA 6) on the R W  (■) and R W  + Protac(«) clotting times. The mean normal 
clotting times are indicated by the broken lines.
PNP N1 N2 N2 N4 aPA1 aPA2 aPA3 aPA4 aPA5 aPA6
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Figure 27 Effect of the addition of purified immunoglobulin
Normal subjects (N1 - N4 ■) and patients with the antiphospholipid syndrom e (aPA1 -a P A  6 
on the endogenous APC ratio.
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Figure 28 D ose response effect of added purified immunoglobulin
Pooled normal plasm a (■) and a patient with the antiphospholipid syndrome (aPA 6
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4.4. Discussion
Using the phenomenon o f  aPA interference in APCR screening tests, I developed a 
highly sensitive test for the detection o f  aPA associated APC resistance using 
endogenous protein C activation. Using this method, I have demonstrated A PCR in 91% 
o f the patients studied with aPA; a far higher proportion than has previously been 
reported using APTT based APCR screening tests. This increase in sensitivity has been 
achieved through the use o f rate-lim iting concentrations o f a phospholipid preparation, 
that is rich in PS and zwitterionic phospholipids, which are known to enhance the APC 
dependent degradation o f factor V (Pecheniuk 2003; Smirnov et al 1994) through 
preferential binding o f the APC Gla dom ain (Smirnov et al. 1998). Furthermore, the 
requirement o f PE for APC anticoagulant activity and the PE dependence o f  some 
antiphospholipid antibodies provide a basis for the selective inhibition o f the protein C 
pathway in the pathogenesis o f aPA (Balada et al. 2001; Berard et al 1996; Esmon et al. 
2000; Sanmarco et al 2001; Sugi et al. 1999; Sugi et al. 2004). By contrast, the APC 
resistant phenotype was only detected in 36% o f  aPA patients using a phospholipid 
source deficient in PS and SM, and known to be insensitive to lupus anticoagulant. 
Furthermore, the response to APC was m uch w eaker using this phospholipid, in normal 
and abnormal samples, indicating that the selection o f phospholipids is crucial in the 
determination o f APC resistance.
Titration o f the phospholipid showed that in this in vitro method, at least, APC has a 
higher requirement for phospholipid than the prothrombinase complex, as APC activity 
was impaired at higher phospholipid levels than the R W  mediated clotting time. This 
may explain how in the majority o f cases (33/40), high EAPCR was predominantly the 
result o f inhibition o f endogenous APC action by aPA, rather than a prolongation o f the 
basal clotting time by LA activity.
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High EAPCR was found in 96% (27/28) o f  patients fulfilling the modified Sapporo 
criteria for definite APS (M iyakis et al 2006). Only 3/20 o f the aPA negative control 
group demonstrated high EAPCR (one had arterial stroke, one recurrent miscarriage and 
one VTE). The reasons for this are unclear, but APC resistance in the absence o f factor
V Leiden is known to be an independent risk factor for both thrombosis (de Visser et al 
1999) and pregnancy morbidity (Rai et al. 1996). Furthermore, increases in plasma 
factor VIII :C (Chitolie et al 2001)) or prothrombin, and low levels o f  free protein S (de 
V isser et al. 2005)are also known to cause APC resistance. As may have been expected, 
the EAPCR showed a positive correlation with the APTT based APCR ratio, but only 
3/42 (7.0%) aPA positive patients gave results below the normal cut-off value for the 
APTT based method, demonstrating the increased sensitivity o f the EAPCR method. 
This was not surprising, since the APTT-based method is prim arily intended as a 
screening test for factor V Leiden.
Despite the exclusion o f patients known to be deficient in protein S (i.e., patients with 
known congenital deficiency or those receiving vitamin K antagonists), from this cohort 
o f patients, free protein S showed a significant correlation with EAPCR. This indicates 
that free protein S concentration may be a confounding variable in this assay.
EAPCR showed weak negative correlation with d R W T  ratio and a highly significant 
negative correlation with IgG anticardiolipin, but not IgM anticardiolipin antibody 
levels. In several cases very low EAPCR (< 0.50), similar to those encountered in factor
V Leiden patients, were observed in patients with a poor clinical history whose only 
previous abnormal finding was a persistently raised IgG anticardiolipin. This is 
consistent with the findings o f Nash et al (2004), who showed that the anticardiolipin 
assay is required for sensitive screening for the antiphospholipid syndrome. Most 
patients with raised IgG a n t i^ G P I  demonstrated resistance to APC as previously 
reported by M artinuzzo et al (1996) who reported that acquired APC resistance in
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patients with aPL was associated with anti-p 2 GPI rather than an in vitro interference by 
LA. However, the converse was not true, in that most patients with high EAPCR did not 
have raised levels o f IgG a n t i^ G P I ,  which is contrary to the findings o f  Galli et al 
(1998) who reported that APC resistance was strictly ^ G P I-d ep en d en t. (Galli, 
Ruggeri, & Barbui 1998). At the time o f  this part o f my study, IgM anti-p 2 GPI antibody 
assays were not readily available.
Using purified IgG from patients with APS, I was able to demonstrate that, in addition 
to the expected lupus anticoagulant effect, the antibodies interfered with the ability o f 
activated endogenous protein C to prolong the R W  clotting time. This effect was 
highly variable, reflecting the heterogeneous nature o f  aPA, but the addition o f 
increasing amounts o f IgG caused acquired APC resistance in a dose response manner. 
Thus, I showed that the resistance to APC observed in these patients was an antibody- 
mediated effect, rather than a quantitative defect in the components o f  the protein C 
pathway. Two o f the IgG fractions without anti-p 2 GPI activity produced APC 
resistance, confirming that, while a n t i^ G P I  antibodies may contribute towards APC 
resistance in some patients, a n t i^ G P I  antibodies are not prerequisite for aPA 
associated resistance to APC.
There are several proposed mechanisms for aPA inhibition o f the protein C pathway;
Inhibition o f thrombin formation leading to decreased protein C activation has been
proposed as a possible mechanism but this is unlikely as high levels o f throm bin favour
coagulation rather than protein C activation (Griffin 1995), although this is dependent
on the site o f thrombin generation and the density o f thrombomodulin present (Lane et
al 2005). It has also been reported that antibodies may bind protein C and protein S
directly (Oosting et al. 1993a; Oosting et al 1993b), possibly inhibiting the assembly o f
the protein C complex (Malia et al 1990). This may occur through direct interference
with the residues responsible for APC-protein S binding or through the inhibition o f
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protein S binding to phospholipid, rather than the inhibition o f  Gla domain-dependent 
binding o f  APC to phospholipid p er se (Preston et al. 2005).
It has been reported that aPA increase the affinity o f  C4b binding protein for protein S 
thus causing acquired deficiency o f free protein S (Atsumi et al. 1997). Anti-(32GPI 
strongly inhibits the binding o f APC at concentrations which cause only weak inhibition 
o f phospholipid-dependent prothrombinase activity (Mori et al. 1996) thus producing a 
net prothrombotic effect. However, p2GPI binding to membranes with physiological 
anionic phospholipid content is relatively weak in comparison to plasm a coagulation 
proteins (Harper et al. 1998) and this has led to speculation o f  the role o f  anti-p2GPI 
antibodies in the pathology o f aPA. It has been shown that p2GPI is necessary for the 
inhibition o f protein C activity by some monoclonal anticardiolipin antibodies (Ieko et 
al. 1999) and that this is achieved by increased binding to phospholipid surfaces 
facilitated by the dimerisation o f p2GPI by aPA molecules. (Takeya et al 1997). Given 
the heterogeneous nature o f aPA, it is probable that more than one species o f  antibody is 
responsible for the inhibition o f factor Va cleavage by APC. Anti-prothrom bin has been 
shown to cause LA activity by a mechanism similar to that o f p2GPI (Simmelink et al 
2001), and was recently reported to inhibit the inactivation o f factor Va by activated 
protein C (Galli et al. 2005). It seems reasonable to suggest that anti-prothrombin could 
also cause aPA associated APCR by com petition for phospholipid surfaces.
In conclusion, I demonstrated an APCR phenotype, rarely shown by conventional
APTT-based APC resistance screening tests, in the majority of patients with aPA in the
absence o f FV Leiden. This was an antibody mediated effect, which was partially due to
the LA activity prolonging the baseline clotting time, but the main effect was a
significant inhibitory effect on the activity o f endogenous APC. Having confirmed that
APC activity has a higher requirement for phospholipid than that o f the prothrombinase
complex, it seemed reasonable to predict that this would result in a net prothrombotic
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effect when aPA causes competition for phospholipid binding sites. I believe that this 
goes some way to explaining the ‘lupus anticoagulant paradox’.
This study suggests that this could be a useful test in identifying APC resistance in APS. 
However, this was a retrospective study, from a single centre. M ost patients referred to 
our haematology clinic have no underlying autoimmune disease, i.e., they have primary 
APS. Furthermore, the patients selected were positive for aCL and/or d R W T  on at 
least two occasions, and these factors may have contributed to a selection bias. Ideally, 
it would be useful to conduct a prospective study o f newly referred patients with 
suspected APS, and conduct serial studies on the same patients. Unfortunately, like so 
many other LA tests and global clotting tests, this method is unsuitable for patients 
receiving oral anticoagulation or heparin therapy.
It was clear that further work was required to elucidate the precise m echanisms and 
significance o f acquired APCR in aPA patients. The rapid technological developments 
in the measurement o f thrombin generation, which were occurring during the course o f 
this thesis, raised the possibility o f investigating the prothrombotic effect o f  aPA using 
an endogenous thrombin potential (ETP) based APC sensitivity assay.
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Chapter 5. The Development and characterisation of an in vitro 
thrombin generation assay to assess the protein C pathway
5 .11ntroduction
Although antithrombin is the principal inhibitor o f  free thrombin, the protein C pathway 
is the major feedback mechanism to control the amount o f throm bin generated in vivo. 
The protein C pathway also plays a m ajor role in localising throm bin generation to the 
site o f injury (Oliver et al. 2002), as APC does not regulate throm bin production on the 
platelet surface but acts on the vascular endothelium. Consequently, although excessive 
thrombin generation per se is strongly associated with hypercoagulable states, the 
amount o f thrombin formed in the presence o f APC is probably more significant than 
the total amount o f thrombin generated in its absence, w hen determining thrombotic 
risk. This is particularly true o f the APS, as it has been reported that overall thrombin 
generation is reduced in the majority o f  cases (Hanly & Smith 2000), w hich would be 
expected to cause a bleeding disorder rather than thrombosis.
With the addition o f phospholipid vesicles and rhAPC, it is possible to measure the 
effect o f the protein C system on amount o f throm bin formed, or the APC sensitivity 
ratio (nAPCsr). This may be used to measure changes in sensitivity to APC caused by 
protein S deficiency, oral contraception and pregnancy (Nicolaes et al. 1997). The 
nAPCsr is reported to be a strong risk factor for venous thrombosis (Tans et al 2003).
In order to study thrombin generation in patients with aPA, I developed an automated 
ETP method that was sensitive to APC, with conditions as close to physiological 
concentrations as possible. It was im portant that the assay was as sensitive to as many 
recognised prothrombotic variables as possible. As APC has a minimal effect on 
thrombin generation on platelets (Oliver et al 2002), it was neither necessary nor 
desirable that the method used platelet rich plasma. However, it was necessary to 
provide a phospholipid surface for the inactivation o f factor Va by APC.
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In chapter 3, I showed that the existing methods for assessing the protein C pathway 
were insensitive to protein S deficiency. The Russell’s viper venom method, discussed 
in chapter 4 showed an improvement in sensitivity to protein S, but I felt that it was 
important that the thrombin generation method that I was to use was more sensitive to 
fluctuations in protein S, especially as aPA interference with protein S had been 
implicated in the pathology o f APS (M alia et al 1990).
I therefore used the thrombin generation method to investigate samples from a previous 
study o f the combined oral contraceptive pill (COC) (Mackie et al. 2001), where 
decreased protein S levels had been observed in association with 3rd generation 
progestogens. COC use has been associated with a 3-6 fold increase in relative risk o f 
venous thromboembolism (Vandenbroucke et al. 2001; W orld Health Organization 
1998). It has previously been reported that 3rd generation COCs (3rd generation) may 
cause greater resistance to APC than 2nd generation COCs (2nd generation)(Rosing et al 
1997; Simioni et al. 1996) and this has been proposed as a possible mechanism o f the 
reported increased risk o f VTE. I knew that the changes observed in protein S and 
sensitivity to APC were relatively small, so this represented an ideal opportunity to 
ascertain the sensitivity and potential utility o f the method.
I also wanted to study the kinetics o f throm bin generation in plasma from patients with 
APS, to ascertain whether this could explain the increased risk o f thrombosis. It has 
been variously reported that aPA inhibit throm bin generation (Hanly et al 2000; Sheng 
et al. 2001a) or accelerate throm bin generation through disruption o f annexin V binding 
(Rand, Wu, & Giesen 1999) or inhibition o f TFPI (Adams et al. 2004).
The aims o f this section o f my thesis were:
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• To use the knowledge that I obtained from the RVV based method to establish 
the optimal conditions for measuring APC resistance using a sub-sampling 
thrombin generation method
• To ascertain whether this technique could be useful in the investigation o f the 
putative prothrombotic mechanisms o f APS.
• To standardise this method and transfer it to an automated platform.
• To identify the key determinants o f  this assay, with particular reference to 
conditions causing acquired resistance to APC.
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5.2 Methods and materiais
5.2.1 Patients and samples
Sample collection was performed as described in the methods chapter. Normal reference 
ranges were established in 30 healthy normal subjects (20 females, 10 males; mean age 
34 years). None o f the normal subjects were using anticoagulants, com bined oral 
contraceptives, or any other drugs known to affect the coagulation system, at the time o f 
testing.
The influence o f plasma prothrombin levels and free protein S on throm bin generation 
was studied in women receiving COCs. The effect o f factor V Leiden, aPA and acquired 
TFPI deficiency were studied in plasma from patients referred to the haematology 
outpatient clinics at UCLH for investigation o f throm bophilia or pregnancy morbidity. 
The effect o f factor VIII concentration was performed by adding purified factor VIIII to 
plasma from a patient with severe haem ophilia A. None o f  these patients were receiving 
oral anticoagulants or heparin at the time o f testing.
5.2.1.2 Women receiving the oral contraceptive p ill
In a previous study we investigated the impact o f omitting the pill free interval (PFI) on 
a variety o f haemostasis activation markers and inhibitors, and any differences in 
women receiving combined oral contraceptives (COCs) containing 30pg ethinyl 
estradiol and either levonorgestrel (2nd generation) or desogestrel (3rd generation). It was 
found that free protein S levels were lower in 3rd generation than in 2nd generation COC 
users. Furthermore, protein S levels decreased in women switching from 2nd to 3rd 
generation COCs and this was m irrored by an increase in protein S in women switching 
from 3rd to 2nd generation COCs. Against this background, I decided to investigate 
whether this decrease in protein S was associated with the reported increase in APC
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resistance. As increased plasm a prothrombin levels have also been reported to influence 
resistance to APC, this was also investigated
This was part o f a larger prospective, non-randomised, comparative study previously 
reported (Mackie et al 2001). Due to limited sample volume, and to avoid the adverse 
effect o f re-freezing and thawing samples, I investigated samples from a sub-set o f 26 
COC users randomly selected from the original study. These were healthy established 
users o f 2nd or 3rd generation COCs. The women omitted one pill free interval (PFI), 
switching immediately either to the opposite formulation for one cycle, or continuing 
the same pill. The four subgroups were designated.
AA Remained on 2nd generation throughout (n=6 )
AB Started on 2nd and switched to 3rd generation (n=7)
BB Remained on 3rd generation throughout (n= 6 )
BA Started on 3rd and switched to 2nd generation (n=7)
In subgroups AA and BB, after one monitored cycle o f 21 pills followed by a seven day 
PFI, the women were asked to omit the next PFI. In subgroups AB and BA, after one 
monitored normal COC cycle and the PFI that followed the women were asked to omit 
the next PFI and start taking the opposite COC type immediately. Venesection followed 
the initial PFI, after 1 cycle (21 tablets) and 2 cycles (42 tablets) o f continuous pill 
taking. These were designated sample I, sample II and sample III respectively.
5.2.2 Development of sub-sampling technique
Initially I concentrated on developing a manual sub-sampling technique, using a method 
based on those o f Nicolaes et al (1997) and Rosing et al (1999). APC resistance was 
measured as a sensitivity ratio (nAPCsr) in an amidolytic assay o f tissue factor initiated
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thrombin generation, with and without exogenous rhAPC. M easurement o f throm bin 
generation was performed in plasma defibrinated using Ancrod at 37°C.
Initial experiments used 1/4 diluted Innovin (Dade Behring) as a source o f tissue factor 
and freshly prepared phospholipid vesicles. This resulted in consistent throm bin 
generation, but negligible APC activity at lOnM. Increasing the APC concentration had 
little effect (data not shown), and did not seem to be a reasonable option as this would 
involve plasma APC concentrations far in excess o f those seen in vivo. I inferred that 
the absence o f visible APC activity was most probably due to the rapid accumulation o f 
FVa having a swamping effect on the APC.
I titrated Innovin to examine the effect o f tissue factor concentration and found that by 
using a tissue factor dilution o f  1:32 (final dilution 1/192) that a good anticoagulant 
response was achieved. The final concentration o f  tissue factor at this dilution was 
approximately 20 pM as determined using the IMUBIND® Tissue Factor ELISA 
(American Diagnostica Inc, Stamford, C T ) .).
Using these conditions, I could achieve an e x P 'apc/ETP+apc ratio o f approxim ately 2.5. 
Although the initial results were encouraging, the day to day imprecision o f  the method 
was unacceptably high (CV in the order o f  25%). As the reconstituted rhAPC was 
stored in aliquots at -80°C in a buffer containing 1% albumin I deemed this an unlikely 
source o f  variation. Using Innovin within 8  hours o f reconstitution partially eliminated 
the variation, as did the use o f freshly prepared buffers (<14 days). I suspected that the 
remaining imprecision was due to oxidation o f the phospholipid used to prepare the 
vesicles. This was overcome by using the phospholipid preparation described in 
methods chapter.
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5.2.3 A thrombin generation-based APC sensitivity test using an automated 
coagulometer (ACL 9000).
In order to follow up these initial findings, it was necessary to screen a large number o f 
patients with aPA using an APCR ETP method. The sub-sampling technique, while 
useful with small numbers o f samples, was technically difficult and time consuming. I 
needed to develop an automated version o f  the same test. This was achieved by constant 
measurement o f thrombin generation using a slow reacting thrombin substrate 
(Pefachrome TG) using an Instrumentation Laboratory ACL9000. To improve 
sensitivity to factor VIII, the tissue factor concentration was reduced to 7 pM (Innovin 
at a final dilution o f 1/600). As reducing the tissue factor concentration slows the 
activation o f factor V to factor Va, I was able to reduce the concentration o f  rhAPC to 5 
nM. I also reduced the phospholipid vesicle concentration to 20 pM  in order to increase 
sensitivity to aPA.
The final method used is described in full in the methods chapter. Results were 
displayed cumulatively (Figure 29) or as the am ount o f throm bin generation against 
time (Figure 30). This allowed the calculation o f total throm bin generation, lag phase to 
the start o f thrombin generation and peak throm bin generation.
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Figure 29: Graphical representation of cumulative thrombin generation. 
Showing total, a2  macroglobulin bound and free thrombin against time.
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Figure 30: Graphical representation of free thrombin overtim e.
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5.3 Results
5.3.1 Subsampling method
The first experiments to determine optimal dilutions o f  tissue factor were performed in 
microtitre plates. Initial attempts showed that the timing o f the subsampling was critical. 
I originally planned to sample at 20-second intervals, but as can be seen from figure 31, 
this time interval was too long, as this resulted in missing the peak throm bin generation 
at the 1:4 thromboplastin dilution. It was also clear that use o f high tissue factor 
concentrations were unsuitable, as the rush o f  thrombin generation happened too 
quickly to gain useful information, and at high tissue factor concentrations APC had 
little or no anticoagulant action. After several attempts, I concluded that if  continuous 
mixing was employed, the 1:32 throm boplastin dilution gave the optimal conditions 
with peak thrombin generation at around 80 seconds. At this dilution, 10 nM  o f rhAPC 
reduced both peak thrombin generation and 0 C2  macroglobulin-bound throm bin by 
approximately 50%, which was ideal for my purposes (Figures 32 and 33).
However, although the precision o f the throm bin generation without added APC was 
satisfactory for CC2 macroglobulin-bound throm bin with a CV o f 4.5%, there was some 
variability in the time taken to peak throm bin concentration (Figure 32). The degree o f 
imprecision with added rhAPC was unsatisfactory with a CV o f  20% for ot2  
macroglobulin-bound thrombin, and 21% for maximum peak height (Figure 33).
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Figure 3 1 : Titration of tissue factor to determ ine optim al conditions for thrombin generation. 
Thromboplastin dilution 1:4 blue; 1/32 magenta; 1/128 green
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Figure 32: Initial thrombin generation curves using pooled normal plasma. 
Four replicate curves are shown.
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Figure 33: Initial thrombin generation curves with added APC using pooled normal plasma.
Four replicate curves are shown.
As the assay was so time consuming and the phospholipid reagent frequently 
deteriorated during an assay run (as judged by visible opacity and increased 
imprecision), it was necessary to set a 6 -hour expiry time from the end o f  sonication. As 
discussed in the methods section, measures were taken to stabilise the phospholipid 
preparation (prevention o f oxidation), and this im proved the day to day imprecision, 
with CVs o f 12% and 4.5% for ot2 macroglobulin-bound thrombin, with and without 
rhAPC respectively (Figures 34 and 35). However, a 12% CV was still high, so I 
normalised all results against an aliquot o f  pooled normal plasma run with each batch o f 
tests, in order to minimise run-to-run variation.
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Figure 34: Thrombin generation showing improved precision after lipid stabilisation measures, 
(four replicate curves for pooled normal p lasma are shown).
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Figure 35: Thrombin generation w ith APC, showing improved precision after lipid stabilisation 
measures
(four replicate curves for pooled normal plasma are shown).
Using this subsampling method, it was not possible to calculate the area under the curve 
(AUC), as it uses unequal timing and this precludes the use o f the available 
mathematical models. However, the relationship between peak height and 0 L2
110
macroglobulin-bound throm bin was studied in a pooled normal plasma. This showed 
that the relationship was fairly constant, with a mean ratio o f 3.48, and a CV o f 10.2%.
5.3.1.1 The effect of oral contraceptive use
Samples I and II taken at the end o f the first pill free interval (PFI) and after one cycle 
o f pill taking, showed that users o f the 3rd generation COCs (BB/BA) had significantly 
lower free protein S levels (Sample I, 0.66 vs. 0.76, p = 0.0006, sample II, 0.61 vs. 0.76, 
p <0.0001) than those using 2nd generation COC (AA/AB). Users o f 3rd generation 
COCs also had significantly higher nAPCsr values (1.64 vs. 1.33, p = 0.009) after the 
PFI, although these differences were not apparent at the end o f  the first COC cycle 
(Table 14). Users o f 2nd generation COCs (AA/AB) showed a significant increase in 
nAPCsr but no differences in free protein S (Figure 36) between samples collected after 
the first monitored PFI and after one cycle o f pill taking. In contrast, users o f the 3rd 
generation COC (BB/BA) showed a significant decrease in free protein S that was 
accompanied by a significant increase in nAPCsr after one cycle o f pill taking (Table 
14, Figure 37).
Table 14: Differences in free protein S antigen (fPS), normalised APC sensitivity ratio (nAPCsr) 
and plasma prothrombin levels in subjects receiving 2nd and 3rd generation COCs 
2 nd generation (AA & AB); 3rd generation COCs (BB & BA), between the end of the first PFI and 
after one cycle of COC use (sam ples I & II). Results are shown a s mean ± 2SD; paired t-test *p 
< 0.005, **p< 0.0001.
F ree protein S  (iu/ml) nA PC sr Prothrom bin (lU/ml)
S am p le AA/AB BB/BA AA/AB BB/BA AA/AB BB/BA
I (End o f PFI) 0 .7 6  ± 0 .2 0 0 .6 6  ± 0 .1 8 1 .3 3  ± 0 .4 2 1 .6 4  ± 0 .4 4 1 .0 6  ± 0 .2 4 1 .13  ± 0 .3 6
II (After 21 pills) 0 .7 6  ± 0 .1 4 0.61  ± 0.18** 1 .6 9  ± 0 .5 8 * * 1 .8 7  ± 0 .6 0 * 1 .1 0  ± 0 .3 4 1 .2 0  ± 0 .4 0 *
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Figure 36: R esistance to APC and free protein S antigen levels for group AA
Women who remained on levonorgestrel 2 nd generation (n = 6). Data is shown for free protein S
antigen (X) m easured by ELISA using a specific m onoclonal antibody and APC resistance
expressed as the nAPCsr (a). The error bars show  the 95% confidence intervals. PFI = pill free
interval.
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Figure 37 R esistance to APC and free protein S antigen levels for group BB 
Women who remained on 3rd generation COCs (n = 7). Data is shown for free protein S antigen 
(X) m easured by ELISA using a specific monoclonal antibody and APC resistance expressed  as  
the nAPCsr (a). The error bars show  the 95% confidence intervals. PFI = pill free interval.
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When subjects were switched from one COC type to another (groups AB and BA), there 
were marked, mirror-image changes in protein S levels and nAPCsr between sample II 
and sample III (Figs 38 & 39). Protein S levels decreased significantly when changing 
from 2nd to 3rd generation COCs and increased when changing from 3rd to 2nd generation 
COCs (Table 15). Although nAPCsr showed far greater variability than free PS within 
each sub group, nAPCsr was significantly higher in subjects using 3rd generation COC 
during the PFI (Table 14) and on crossover (Table 15). Furthermore, the changes in 
nAPCsr observed when changing COC type were mirror images o f those observed for 
free PS.
Table 15: C hanges in free protein S  antigen (fPS), normalised APC sensitivity ratio (nAPCsr) 
and plasma prothrombin levels when changing COC type.
AB = changing from 2nd to 3rd generation COC, BA = changing from 3rd to secon d  generation  
COCs. Results are shown as mean ± 2SD; *p<0.05, **p<0.005, ***p<0.0001.
Sam ple II III
After 21 pills After 42 pills
Free protein S (iu/ml) AB 0.74 ± 0 .1 4 0.59 ± 0.08***
BA 0.60 + 0.14 0.74 ±0.16***
nAPCsr AB 1.82 ± 0 .3 6 1.92 ± 0 .3 6 *
BA 1.97 ± 0 .6 8 1.65 ±0.64**
Prothrombin (lU/ml) AB 1.09 ± 0 .4 2 1.03 ± 0.16
BA 1.13 ± 0 .3 6 1.12 ± 0 .3 6
A significant increase in prothrombin concentration was observed between the PFI and 
one cycle o f COC use (mean ± SD, 1.10± 0.14 to 1.15±0.19 IU/ml, p = 0.01), but there 
were no significant differences in plasm a prothrom bin levels when the pill type was 
switched (Table 15).
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Figure 38: Group AB were long term 2 nd generation COC users who switched to 3rd generation  
immediately after sam ple II (n=6).
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Figure 39: Group BA were long term 3rd generation COC users who switched to 2nd generation  
immediately after sam ple II (n=7).
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5.3.1.2 The effect of Prothrombin
The influence o f plasm a prothrom bin levels on ETP  and ETP+APC was investigated in 
samples from 47 women receiving COCs. Plasma prothrombin concentration correlated 
significantly with both ETP  (Figure 40) and ETP+apc (Figure 41).
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Figure 40: A graph of plasma prothrombin levels against ETP
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Figure 41: A graph of plasm a prothrombin levels against ETP+APC
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5.3.1.3 The effect of plasma protein S levels
The influence o f free protein S on ETP  and ETP+apq was investigated in samples from 
47 patients and controls. Free protein S had no discemable effect on ETP  (data not 
shown), but showed a significant negative correlation with ETP+apc (Figure 42), despite 
a relatively narrow range o f free protein S values. All four samples below the normal 
female reference range (0.58 -  1.14 IU/mL) gave ETP+apc values o f >1.59, and all 
samples with free protein S values o f < 0.70 IU/mL gave ETP+APC values o f  >1.20 
suggesting that this method is sensitive to reduced protein S levels.
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Figure 42: A graph of free protein S  against e t p +apc
5.3.1.4 The effect of antiphospholipid antibodies
Having obtained a degree o f standardisation using the subsampling method, I studied 
thrombin generation in sixteen patients (not receiving anticoagulants) with APS (Table 
16). These patients had a broad range o f clinical and laboratory findings, which I felt,
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were representative o f  aPA positive patients. Ten o f the sixteen patients had high 
nAPCsr as judged by their a i  macroglobulin-bound thrombin levels.
Table 16: Characteristics of aPA positive patients studied
VTE = venous thromboembolism, IUFD = intrauterine fetal death, Cl = cerebral ischaemia, FH = family 
history. aCL = anticardiolipin, p2GPI = anti-p2 glycoprotein-l.
P a tien t
C lin ica l
d e ta ils
dRVVT IgG aCL IgM aC L PzGPI
1 VTE familial APS 1.37 >84 6.0 29.9
2 SLE stroke 2.14 89.6 5.2 56.8
3 IUFD + Cl 1.45 80.5 7.2 19.2
4 SLE VTE 1.15 67.5 61.1 5.0
5 VTE 0.98 45.7 3.4 44.2
6 RM migraine 1.08 22.3 0 0.6
7 VTE 1.21 18.5 0 10.7
8 IUFD 1.15 7.2 0 34.2
9 TIA+ RM 0.98 4.7 0.2 5.3
10 Livedo and VTE 0.98 4.7 0.2 5.3
11 Cl 1.62 0.9 0.3 1.6
12 FH VTE, asymptomatic 1.23 0.3 0 nd
13 APA 1.08 18.7 8.2 2.9
14 TIA ITP 1.66 4 3.0 5.0
15 DVT 1.00 17.6 0.6 3.3
16 CVA 1.02 9.5 0.0 0.3
Table 17: Thrombin generation in patients with aPA studied
Normal values are indicated by black type, abnormally low values in blue and raised values in 
red. Reference ranges from the automated method: nAPCsr 0 .57 -  1.23, ETP 0.73 -  1.06 and 
ETP+APC 0 .4 2 - 1 .0 7
P a tien t C lin ical
d e ta ils
n A P C sr ETP e t p *apc
1 VTE familial APS 2.57 0.33 0.85
2 SLE stroke 2.25 0.22 0.49
3 IUFD + Cl 1.16 0.61 0.73
4 SLE VTE 0.86 1.11 0.96
5 VTE 1.48 1.26 1.86
6 RM migraine 1.00 0.63 0.62
7 VTE 1.45 0.91 1.31
8 IUFD 0.75 0.71 0.54
9 TIA+ RM 1.36 0.88 1.19
10 Livedo and VTE 1.25 1.23 1.56
11 Cl 1.48 1.12 1.70
12 FH VTE, asymptomatic 0.73 1.30 0.97
13 SLE +CI 2.51 0.66 1.65
14 TIA ITP 1.70 0.59 1.00
15 DVT 1.61 0.66 1.07
16 CVA 0.46 1.50 0.69
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This preliminary data suggested, the majority o f patients with aPA had an abnormal 
nAPCsr ratio. I studied the raw  data from these patients and found several different 
patterns o f thrombin generation that the nAPCsr alone could not show. If  the amount o f 
thrombin generated with and with out APC were expressed relative to that o f  pooled 
normal plasma, i.e., ETP+apc and ETP, it became apparent that some plasmas with 
raised nAPCsr had low ETP and ETP+apc, some has raised ETP and ETP+apc, while 
others had normal ETP and raised ETP+apc (Table 17).
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When I examined the actual thrombin generation curves themselves, the picture became 
more complicated still. Figure 43 shows the curves from patient 1. The time of peak 
thrombin formation was similar for both the patient and normal plasma, with the 
addition of APC giving a slightly longer time. It was clear that the amount of thrombin 
produced by the patient’s plasma was significantly less than that of the normal plasma 
in the absence of APC. However, broadly similar amounts of thrombin were generated 
in both plasmas when APC was added. Although there was a poor anticoagulant 
response to APC, as shown by the nAPCsr, the amount of thrombin generated in the 
presence of APC was normal.
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Figure 43: Thrombin generation curves from patient 1.
Pooled normal plasma w ithout APC is shown in red + 
Pooled normal plasma with APC is shown in blue + 
Patient’s plasma w ithout APC is shown in green ♦. 
Patient’s plasma with APC is shown in m agenta ♦ .
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Patient 10 had a raised nAPCsr, raised ETP and ETP+apc. The thrombin generation 
curves show a faster rate o f thrombin generation, as judged by a reduced lag phase prior 
to thrombin generation and a shorter time to peak thrombin generation (Figure 44). In 
the absence o f APC, peak thrombin generation in the patient’s plasma is less than that 
o f the normal plasma, although, the CC2 macroglobulin-bound thrombin are the opposite. 
When APC is added, both the peak and a i  macroglobulin-bound thrombin levels were 
much higher than that of the normal plasma. Indeed the patient plasma produced levels 
o f thrombin in the presence o f APC that were similar to those seen in normal plasma 
without APC, i.e. a considerable excess o f thrombin was produced.
700
600
500
400
300
200
100
0
400 500 600100 20 0 3000
T im e (s)
Figure 44: Thrombin generation curves from patient 10.
Pooled normal plasma without APC is shown in red + 
Pooled normal plasma with APC is shown in blue + 
Patient’s plasma without APC is shown in green ♦. 
Patient’s plasma with APC is shown in m agenta ♦.
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Patient 14 had a strong lupus anticoagulant, and this was reflected by a long lag phase 
before thrombin generation and peak thrombin generation at >120 seconds (Figure 45). 
As the subsampling intervals were longer after this time, it appears that I m issed the 
peak thrombin generation with APC in this plasma. However, the final 012  
macroglobulin-bound thrombin levels with and without APC are almost identical, 
suggesting that the peak heights would have been similar, i.e., an almost complete 
resistance to APC. In order to capture the peak throm bin generation times in patients 
such as this, regular subsampling would have to be performed over a much wider time 
frame.
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Figure 45: Thrombin generation curves from patient 14.
Pooled normal plasma without APC is shown in red + 
Pooled normal plasma with APC is shown in blue + 
Patient’s plasma without APC is shown in green ♦. 
Patient’s plasma with APC is shown in m agenta ♦.
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Plasma from patient 13 demonstrated a slight increase in lag time and time o f peak 
thrombin generation (Figure 46). The patient’s plasma generated less throm bin that the 
normal plasma in the absence o f  APC, but again, the patient’s plasma demonstrated a 
poor anticoagulant response to APC.
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Figure 46: Thrombin generation curves from patient 13.
Pooled normal plasma without APC is shown in red + 
Pooled normal plasma with APC is shown in blue + 
Patient’s plasma without APC is shown in green ♦ . 
Patient’s plasma with APC is shown in m agenta ♦ .
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Plasma from several patients showed reduced throm bin generation and increased lag 
phase and time to peak throm bin generation, yet a very poor response to APC. Figure 
47, which shows the thrombin generation curves from patient 2, was typical o f  this type 
of response. It is clear that, once again, that the thrombin generation peak for the 
patient’s plasma was not detected, as this would have occurred after the period o f 
regular subsampling, i.e., > 140 seconds. In order to capture all the thrombin generation 
peaks, it would be necessary to subsample frequently up to 300 seconds. This would 
require at least 60 subsamples per patient sample, which would be impractical.
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Figure 47: Thrombin generation curves from patient 1.
Pooled normal plasma without APC is shown in red 
Pooled normal plasma with APC is shown in blue 
Patient’s plasma without APC is shown in green.
Patient’s plasma with APC is shown in m agenta.
The subsampling technique proved to be very useful in showing the heterogeneity o f 
thrombin generation and response to APC in patients with aPA, but the method was 
exceptionally labour intensive and did not cover all relevant time points. It was clear 
that a more practical method would be required if  larger number o f samples were to be 
studied.
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5.3.2 Automated thrombin generation method
By using a tissue factor concentration o f  approximately 7pM (Innovin diluted at 1:600) 
as judged by a tissue factor ELISA, it was possible to achieve an APC ratio (thrombin 
generation without APC: throm bin generation with APC approximately 3:1). Tissue 
factor ELISA remain poorly standardised, as there is no international standard for the 
determination o f relative potencies, and assays are frequently non-parallel. 
Consequently, I have used both the dilution and assayed tissue factor concentrations 
throughout this thesis. Within assay im precision for ETP  and ETP+apc was 4.2% and 
10.6% respectively, with between run im precision o f 9.9% and 15.4% using freshly 
prepared phospholipid vesicles. Using the stable phospholipid emulsion (Rossix), within 
run imprecision values o f 4.5% and 6.5%, and between-run values o f  8 .6 % and 7.9% 
were obtained. The mean APC ratio (i.e., the amount o f thrombin generated without 
APC divided by that formed with APC) was slightly higher with fresh vesicles than 
using the emulsion (3.5 v 2.9). Consequently, values were normalised against PNP to 
minimise this variation, as described earlier. Absorbance change was abolished by the 
addition of 0.1 mg/ml o f recombinant hirudin. The reference ranges and all thrombin 
formation kinetics data were established using freshly prepared phospholipid vesicles.
Normal reference ranges were established in 30 healthy normals (20 females, 10 males; 
mean age 34 years) not using drugs known to affect the coagulation system. There was 
no difference in median ETP  between male and females, but women gave significantly 
higher ETP+apc values than m en (Table 18). The mean time o f peak throm bin formation 
was 98 seconds (standard deviation 14 seconds) without APC and 113 seconds 
(standard deviation 21 seconds) w ith APC.
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Table 18: Reference ranges for ETP  and E7P+apc: Median (2.5th - 97.5th percentiles)
Male (n=10) Female (n=20) All (n=30)
ETP 0.90 (0.73-1.05) 0.93 (0.77-1.06) 0.93 (0.73-1.06)
ETP+apc 0.63** (0.41-0.95) 0.89 **(0.72-1.07) 0.83 (0.42-1.07)
nAPCsr 0.74 (0.56-0.93) 1.01 (0.80-1.23) 0.91 (0.57-1.23)
**P = 0.0001
As would be expected, factor V Leiden caused a marked increase in ETP+apc in the 
seven heterozygous patients studied (median 1.84 [IQR 1.77-2.32, P < 0.0001]). A 
small but significant increase in ETP  was also observed (median 1.07; IQR 0.8-1.28).
Although women receiving the combined oral contraceptive pill (COC) were excluded 
from the normal reference range, eight additional women receiving COCs were tested. 
As I have demonstrated using the subsampling method, COC use is associated with 
APC resistance in thrombin generation assays and both the ETP  and ETP+apc values 
were significantly higher than female reference ranges (ETP  median 1.03 [95% 
range0.86 - 1.23]; ETP*apc 1.26 [1.07 - 1.68]).
5.3.3. The effect of plasma factor VIII levels
In developing the automated method, I had reduced the tissue factor concentration with 
the aim o f making the method sensitive to factor VIII. In order to study the effect o f  
factor VIII concentration on ETP  and ETP+apc, varying quantities o f  factor VIII 
concentrate (Alphanate®, Grifols, Cambridge, UK) was added to plasma from a patient 
with severe haemophilia A. Increasing factor VIII concentration caused a dose 
dependent increase in both ETP  and ETP+apc with near normal levels observed at a 
factor VIII concentration o f 0.10 IU/ml (Figure 48).
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Figure 48: The effect of plasma factor VIII concentration on thrombin generation.
Purified factor VIII concentrate w as added to plasm a from a severe haemophiliac. ETP  is 
represented by the shaded blue bars and ETP+Apc is represented by solid red bars.
5.3.4. The effect of plasma tissue factor pathway inhibitor levels
In order to investigate the influence o f tissue factor pathway inhibitor (TFPI) activity on 
ETP and ETP+apc, a polyclonal antibody (rabbit anti-human TFPI IgG, American 
Diagnostica Inc.) known to block TFPI function, was added to normal plasma to give 
concentrations o f 12.5 -  200 ng/mL i.e., a maximum o f 0.2 mL o f antibody at 1.25 g/L 
were added to 1ml o f plasma. Although a buffer control was used to control for the 
effect o f dilution, an irrelevant antibody control was not used. Thrombin generation was 
performed with and without rhAPC on the ACL9000 using the continuous measurement 
method. The progressive blocking o f TFPI function caused a dose dependent increase in 
ETP a?c o f up to 50% in normal plasm a and a modest decrease in ETP  (Figure 49). 
Furthermore, when TFPI antigen and thrombin generation were studied in 32 plasma 
samples from a range o f patients (aPA positive and negative, but no factor V Leiden) 
and controls, a significant negative correlation was observed between TFPI antigen and
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Figure 50: TFPI antigen vs ETP +APC
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Figure 51: TFPI antigen vs. ETP
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5.4 Discussion
Although the results from my RVV clotting test were encouraging, there is no routine 
test that quantitatively measures the thrombin forming capacity o f a plasm a sample. In 
order to understand the mechanisms by which aPA caused resistance to APC, it was 
necessary to develop a method to assess throm bin generation in the presence o f APC. 
Initially I concentrated on developing a manual sub-sampling technique. APC resistance 
was measured as a sensitivity ratio (nAPCsr) in an amidolytic assay o f  tissue factor 
initiated thrombin generation, with and without exogenous rhAPC.
Tissue factor ELISA remain poorly standardised, as there is no international standard 
for the determination o f relative potencies, and assays are frequently non-parallel. 
Furthermore, the manufacturers o f throm boplastin reagents containing recombinant 
human tissue factor do not routinely provide the tissue factor concentrations for their 
reagents. Consequently, while I have attempted to estimate the tissue factor 
concentration wherever possible, I believe that the dilution may be more reliable and I 
have used both throughout this thesis.
Initial experiments using Innovin diluted at approximately 1/8 resulted in consistent 
thrombin generation, but no detectable APC activity at 5nM. Increasing the APC 
concentration did not seem to be a reasonable option as this would require plasm a APC 
concentrations far in excess o f those seen in vivo. I inferred that the absence o f 
detectable APC activity was most probably due to the rapid accumulation o f FVa 
having a swamping effect on the APC as previously described (Curvers et al. 2002a), 
and I subsequently improved the sensitivity by reducing the tissue factor concentration. 
It was found that using throm boplastin within 8  hours o f reconstitution, and the use o f 
freshly prepared buffers improved the precision o f the method. I identified the 
phospholipid preparation as the other important source o f  variability and overcame this
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by storing multiple aliquots o f a single preparation under nitrogen, at -80°C, thus 
preventing oxidation.
5.4.1 Oral contraceptive use
Thrombin generation assays are notoriously difficult to standardise, due to 
methodological variation and the technical difficulty. My aims were twofold: I wanted 
to evaluate the utility o f the ETP for the detection o f small changes in haemostatic 
systems; I also wanted to corroborate the findings o f increased APC resistance 
associated with 3rd generation COC.
There are several potential explanations for the reported excess risk o f  venous 
thrombosis associated with 3rd generation COCs compared to 2nd generation COCs. 
Rosing et al (1997) reported that users o f the 3rd generation COC dem onstrated an 
acquired increase in resistance to APC, measured in endogenous throm bin potential 
(ETP) assays, which resulted in excess throm bin generation, and that the ETP based 
APC resistance is a risk factor for venous throm boembolism (Tans et al 2003).
A number o f previous studies have shown that protein S is decreased in women 
receiving COC pills (Archer, Mammen, & Grubb 1999; Granata et al. 1991; W inkler et 
al. 1999)It is known that Ethinylestradiol alone, may cause decreased protein S, and this 
may take 4 weeks to reverse (van Ommen et al. 1999). In sample I o f this study, protein 
S levels were lower in users o f 3rd generation COCs than 2nd generation COCs. 
However, although users o f both types showed a significant increase in nAPCsr and 
plasma prothrombin concentration, only women receiving 3rd generation COCs showed 
a concomitant decrease in protein S levels. Although I did not find a significant 
relationship between plasma prothrombin concentration and nAPCsr, prothrombin 
concentration did correlate, albeit weakly, with ETP and ETP+apc, so it is probable that 
the differences in nAPCsr between pill types and between samples I and II were due in
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part to the increase in prothrom bin levels (Curvers et al. 2002b). Switching from 2nd to 
3rd generation COCs caused a significant decrease in protein S antigen, mirrored when 
switching COCs in reverse fashion. Tans et al (2000) have shown a similar decrease in 
protein S in association with DSG COC. While inherited protein S deficiency is 
associated with an increased risk o f  thrombosis, and family studies (Simioni et al. 1999) 
have shown a high relative risk o f VTE in congenital protein S or C deficiency 
compared to non-carriers. However, the exact relationship between protein S deficiency 
and thrombosis has recently been questioned (Liberti et al 1999).I have shown a strong 
association between protein S levels and nAPCsr.
This study independently confirms R osing’s observations (1997), that nAPCsr is higher 
in women receiving DSG than LNG containing COCs. It is probable that both increased 
plasma prothrombin and reduced protein S levels contribute to the loss o f APC co-factor 
activity and hence the relatively increased nAPCsr results linked with 3rd generation 
COCs. Tissue factor pathway inhibitor (TFPI) affects the initiation phase o f  coagulation 
and, as I have shown, may influence ETP APC sensitivity assays. It was not possible to 
measure TFPI levels in these samples (due to insufficient stored plasma) but as reduced 
TFPI levels have been reported in COC users (Dahm et al. 2006), this may also have 
influenced the results. A recent study (Kemmeren et al. 2004) suggested that the 
differential effects o f 2nd and 3rd generation COCs on the protein C pathway are due in 
part to the greater protective effect o f levonorgestrel on the estrogen-mediated effects on 
protein S levels. This, in association with APCR, may be implicated in the 
pathophysiology o f thrombosis in COC users. It is likely that COC users whose nAPCsr 
are in the highest percentiles may be at greatest risk, but a further triggering factor may 
be necessary before actual thrombosis occurs.
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5.4.2 Antiphospholipid antibodies
These initial results suggested that the subsampling method was a sensitive indicator for 
abnormalities in the protein C anticoagulant pathway. I was keen to find out whether I 
could use the same technique to study the procoagulant effects o f antiphospholipid 
antibodies. I studied plasm a from sixteen patients with aPA, and found abnormalities in 
the thrombin generation curves in twelve. While increased nAPCsr were found in 
eleven patients, the underlying abnormalities were very heterogeneous. Thrombin 
generation, in the absence o f  APC, was reduced, normal or increased, with normal times 
for peak thrombin generation, accelerated throm bin generation and delayed thrombin 
generation all observed. In most cases throm bin generation in the presence o f  APC was 
normal or increased. In some cases, a prolonged lag time to the start o f  thrombin 
generation and delayed peak throm bin generation, analogous to the lupus anticoagulant 
effect were observed in association w ith increased throm bin generation in the presence 
o f APC. If these results were representative o f  APS patients, they could go a long way 
towards explaining the prothrom botic phenotype observed in APS. Although 
antithrombin is the principal inhibitor o f free throm bin, the protein C pathway is the 
major feedback mechanism to control the am ount o f thrombin generated in vivo. The 
protein C pathway also plays a major role in localising thrombin generation to the site 
o f injury as it has been reported that APC does not regulate thrombin production on the 
platelet surface (Camire et al. 1998; Taube et al 1999) but acts on the vascular 
endothelium(01iver et al 2002), although this has been disputed (Briede et al. 2001). 
Consequently, although excessive throm bin generation per se is strongly associated 
with hypercoagulable states, the amount o f thrombin formed in the presence o f APC is 
probably more significant than the total amount o f thrombin generated in its absence, 
when determining thrombotic risk. This is particularly true o f the aPA, as it has been
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reported that overall throm bin generation is reduced in the majority o f cases, which 
would be expected to cause a bleeding disorder rather than thrombosis.
However, there were several drawbacks associated with using this subsampling method 
to study aPA. The method was labour intensive, involving in excess o f 60 pipetting 
steps per sample tested. No more than four patient samples per day could be tested. 
Even when taking 36 subsamples from each sample, it was possible to miss the peak 
thrombin generation, either due to accelerated throm bin generation with a short peak, or 
delayed thrombin generation giving a peak after the end o f  frequent sampling. It was 
simply not practical to subsample every 10 seconds for 3-4 minutes for each limb o f the 
test. The subsampling requires a high degree o f dexterity and accurate tim ing is 
paramount. Not surprisingly, it was not always possible to achieve the degree o f 
precision required and some samples are wasted as a result.
5.4.3 Continuous automated monitoring of thrombin generation
While the subsampling thrombin generation method yielded some very interesting 
results, it was clear that I would have to develop a less labour intensive method to 
measure thrombin generation and sensitivity to APC. As I did not have access to 
specialised equipment at the time, a method which could be performed using a standard 
laboratory coagulometer was highly desirable. In order to achieve this, several problems 
had to be addressed. The short time interval between measurements resulted in a ‘noisy’ 
signal, which required a moving average logarithm to smooth the signal and allow the 
results to be recorded and displayed graphically.
The selection o f tissue factor concentration was critical, as too high a concentration
would lead to the rapid formation o f  factor Va, thus swamping the APC, while at
concentrations o f <5pM, interference from in vitro contact activation can be a major
factor (Luddington & Baglin 2004), requiring the addition o f com trypsin inhibitor to
blood collection tubes for its abolition. Furthermore, at low tissue factor concentrations,
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the TFPI dependent action o f  protein S far exceeds its APC cofactor activity (Hackeng 
et al. 2006). I found that at tissue factor concentrations in excess o f 8pM, the speed o f  
the reaction swamped the APC, so that APC concentrations in excess o f  20nM  were 
required. By using a tissue factor concentration o f approximately 7pM (Innovin diluted 
at 1:600) it was possible to achieve a useful APC ratio (thrombin generation without 
APC: throm bin generation with APC approximately 2.5:1). Increasing the concentration 
o f APC is known to increase the APC ratio (Nicolaes et al 1997), but in my assay this 
was at the expense o f increased imprecision in the ETP+A?C measurement. There was 
still some between assay variation, and normalisation against pooled normal plasma 
(PNP) was used as previously suggested (Curvers et al 2002b; Nicolaes et al 1997).
Traditionally, ETP based APC sensitivity tests have been reported as a norm alised ratio 
o f the ETP value with and without APC relative to PNP. A major drawback o f  this 
approach is that the ratio is not quantitative, as it does not take into account the baseline 
level o f thrombin generation. This makes the normalised ratio relatively insensitive to 
factor VIII concentration (de Visser et al 2005). By measuring the amount o f  thrombin 
produced relative to that o f PNP, and reducing the tissue factor concentration, I have 
been able to make the assay sensitive to increased factor VIII concentration. Rosing et 
al (2004) has suggested that using this approach to detect the failure o f  the protein C 
system to down regulate excessive thrombin generation rather than using a simple ratio, 
may be more representative o f physiological processes.
In a system such as this, it is necessary to provide a phospholipid surface for both 
thrombin generation and for the APC complex to form. The source o f phospholipids 
used for the assay proved to be a difficult decision. Initially I used freshly prepared 
phospholipid vesicles. This produced a well-defined thrombin generation peak, but the 
preparation was time consuming, and their stability was limited to 6 hours. Using a 
stable phospholipid emulsion (kindly provided by Steffen Rosen at Rossix) significantly
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reduced the time required to perform the assay and gave very similar results in terms o f 
the quantities o f throm bin generated and, although the APC ratio was slightly lower, the 
precision o f the method improved. However, the signal was ‘noisier’ than that obtained 
using the freshly prepared vesicles, so that it was frequently difficult to obtain a well- 
defined throm bin peak or determine the lag phase prior to the throm bin generation 
burst. The method by which the ACL7000 mixes the plasma and reagents in the test 
rotors creates turbulence, w hich can result in a noisy signal, and this is exacerbated by 
turbidity in the reagents or plasma. As I was prim arily interested in the total amount o f 
thrombin generated, rather than the kinetics, this did not present a significant problem. 
However, if  this method was to be used to study the kinetics o f throm bin generation, 
freshly produced vesicles, or some way o f reducing turbulence during measurement 
would be required. Due to this turbulence and the relatively high concentration o f  tissue 
factor used in this method, little useful inform ation about the lag time before thrombin 
formation could be obtained.
A limitation o f any chromogenic m ethod for measuring thrombin generation is that the 
plasma must be defibrinated prior to use. Fibrin does not readily allow the passage o f 
light and so the large change in optical density at the point o f coagulation masks the 
smaller changes in OD caused by the cleavage o f the substrate. Clearly this precludes 
the use o f platelet rich plasm a (PRP). W hile the use o f PRP undoubtedly provides a 
great deal o f information about throm bin generation on the platelet surface, it is 
doubtful that it tells us a great deal about the anticoagulant pathways. It is now 
generally accepted that the site o f throm bin generation is different from the site o f APC 
dependent degradation o f factor Va and V illa  (Hoffman et al 2001). Oliver et al (2002) 
showed that APC activity was considerably more potent on phospholipid surfaces and 
endothelial cells than platelets. For this reason, when APC resistance is studied in PRP
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using throm bin generation, relatively high concentrations o f APC are required even at 
low tissue factor concentrations (Regnault et al. 2003).
My assay is sensitive to the factor V Leiden mutation, COC use, increased levels o f 
prothrombin, and reduced levels o f  protein S and TFPI as been previously described for 
the ETP-based normalised APC ratio {nAPCsr) (de Visser et al 2005). However, as I 
used a quantitative approach to measure ETP+apc, my assay was also sensitive to factor 
VIII concentration. It has been suggested that raised thrombin generation alone is 
predictive o f deep vein throm bosis (Brummel-Ziedins et al. 2005), although the reported 
odds ratio was relatively low (OR 1.6). Tans et al (2003) reported that the nAPCsr was 
a more useful test in determ ining throm botic risk (odds ratio o f 2.4 for women and 7.5 
for men). As ETP+apc is sensitive to additional risk factors, it is interesting to speculate 
whether this measurement could be more useful than the nAPCsr in this context.
My preliminary data suggested that, in the aPA positive patients studied, thrombin 
generation was abnormal, w ith a variable anticoagulant response to APC. It has also 
been possible to establish a possible mode o f  action for lupus anticoagulants, which 
explains both the observed prolonged in vitro clotting time and the paradoxical increase 
in markers o f in vivo throm bin generation and throm botic risk, i.e., delayed onset o f 
thrombin generation, which is analogous to a prolonged clotting time, with a failure o f 
APC to inhibit thrombin generation. In developing and characterising a more rapid 
automated method for ETP-based sensitivity to APC, I paved the way for a more in 
depth study o f APC resistance associated with the antiphospholipid syndrome.
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6. A Study of the Protein C Pathway in Patients with 
Antiphospholipid Antibodies
6.11ntroduction
There are conflicting reports about aPA and throm bin generation. It has been reported 
that aPA increase in vitro throm bin generation (Adams et al 2004; Lean et al. 2006; 
Liestol et al 2007; Rand et al 1999), prolong the time to peak throm bin generation and 
reduce peak thrombin generation (Regnault et al 2003), or inhibit throm bin generation 
(Hanly et al 2000; Sheng et al 2001a). Several authors have implicated aPA in the 
inhibition o f APC (Aznar et al 1997; Gennari et al. 2002), with IgG with LA activity 
(Borrell et al. 1992; N ojim a et al. 2002; Regnault et al 2003) and anti P2 GPI reported to 
be the antibodies responsible (Galli et al 1998; Gennari et al. 2003; M artinuzzo et al 
1996; Mercier et al 1998; Viveros et al 2005). It has been reported that P2 GPI is 
necessary for the inhibition o f protein C activity by IgM human monoclonal 
anticardiolipin antibodies (Ieko et al 1999) and that this may be achieved by increased 
binding o f P2 GPI to phospholipid surfaces facilitated by the dimerisation o f  P2 GPI by 
aPA molecules (Takeya et al 1997). To date, the only published studies o f aPA 
associated APC resistance, that used a throm bin generation-based assay (Lecompte et 
al. 2007; Regnault et al 2003) reported that IgG from 7/8 patients w ith LA inhibited 
APC, and that and that in patients with LA both throm bin generation and APC activity 
were inhibited (Lecompte et al 2007; Regnault et al 2003).
The binding o f P2 GPI to anionic phospholipids is dependent on four highly conserved 
hydrophobic amino acids sequence at positions 313-316. A missense mutation at codon 
316 (TGG > TCG) replaces Trp316 with Ser316, resulting in a P2 GPI molecule which is 
unable to bind phosphatidyl serine (Horbach et al. 1998b; Nash et al. 2003; Rahgozar et 
al. 2007). I used plasma and immunoglobulin from a patient with anti-p2 GPI antibodies
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who was also homozygous for the Trp316Ser mutation (Nash et al 2003) to study the 
effect o f anti-p 2 GPI: P2 GPI interactions on thrombin generation and APC function.
My initial work, discussed in the previous chapters, suggested that acquired APC 
resistance in patients with aPA may be more common than previously thought, and that 
anti-p2 glycoprotein-I antibodies were not prerequisite for this phenomenon. The data 
obtained using the subsam pling method showed that the behaviour o f aPA was 
extremely heterogeneous with respect to their action on the procoagulant and natural 
anticoagulant pathways. I now  sought to use automated thrombin generation to study 
these mechanisms in more detail.
There were several questions that needed to be answered:
• How prevalent were the abnormal throm bin generation patterns that I found 
using the subsampling method?
• Is abnormal throm bin generation in APS patients antibody mediated, or are there 
other mechanisms?
• Do monoclonal antibodies react in the same way as affinity purified 
immunoglobulin from APS patients?
• Do anti P2 GPI antibodies cause resistance to APC, and if  so, how?
• Can aPA from a patient homozygous for the Trp316Ser P2 GPI mutation cause 
APC resistance?
• Can aPA cause resistance to APC independently o f P2 GPI?
6.2. Methods
6.2.1. Patients and samples
Venous blood was collected as described in the methods chapter. Plasma from 118
unselected patients, with a range o f clinical conditions, sent for antiphospholipid
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screening at our laboratory were studied (Table 19). None o f the patients had an acute 
thrombotic event, were receiving anticoagulants or were known to be pregnant at the 
time o f testing. Seven patients with the factor V Leiden mutation were analysed 
separately, as this m utation has a profound effect on APC sensitivity. Two o f these 
patients had aCL but none had LA or anti-p 2 GPI. O f the remaining 111 patients, 62 
were persistently aPA positive (on at least two occasions >12 weeks apart), 40 were 
negative, and 9 had only transient positivity (i.e., tested on more than one occasion, but 
not found to be persistently positive). In four asymptomatic patients aPA were found 
coincidentally to routine coagulation testing. Twenty-five patients fulfilled the modified 
Sapporo criteria for definite APS (M iyakis et al 2006). For the purposes o f this 
classification, moderate titre anticardiolipin or anti-P 2 GPI antibodies were defined as 
>15 GPLU or MPLU.
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Table 19: Clinical conditions of the patients tested (*som e patients had more than one of the 
listed conditions)
Clinical con d ition  aPA p o sitiv e  aPA n eg a tiv e  T ransient aPA
T h rom b osis
Arterial 18 3 2
V enous 11 13 1
P regnancy m orbidity
Recurrent miscarriage (<20 wks) 8 16 2
Intrauterine fetal death (>20 wks) 6 4 1
Preeclam psia 1 2 0
HELLP 3 0 0
Other co n d itio n s
Immune thrombocytopenia 6 0 1
Asymptomatic aPA 4 0 1
Factor V Leiden 3 3 0
Leprosy 1 0 0
Migraine 3 0 0
Leprosy 1 0 0
System ic lupus erythem atosus 2 0 0
Chronic recurrent multifocal osteom yelitis 0 0 1
1 mm unocom prom ised 1 0 0
Lymphoproliferative disorder 1 0 0
Family history of thrombosis 1 0 1
6.2.3 In Vitro immunoglobulin spiking
In order to show that the observed
experiments
impaired response to APC was <
immunoglobulin in aPA patients and, to study aPA antibodies in patients receiving oral 
anticoagulants, it was first necessary to purify IgG and IgM. To date, very little work 
has been published on the effects o f purified IgM from aPA. Freeze-dried, affinity 
purified IgG and IgM extracts were dissolved in defibrinated normal pooled plasma at 
approximately 6 mg/ml and lm g/m L respectively. Doubling dilutions o f these 
preparations were prepared to give 100%, 50%, 25% and 12.5% solutions, which were 
tested using the ETP and ETP+apc methods. IgG and IgM preparations from normal 
subjects and aPA positive patients were tested. The clinical and laboratory 
characteristics are shown in tables 2 0  and 2 1 .
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Table 20: Characteristics of individuals used for preparation of IgG fractions
IgG fraction  .*"u^u s . . .. . an^"p2 C linical history
_ _____________ an tico a g u la n t anticardiolip in  G lycoprotein-I______________________
N1 - - - n on e
N 2  - n on e
N 3  - n on e
a P A  1 + + - V e n o u s  throm boem bolism
a P A  2  - + +  - TIA Retinal vein  throm bosis
a P A  3  + +  + + + +  V e n o u s  throm boem bolism
a P A  4  + +  + + +  + + +  Stroke p reec la m p sia
a P A  5  + + +  - - Stroke SLE TIA
a P A  6  + +  + +  + +  V e n o u s  throm boem bolism
Table 21: Characteristics of individuals used for preparation of IgM fractions
IgG fraction . '^u *:)us| . .. . antj‘p2 C linical h istory
_ _____________a n tico a g u la n t anticardiolip in  G lycoprotein-I______________________ 7
N4 - n on e
N5 - n o n e
N6 - n o n e
aPA7 + +  + +  + +  V e n o u s throm boem bolism
aPA8 + + +  - + +  V e n o u s throm boem bolism
aPA9 +++ +++ +++ Leprosy
aPA10______________ ++________________ +________________ +__________ Stroke p reec la m p sia
Monoclonal anti-p 2 GPI antibodies (Clone 27671Y; a kind gift from Barry Woodhams, 
Diagnostica Stago, Asnieres, France) were used at 60ug/ml in pooled normal plasma. 
This clone (27G7) was originally produced and characterised by A m out et al (1998b). 
This monoclonal antibody dem onstrated LA activity in normal plasma (A m out et al.
1998a) and, although it has been suggested that it may recognise domain I or II o f p2 
GPI, the epitope specificity has not been mapped.
6.2.4. p2  glycoprotein-l experiments
Plasma was obtained from a w om an with the Trp316Ser P2 GPI mutation (Horbach et al 
1998b). She had an obstetric history o f  a stillbirth at 28 weeks, associated with 
hypertension and severe intrauterine growth restriction and also a miscarriage at 9 
weeks. She was persistently positive for IgG anticardiolipin antibodies and IgG antip 2 - 
GPI antibodies. The presence o f  LA was variable, but testing was positive on several 
occasions. Although the patient has a poor obstetric history, it is uncertain whether these 
antibodies are pathogenic. Studies examining the binding o f  the Trp316Ser P2 GPI to
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purified cardiolipin showed markedly reduced binding in comparison with p 2 GPI from 
pooled normal plasm a (Nash et al 2003). IgG was purified from this patient as 
previously described. IgG fractions from a male APS patient with LA, IgG 
anticardiolipin, IgG anti-p 2 GPI and IgG anti-prothrombin, and pooled normal plasma 
were also prepared.
ETP and ETP+apc m easurem ents were performed on plasma from the woman with the 
Trp316Ser p2 GPI m utation
• ETP and ETP+apc measurem ents were performed on the following plasma/IgG 
fraction combinations:
• IgG from the male APS patient was added to pooled normal plasma.
• IgG from the wom an w ith the Trp316Ser P2 GPI mutation was added to pooled 
normal plasma.
• Normal IgG was added to pooled normal plasma.
• IgG from the male APS patient was added to the plasma o f the woman with the 
Trp316Ser p 2 GPI m utation
• IgG from the w om an w ith the Trp316Ser p 2 GPI mutation
Purified human p2GPI protein (SCIPAC Ltd, Sittingboume, UK) was added to the 
following plasmas at several concentrations (25, 50, 100 and 200 mg/L):
Pooled normal plasma
The plasma o f a healthy individual with low plasma p 2 GPI 
Plasma from the woman with the Trp316Ser P2 GPI mutation
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6.2.5 Antiphospholipid antibody preincubation experiments
In order to investigate the possible specificity o f aPA, im munoglobulin fractions were 
preincubated with plasma, APC and tissue factor prior to measurement o f ETP+apc. This 
was performed using the subsampling endpoint method. I was unable to preincubate 
antibodies with APC in plasm a as APC is rapidly inactivated (Neese, Pratt, & Church 
1994). Consequently, it was not possible to examine the effect o f anti-p 2 GPI and P2 GPI 
complexes on APC in plasma, prior to the initiation o f coagulation.
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6.3 Results
6.3.1 Thrombin generation in patients with and without aPA
When all 118 patients were studied, no significant difference in ETP between aPA 
positive and negative patients was observed. ETP values for aPA positive patients (p = 
0.008), aPA negative patients and (p = 0.03), patients with factor V Leiden (p = 0.02) 
were all significantly higher than the normal healthy subjects (Table 22 and Figure 52). 
ETP+apc values in aPA positive patients were significantly higher than those in aPA 
negative patients (Table 22 and Figure 53; P = 0.02). All patient groups had 
significantly higher ETP+apc values than the normal healthy subjects (all P < 0.0001). It 
was notable, that the transiently aPA positive patients gave very similar ETP and 
ETP+apc values to the aPA negative patients, although the numbers were too small to 
draw any significant conclusions (Tables 22 and 23). If  the nAPCsr was used to express 
the thrombin generation data, no significant differences between aPA negative and 
positive patients was observed and the transiently positive patients had values similar to 
the aPA positive patients (Table 23)
In the aPA negative patients high ETP, ETP+apc and nAPCsr values were found in 
17/40 (43%), 22/40 (55%) and 18/40 45% respectively, while in the aPA positive 
patients these figures were 28/62 (45%) 42/62 (6 8 %) and 38/62 (61%). 5/9 (56%), 6/9 
(67%) and 6/9 (67%) o f the transiently positive patients had abnormal ETP, ETP+apc 
nAPCsr values. There were no significant differences in the association o f  aPA status 
with high ETP, ETP+apc or nA PCsr values, as judged by Fisher’s exact test.
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Table 22: ETP results in patients with and without aPA
Mann Whitney U test compared with normal subjects ** P < 0.01; § P < 0.05
Norm al 
healthy  
su b jec ts  
(n = 2 8 )
P ersisten tly  
a P A  positive  
p atien ts (n = 
6 2 )
a PA  
n eg a tiv e  
patients  
(n = 4 0 )
Transiently  
positive  aP A  
patients  
(n = 9)
F actor V 
L eiden
(n = 8)
M edian 0 .9 3 1.05** 1 .0 1 § 0 .9 5 1 -07§
IQR 0 . 8 4 - 1 . 0 2 0 . 8 5 - 1 . 2 2 0 . 8 8 - 1 . 1 7 0 . 8 8 - 0 . 9 7 1 .0 0 - 1 . 1 1
Minimum 0 .7 3 0 .7 3 0 .7 5 0 .7 5 0 .7 8
Maximum 1 .0 7 1 .6 6 1 .1 0 1 .1 0 1.31
Table 23: ETP+APC results in patients with and without aPA
Mann Whitney U test com pared with normal subjects ** P < 0.0001; §  P = 0.0001
Norm al 
healthy  
su b je c ts  
(n = 2 8 )
P ersisten tly  
a PA positive  
p a tien ts  (n = 
6 2 )
aP A  
n eg a tiv e  
patients  
(n = 4 0 )
Transiently  
aP A  positive  
patients  
(n = 9)
F actor V  
L eiden
(n = 8)
M edian 0 .8 3 1.46** 1 2 3 § 1 25§ 1.84**
IQR 0 . 7 3 - 1 . 0 0 1 . 0 4 - 1 . 7 9 1 .0 8  -  1 .5 6 1 . 0 8 - 1 . 5 6 1 .7 7 -2 .3 2
Minimum 0.41 0 .61 0 .6 4 0 .8 9 1 .57
Maximum 1 .09 2 .8 4 3 .3 8 1 .7 9 3 .1 8
Table 24: nAPCsr results in patients with and without aPA
Mann Whitney U test com pared with normal subjects ** P < 0 .0 0 0 1 ; §  P = 0.0001
Normal 
healthy  
su b jects  
(n = 28 )
P ersisten tly  
a P A  positive  
p a tien ts (n = 
62 )
a PA  
n eg a tiv e  
p atien ts  
(n = 4 0 )
Transiently  
aP A  positive  
patients  
(n = 9)
F actor V 
L eiden
(n = 8)
M edian 0 .9 3 1.42** 1 -21 § 1.48§ 1.77**
IQR 0 . 8 4 - 0 . 9 3 1 .0 4  -  1 .62 0 . 9 3 - 1 . 5 1 1 . 2 2 - 1 .6 1 1.61 - 2 . 4 3
Minimum 0 .7 3 1 .0 4 0 .6 5 0 .9 3 1 .44
Maximum 1 .0 7 2 .9 0 2 .3 8 1 .88 3 .1 4
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Figure 52: ETP values in normal subjects, aPA negative patients (aPA neg), persistently aPA  
(aPA +ve), patients with transiently positive aPA, and patients with factor V Leiden (FVL).
The broken line indicates the 9 7 .5 h percentile of normal.
5.00 P = 0.02
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Figure 53: e TP+apc values in normal subjects, aPA negative patients (aPA neg), persistently 
aPA, patients with transiently positive aPA, and patients with factor V Leiden (FVL)
The broken line indicates the 97 .5 th percentile of normal.
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W hen ETP and ETP+apc were studied by clinical group, aPA status had no significant 
effect on the median ETP value (Figures 54 and 55). There was no significant 
association between aPA status and the incidence o f high ETP within the clinical 
groups. However, the ETP was significantly higher in the pregnancy m orbidity group 
than in the throm bosis group (P = 0.007).
ETP+apc values were significantly higher in thrombosis patients who were aPA positive, 
than in those who were aPA negative (P = 0.0007). Moreover, significantly more aPA 
positive patients than aPA negative patients with thrombosis had high ETP+apc values: 
aPA positive 15/27 (56%) v aPA negative 4/21 (19%); Fishers exact test P = 0.01 
However, aPA status had no significant effect on ETP+apc values in the pregnancy 
morbidity group (Figure 55), but, ETP+apc values were significantly higher in the 
pregnancy morbidity patients than in throm bosis patients (P = 0.001).
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Figure 55: ETP+APC by clinical group.
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No significant differences in time to peak thrombin generation, with or without APC 
were observed between aPA positive and aPA negative patients (Tables 24 and 25). 
Although it was not always possible to obtain clearly defined throm bin generation 
peaks, it was clear that some aPA positive patients demonstrated increased time to peak 
thrombin formation, while others appeared to have accelerated thrombin formation with 
and without APC.
T able 25: Time to peak thrombin generation without APC
Norm al 
healthy  
su b jects  
(n = 2 8 )
P ersisten tly  
aP A  positive  
patien ts (n = 
6 2)
a PA  
n eg a tiv e  
patien ts  
(n = 4 1 )
T ransiently  
aP A  positive  
patients  
(n = 9)
F actor V 
L eiden
(n = 8)
M edian 105 110 1 0 0 100 90
IQR 9 3 - 1 1 0 9 0 - 1 2 0 9 8 - 1 2 0 9 3 - 1 2 5 9 0 - 9 3
Minimum 90 8 0 8 0 90 9 0
M aximum 120 1 60 1 4 0 140 1 00
Table 26: Time to peak thrombin generation with APC
Normal P ersisten tly aP A T ransiently F actor V
healthy aP A  positive n eg a tiv e aP A  positive L eiden
su b jects patien ts (n = patien ts patients
(n = 28) 62) (n = 4 1 ) (n = 9) (n = 8)
M edian 120 130 11 0 1 10 12 0
IQR 1 1 3 - 1 3 0 1 0 0 - 1 4 0 1 0 0 - 1 2 0 1 0 0 - 1 2 0 9 8 - 1 4 0
Minimum 100 80 8 0 8 0 90
M aximum 1 40 2 1 0 140 140 14 0
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O f the 25 patients who met the revised Sapporo criteria (M iyakis et al 2006), twenty 
(80%) had a raised nAPCsr, thirteen (52%) had raised ETP and nineteen (76%) had 
raised ETP+apc (Table 27). There was no obvious association between ETP or ETP+apc 
and clinical presentation, LA, aCL or a n t i^ G P I  positivity.
Table 27: Characteristics of patients meeting the Sapporo criteria for definite antiphospholipid 
syndrome.
Patient Clinical presentation LA ig G igM p 2 ig G p 2 igM nAPCsr ETP
e t p *apc
1 TIA + arterial stroke + - ++ - +++ 0.88 1.01 0.89
2 Arterial stroke - +++ - - - 1.00 0.94 0.94
3 DVT + + - + + + - + + 1.16 0.84 0.98
4 DVT ++ - - - ++ 0.93 1.08 1.01
5 Arterial stroke + ++ - - - 0.80 1.30 1.04
6 RM - ++ + - + 1.26 0.85 1.07
7 ITP TIA + arterial stroke +++ - - - - 2.10 0.60 1.26
8 Recurrent DVT + PE + ++ - + - 1.64 0.83 1.36
9 RM - ++ - - - 1.61 0.85 1.37
10 Ret vein thrombosis + TIA - ++ - - - 1.26 1.14 1.43
11 DVT ++ ++ - - - 1.72 0.89 1.54
12 DVT - ++ - - - 2.24 0.69 1.56
13 Preeclampsia - ++ - - - 1.29 1.23 1.58
14 RM + - - - - 1.24 1.32 1.64
15 TIA ++ - - - - 1.37 1.23 1.68
16 Cl 2° to arterial disease ++ - - - + 1.49 1.19 1.77
17 TIA + arterial stroke +++ - ++ - - 2.79 0.65 1.81
18 TIA + arterial stroke ++ + - - ++ 1.44 1.26 1.82
19 RM + preeclampsia - - - +++ - 1.58 1.17 1.85
20 IUFD + preeclampsia + + - - + 1.51 1.29 1.95
21 Cl 2° to arterial disease +++ + - - - 1.94 1.09 2.11
22 RM + - - - - 1.62 1.33 2.15
23 DVT +++ + + - ++ 2.90 0.80 2.31
24 DVT ++ - - - - 1.72 1.66 2.84
25 Cl 2° to arterial disease + +++ - + + 2.45 1.67 4.09
Median 1.51 1.09 1.58
25th percentile 1.26 0.85 1.26
75th percentile 1.72 1.26 1.85
Minimum 1.24 0.65 1.26
Maximum 2.90 1.67 4.09
Cl = cerebral ischaemia; DVT = deep vein thrombosis; TIA = transient ischaemic attacks; RM = recurrent miscarriage; 
PE = pulmonary embolism
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6.3.2 The effect of IgG and IgM from patients with aPA on thrombin generation
IgG fractions prepared from three normal healthy subjects and five patients with APS, 
were added to pooled normal plasm a to examine the effect on ETP and ETP+apc. ETP 
was reduced by 4/5 IgG fractions, while ETP+apc was increased by 3/5 fractions (Table 
28; Figures 56 and 57). It was notable that fraction aPA5 (a patient with no detectable 
anti-(3 2 GPI) inhibited thrombin generation in the absence o f  APC but also inhibited APC 
activity. The time to peak throm bin generation with and w ithout APC was prolonged by 
both aPA5 (Figure 58) and aPA 6 .
Table 28: The effect of IgG fractions on ETP and ETP+APC
IgG fraction IgG c o n e  (m g/m l) nA PC R sr ETP ETP +APC
N1 4 .3 1 .0 5 0 .9 9 1 .0 4
N2 3 .7 1 .0 7 0 .8 9 0 .9 5
N3 4.1 1 .0 0 0 .8 8 0 .8 8
aP A  1 5 .3 1 .02 0 .9 6 0 .9 8
aP A  2 6 .0 1 .0 3 0 .8 6 0 .8 9
aP A  3 4 .5 1 .08 0 .9 2 0 .9 9
aP A  4 4 .3 1 .2 0 0 .8 9 1 .0 7
aP A  5 6 .7 2 .3 0 0 .7 6 1 .7 5
aP A  6 6 .9 2 .2 9 0 .7 8 1 .7 9
IgM fractions prepared from three normal healthy subjects and four patients w ith APS, 
were added to pooled normal plasma to examine the effect on ETP and ETP+apc. ETP 
was reduced and ETP+apc was increased by all four IgM fractions from patients with 
APS. (Table 29; Figures 56 and 57).
Table 29: The effect of IgM fractions on ETP and ETP+APC
IgM fraction IgM c o n e  (m g/m l) nA PC R sr ETP ETP +APC
N4 1.1 1 .0 9 0 .9 9 1 .08
N5 1.5 1 .1 0 0 .9 6 1 .06
N6 1.2 1 .2 4 0 .9 6 1 .04
aP A 7 1.1 1 .5 6 0 .8 2 1 .28
aP A 8 0 .6 1 .6 9 0 .7 8 1 .32
aP A 9 1.6 2.51 0 .5 3 1 .3 3
aP A 10 0 .7 2 .8 2 0 .6 2 1 .7 5
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Figure 56: The effect of the addition of purified immunoglobulin to normal plasm a on ETP. The 
broken line indicates the normal lower limit.
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Figure 57: The effect of the addition of purified immunoglobulin to normal plasma on ETP 
The broken line indicates the normal upper limit.
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Figure 58: The effect of 6.7 mg/ml purified IgG from a patient (aPA5) with antiphospholipid 
antibodies on normal plasma
If fraction aPA9 (a patient with leprosy) was omitted from the analysis, the ETP and 
E T P +a pc  values obtained by spiking o f normal plasm a with immunoglobulin (IgG and 
IgM) from patients with APS showed a significant negative correlation (Figure 59).
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Figure 59: The effect of the addition of purified immunoglobulin to normal plasma on the 
relationship between ETP and ETP+apc.
The point shown in red w as from a patient with immune IgM secondary to leprosy and w as  
excluded from the analysis.
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The addition o f 6 , 3, 1.5 and 0.75 mg/mL o f IgG purified from pooled normal plasma to 
the same pooled normal plasm a produced minor changes in ETP and ETP+apc o f < 6 % 
(Figure 60). The addition o f  similar quantities o f IgG from a patient with APS (aPA5) 
produced a dose dependent inhibition o f  thrombin generation o f up to 23% in the 
absence o f  APC and a 59% increase in ETP+apc as a result o f the inhibition o f APC 
activity (Figure 61).
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Figure 60: The effect of increasing concentrations of normal IgG on normal plasm a (n = 3)
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Figure 61: The effect of purified IgG from a patient with APS (aPA5) on normal plasma
154
6.3.3 The effect on APC function of preincubation with immunoglobulin
In order to investigate the possible specificity o f aPA, immunoglobulin fractions from 
patients with APS were preincubated with plasma, APC and tissue factor prior to 
measurement o f ETP+apc. The addition o f  purified immunoglobulin increased ETP+apc 
as previously demonstrated. In aPA fractions 1 , 3 , 7  and 9, this was more pronounced if  
the aPA were first incubated with APC, while in aPA fractions 2 and 6 , preincubation 
with plasma produced the largest increases in ETP+apc (Figure 62). No clear pattern was 
evident, although preincubation with plasma or APC appeared to inhibit APC activity to 
a greater extent than incubating the aPA fractions with the tissue factor/CaCl2 start 
reagent.
■  No lg
■  Ig + plasma
□  lg + APC
□  Ig +TF
0.8
0.6
0.4
aPA1 aPA2 aPA3 aPA6 aPA7 aPA9N1 N5
Figure 62: The effect on APC function of preincubation with immunoglobulin.
ETP+apc w as performed on pooled normal plasm a in the a b sen ce  of immunoglobulin (No Ig),
and preincubation of immunoglobulin with plasm a (Ig + plasma), with APC (Ig + APC) and with 
the tissue factor start reagent (Ig + TF).
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6.3.4. The effect of anti p2 GPI monoclonal antibodies on thrombin generation
The addition o f increasing amounts o f  a monoclonal anti-p2GPI antibody (27G7) with 
LA activity (Amout et al 1998a) to pooled normal plasma caused minor decreases in 
ETP o f up to 9% and a dose-dependent increase in ETP+apc o f up to 16% (Figure 63).
1.4 i
■  ETP
■ ETP+APC
Monoclonal antibody concentration (ng/ml)
Figure 63: The effect of a monoclonal anti-(32 GPI antibody on normal plasma
6.3.5 The role of p2 GPI and anti-p2 GPI on thrombin generation
In order to study the role o f p2GPI and anti~p2GPI interaction on thrombin generation, I 
prepared IgG fractions from the following plasmas:
• pooled normal plasma
• a patient homozygous for the T rp316Ser p2GPI mutation with anti-p2GPI
• a patient with potent aPA and wild-type p2GPI (aPA 6 )
These were added to normal plasma (wild type p2 GPI) and to plasma from the patient 
homozygous for the Trp316Ser p 2  GPI mutation.
ETP and e t p +apc values for plasma from the Trp316Ser patient and a 50:50 mix with 
normal plasma were very similar (ETP 1.25 and 1.20; ETP+APC 0.83 and 0.87 
respectively). Normal IgG produced minor changes in ETP and ETP+Apc as previously
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shown (Figure 60). The IgG purified from the patient w ith anti-p2 GPI and homozygous 
for the Trp316Ser m utation also caused minor reductions ETP and ETP+apc (<10%) 
(Figure 64, Tables 30 and 31).
IgG from a patient w ith potent LA and anti-P2  GPI (aPA 6 ) caused a dose dependent 
decrease in ETP o f up to 14% and dose dependent increases in ETP+apc o f up to 98% in 
normal plasma (Figure 65, Tables 30 and 31). The same aPA IgG fraction inhibited 
thrombin generation to a greater degree in plasm a from the homozygous Trp316Ser p2 
GPI patient, as dem onstrated by a dose dependent decrease in ETP o f up to 45%. 
However, the inhibition o f  A PC function was considerably less than that observed in 
normal plasma with ETP+apc increases o f  82% in normal plasma and 52% in Trp316Ser 
p2 GPI plasma (Figure 4b).
Table 30: The effect of purified IgG and p2GPI phenotype on ETP. Percentage change
P la sm a  p2GPI IgG so u r c e
IgG concentration  m g/m l
1 .5 3 .0 6 .0
Wild type Norm al p la sm a +2% -3% -5%
Wild type
aP A  positive  T r p 3 1 6 S e r  
patien t
-1% -6% -10%
Wild type a P A 6 -4% -3% -14%
T rpSer316 a P A 6 -11% -30% -45%
Table 31: The effect of purified IgG and p2GPI phenotype on ETP+apc Percentage change
P la sm a  p2GPI IgG so u r c e
IgG concentration  m g/m l
1.5 3 .0 6 .0
Wild type N orm al +4% +5% +6%
Wild type
a P A  p ositiv e  T rp 3 1 6 S er  
patient
+1% -3% -5%
Wild type a P A 6 +55% +82% +98%
T rpSer316 a P A 6 +35% +52% +55%
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Figure 64: The effect of purified IgG from a patient with aPA and the Trp-Ser p2GPI mutation on 
wild type plasma
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Figure 65: The effect of purified IgG from a patient with aPA (aPA6) on wild type plasma
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Figure 66: The effect of purified IgG from a patient with aPA (aPA6) on plasma from a patient 
hom ozygous for the Trp316Ser (32 GPI mutation
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Purified P2 GPI protein was added at 50, 100 and 200 mg/mL to normal plasma, plasma 
from an individual known to have a deficiency in P2 GPI and plasma from a patient who 
was homozygous for the Ser316Trp anti-p 2 GPI mutation who also had a n t i^ G P I  
antibodies. p2 GPI produced an increase in ETP o f up to 27% in the P2 GPI deficient 
plasma, but negligible effects in normal plasma or plasma from the patient with the 
Ser316Trp mutation (Figure 67). The effect on ETP+apc was more pronounced with 
dose dependent responses o f up to 20%, 12% and 21% for normal, Ser316Trp plasma 
and P2 GPI deficient plasma respectively (Figure 6 8 ).
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Figure 67: The effect of added p2GPI concentration on ETP in wild type, hom ozygous  
Ser316Trp p2GPI, and p2GPI deficient plasm as
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Figure 68: The effect of added p2GPI concentration on ETP+APC in wild type, hom ozygous 
Ser316Trp p2GPI, and p2GPI deficient plasm as
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6.3.6 A study of a patient with leprosy and aPA
I studied one patient with leprosy in detail. This patient had strong LA activity and an 
IgM anti-p2 GPI titre o f  >1000 M PLU, but no IgG aCL or IgG anti-P 2 GPI. He also had 
a severe acute phase response with a factor VIII:C level o f >400 IU/dL, C reactive 
protein o f 152 mg/mL, an erythrocyte sedim entation rate o f 44 mm/hour and acquired 
APC resistance by the APTT based method (modified APC ratio 1.52, factor V Leiden 
normal). His free protein S level was 0.22 IU/mL, which may have been due to high 
levels o f C4b binding protein.
Both ETP and ETP+apc were increased relative to that o f normal plasm a (Figure 69). 
However when normal plasma was spiked with purified IgM from the same patient, the 
ETP was considerably inhibited, yet the ETP+apc remained high (Figure 70). 
Furthermore, the time to maximum throm bin generation appeared to be delayed. In 
contrast, IgM from normal plasm a had a negligible effect on ETP or ETP+apc (Figure 
71).
These data show that although IgM from this patient inhibits thrombin generation (in 
the absence o f APC), the underlying acute phase response produces an excess o f 
thrombin generation, thus masking the inhibitory effect o f the IgM on ETP.
The ETP+apc was raised in both the patient’s plasm a and in normal plasm a spiked with 
the patient’s IgM, with values o f 1.84 and 1.71, indicating a failure o f APC to down 
regulate thrombin generation. If the results had been reported as nAPCsr values, the 
patient plasma would have given a value o f  1.57, whereas IgM spiking o f normal 
plasma would have given a m uch higher value o f 3.25.
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Figure 69: Thrombin generation in a patient with immune anti-p2 GPI secondary to leprosy 
infection.
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Figure 70: Thrombin generation in normal plasm a with added IgM from a patient with immune 
anti-p2 GPI secondary to leprosy infection (aPA 9).
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Figure 71: Thrombin generation in normal plasma with added IgM from a normal healthy 
subject (N6)
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6.4 Discussion
I studied thrombin generation using the ETP and ETP+apc assays in 118 patients with a 
range o f  clinical conditions, and 30 normal healthy subjects. ETP and ETP+apc were 
higher in almost all patient groups than in normal healthy subjects, suggesting that an 
underlying prothrombotic state is present. It must be emphasised that increased 
throm bin generation as judged by ETP or ETP+apc was not a uniform finding with a 
great deal o f heterogeneity in patients. Low, normal and raised ETP and E T P+apc values 
were all observed. Furthermore, aPA status had no significant effect on the ETP value, 
which would imply that aPA does not increase thrombin generation p e r  se. However, 
ETP+Apc was significantly higher in aPA positive patients than in aPA negative patients, 
and this was most noticeable in patients with a history o f thrombosis.
The same could not be said o f  w om en with a history o f  pregnancy m orbidity. These 
women had significantly higher ETP and ETP+apc values than any other group o f 
patients, but the presence o f aPA did not significantly increase throm bin generation 
further. This suggested to me, that another mechanism  was responsible for the increased 
thrombin generation observed in these women, and this was investigated further in the 
next chapter.
The time to peak thrombin generation was slightly longer in aPA positive patients than 
in aPA negative patients or controls. However, there was a great deal o f  heterogeneity 
within the aPA positive group with some patients demonstrating accelerated thrombin 
generation, while others showed marked prolongation. It has previously been reported 
that aPA may accelerate and increase (Lean et al 2006; Liestol et al 2007; Rand et al 
1999) or delay and reduce (Hanly et al 2000; Sheng et al 2001a) in vitro  thrombin 
generation. However, these studies used small numbers o f highly selected patients. My 
data was obtained from a large number o f patients with a wide range o f clinical 
conditions, and these show that the throm bin generation phenotype in APS is much
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more heterogeneous than previously thought, with a wide spectrum o f thrombin 
generation levels and variable resistance to APC.
When I spiked plasma with IgG and IgM from patients with APS, the trend was towards 
decreased ETP and increased ETP+apc. As may have been expected, immunoglobulin 
fractions from moderate to strongly LA positive patients inhibited thrombin generation 
to the greatest degree. These fractions also appeared to delay the onset o f thrombin 
generation and increased the time taken to peak throm bin formation as previously 
reported (Regnault et al 2003). That these immunoglobulin fractions should be 
responsible for the most pronounced APC resistance was less expected. Furthermore, 
ETP and ETP+apc showed a significant negative correlation. In contrast to previous 
published reports, anti-p2 GPI was not prerequisite for APC resistance (Galli et al 1998) 
(Martinuzzo et al 1996; Mercier et al 1998; Viveros et al 2005), as not all fractions 
containing anti-p2 GPI produced APC resistance, and a fraction from a patient with no 
detectable anti-p2 GPI strongly inhibited APC. I concluded it was the ability o f 
antibodies with LA activity to prevent com plex formation o f phospholipid-binding 
proteins on negatively charged phospholipid rather than anti-p 2 GPI specificity p er se 
that was most likely responsible for acquired APC resistance in APS. This is consistent 
with the finding bivalent aPA enhance binding o f  prothrombin to negatively charged 
phospholipid and inhibit APC (Field et al. 2001; Field, Chesterman, & Hogg 2000)
In order to test this theory further, I used plasma and IgG from a patient homozygous 
for the non-binding form o f P2 GPI (Trp316Ser) who had a n t i^ G P I  and LA activity.
It has been suggested that phospholipid binding o f  P2 GPI to negatively charged 
phospholipids causes a conformational change and revealing a neoepitope (Kurosawa, 
Esmon, & Steams-Kurosawa 2000; Kuwana et al. 2005; Matsuura et al 1994; Subang 
et al. 2000). As Trp316Ser P2 GPI is non-binding, it has been proposed that individuals
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who are homozygous for the Trp316Ser mutation may be protected against the 
development o f a n t i^ G P I  antibodies (Horbach et al 1998b). However, anti-p2 GPI 
antibodies have been reported in this patient homozygous for the Trp316Ser mutation 
(Nash et al 2003).
This patient’s plasma and 50:50 mix in normal plasma gave very similar values for ETP 
and ETP+apc, suggesting that the patient’s anti-p 2 GPI antibodies had a negligible effect 
on normal P2 GPI. IgG from the patient produced only minor changes in ETP and 
gyp+APC wjien added to normal plasm a, again suggesting that the patient’s IgG was not 
interacting with the normal P2 GPI. In contrast, when IgG from a patient w ith potent aPA 
(anti-P2 GPI and LA activity) was added to the Trp316Ser plasma in the absence o f 
APC, thrombin generation was inhibited to a greater degree than observed in normal 
plasma. The reason for this is unclear, but it cannot be explained by enhanced binding 
o f a non-binding P2 GPI. As the patient had a high titre o f  anti-prothrombin antibodies, 
this would seem to be an obvious candidate, as anti-prothrombin antibodies have been 
shown to inhibit APC function in the presence o f  calcium (Field et al 2000; Galli et al 
2005). The addition o f normal P2 GPI to the Trp316Ser plasm a did not significantly 
affect ETP or ETP+apc.
It would appear that a n t i^ G P I  antibodies produced in this patient, homozygous for the 
Trp316Ser P2 GPI mutation, are incapable o f inhibiting APC even if  normal P2 GPI is 
added, but that exogenous aPA from a patient with normal P2 GPI may cause APC 
resistance in an apparently p 2 GPI-independent manner.
The same aPA positive IgG fraction caused an increase in ETP+apc in Trp316Ser 
plasma o f approximately 50%; roughly half that observed in normal plasma, thus 
demonstrating that while acquired APC resistance may be caused by anti-p 2 GPI - P2 GPI 
interactions, other mechanisms, independent o f P2 GPI are also present. These data seem
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to support the neoepitope theory (M atsuura et al 1994; Pengo, Biasiolo, & Fior 1995; 
Subang et al 2000), rather increased antigen density being responsible for binding o f 
aPA to P2 GPI on negatively charged surfaces (Sheng et al 1998).
Thrombin generation in the plasm a from the leprosy patient was very different to that o f 
pooled normal plasma spiked with IgM from the same patient. This patient’s IgM 
strongly inhibited APC activity when added to normal plasma. However, the patient had 
a severe acute phase response, resulting in raised ETP, and this masked the inhibitory 
effect o f the aPA on thrombin generation. Clearly, in these situations, the acute phase 
response may have more effect than aPA on throm bin generation. This, in my opinion, 
justified my decision to study patients only after the acute clinical phase had resolved, 
during this work.
In conclusion, I have demonstrated variable throm bin generation and response to APC 
in patients with APS. I have shown that APC resistance is closely associated with LA 
and, while this may be due in part to anti-fLGPI antibodies, P2 GPI independent 
mechanisms also exist. The prolongation o f  the time to peak thrombin generation by 
aPA is analogous to the increased clotting time observed in patients with LA. I have 
shown that LA activity is strongly associated with a resistance to APC and that, while 
LA may delay and reduce throm bin generation in the absence o f APC, in the presence 
o f APC an excess o f thrombin is formed. These data go some way to explaining the 
lupus anticoagulant paradox, and the strong association between LA and thrombosis 
(G allie ta l 2003b).
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Chapter 7. Acquired APC resistance, TFPI and adverse obstetric 
events
7.1. Introduction
Recurrent pregnancy loss, is a com m on problem , with two or more losses in up to 5% of 
women, and three or more losses affecting 1-2% o f women (Sarig et al. 2005). The 
association o f a circulating anticoagulant and pregnancy loss was first described by 
Nilsson et al (1975), who reported the presence o f  “antithrom boplastin” in a woman 
who had three interuterine deaths characterised by placental infarction. Markers o f 
coagulation activation (D-dimer and fibrinopeptide A) are known to increase preceding 
spontaneous abortion (Woodhams et al. 1989). There is a strong association with both 
aPA (Rai et al. 1995) and to a lesser extent congenital thrombophilia (Preston et al. 
1996). In women with recurrent m iscarriage due to aPA, the fetal loss rate may be as 
high as 90% (Rai et al 1995) with the m ajority o f  these occurring in the first trimester. 
The picture with heritable throm bophilia is not so clear, with highly variable 
associations depending upon the defect concerned (Robertson et al 2006)
In the previous chapter, I showed that while ETP or ETP+apc were raised in many 
women with a history o f pregnancy morbidity, aPA status appeared to have no 
significant effect. I decided to study an extended cohort o f women with a history o f 
pregnancy morbidity, to see if  this was a genuine finding rather than simple a type 2  
statistical error. As I dem onstrated in Chapter 5, TFPI is an important determinant o f 
ETP-based APC sensitivity based assays such as ETP+apc, so I also investigated TFPI 
antigen, activity and the frequency o f anti-TFPI antibodies in this group, to ascertain 
whether these factors could explain the increased thrombin generation and resistance to 
APC seen in these patients. I also investigated the effect o f heparin on plasm a TFPI 
levels and the relationship between TFPI, thrombin generation and resistance to APC.
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7.2 Methods
7.2.1 Patients and samples
I studied thrombin generation, plasm a TFPI antigen and activity and anti-TFPI 
antibodies in an extended group o f  52 women (including the 44 women from the 
previous chapter) with a history o f recurrent miscarriage (33), intrauterine fetal death 
(13), preeclampsia (3) or the HELLP syndrome (haemolysis with elevated liver 
enzymes and low platelets, 3). None had known heritable throm bophilia but twenty had 
persistent aPA and six had transient aPA positivity. All samples were taken at least six 
weeks after the end o f pregnancy.
Total TFPI antigen was assayed using the IM UBIND® Total Tissue Factor Pathway 
Inhibitor ELISA kit (American Diagnostica) and the TFPI sensitivity index used the 
method o f Dahm et al (2005) as described in the methods chapter.
7.3 Results
7.3.1 Thrombin generation and pregnancy morbidity
Both ETP and ETP+apc were significantly higher than in women with previous 
pregnancy morbidity than normal w om en (Table 32; Figure 72). Raised ETP and 
ETP+apc values were obtained in 27/52 (52%) and 41/52 (79%) o f women respectively. 
Only 8/52 (15%) had normal throm bin generation by both methods. However, as with 
the smaller series studied in the previous chapter, the antiphospholipid status o f the 
women had no significant effect on ETP or ETP+apc. W hen the data from with 
pregnancy loss were analysed by time o f  loss, again there was no significant effect on 
ETP or ETP+apc (Table 32; Figure 73).
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Table 32: Thrombin generation and TFPI m easurem ents in wom en with a history of pregnancy 
morbidity: Median (interquartile range)___________________________________________________
P a tien t  g r o u p ETP ETP+apc
TFPI Ag  
(ng/m l) TFPI In dex
F em a le  reference  range (n =20) 0 . 7 6 - 1 . 0 7 0 . 7 7 - 1 . 0 6 7 5 - 1 2 0 0 . 9 6 - 1 . 0 1
aP A  posit ive aPA (n = 20)
1 .14
( 0 . 7 8 - 1 . 4 7 )
1 .59
( 1 . 0 3 - 2 . 0 6 )
72
( 4 6 - 1 0 2 )
0 .9 6  
(0.91 - 1 . 0 7 )
Transient a P A  positive (n = 6)
0 .9 4  
(0 .8 6  -  0 .98 )
1 .09  
(0 .9 9  - 1 . 2 3 )
7 4  
(54 - 9 8 )
0 .9 6  
(0 .9 3  -  0 .97 )
aP A  negative  (n = 26)
1 .10
( 0 . 9 4 - 1 . 2 2 )
1.46  
(1 .21 - 1 . 8 1 )
83
( 7 3 - 1 0 3 )
0 .9 6  
(0 .9 2  -  0 .97 )
Recurrent miscarriage (n = 33)
1 .10
( 0 . 8 3 - 1 . 6 6 )
1 .56  
(0 .8 2  -  2 .66)
85
( 3 7 - 1 1 8 )
0 .9 6
( 0 . 8 9 - 1 . 0 6 )
IUFD (n = 13)
1.21
( 0 . 6 5 - 1 . 3 3 )
1 .43  
(1 .0 0  -  1 .94)
69
( 3 5 - 1 0 4 )
0 .9 6  
(0 .9 4  - 1 .0 2 )
P reeclam psia  (n = 3) 0 .9 3 1.49 74 0 .9 4
HELLP (n = 3) 1.01 1 .38 105 0 .9 4
4.00
p < 0.0001
3.50
3.00
2.50 p = 0.003
CLI- 2.00 oo
I— 
LU 1.50 O Ooo
oo1.00
0.50
0.00
Normal aPA aPA Transient Normal aPA aPA Transient
control neg pos aPA neg pos aPA
Figure 72: The effect of aPA status on thrombin generation in women with pregnancy morbidity
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Figure 73: The effect of time of adverse pregnancy event on thrombin generation
7.3.2 TFPI antigen in pregnancy morbidity
A range o f 75 -  120 ng/ml was established for TFPI antigen in 23 normal healthy 
women, o f whom none were receiving anticoagulation or oral contraceptives. I was able 
to study TFPI antigen in 28 o f  the women with previous pregnancy morbidity. No 
significant differences were detected in association with aPA status (Figure 74) and 
time o f pregnancy morbidity (Figure 75). However, the numbers o f  aPA positive and 
late pregnancy morbidity were relatively small and the precludes any firm conclusions 
about lack o f association. Nevertheless, 12/28 (43%) o f women with previous 
pregnancy morbidity had low TFPI antigen, and the median TFPI antigen was 
significantly lower in these women than in normals (78 ng/mL vs. 96 ng/mL 
respectively; P = 0.002).
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Figure 74: The effect of aPA status on TFPI antigen levels
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Figure 75: The effect of time of pregnancy morbidity on TFPI antigen levels
7.3.3 TFPI activity in pregnancy loss
TFPI sensitivity index, which is a measure o f  functional activity, was measured in 20 
normal healthy women, giving a 95% confidence range o f  0.962 -  1.011 (median 
0.987). I studied in 33 o f  the women with previous pregnancy morbidity; recurrent 
miscarriage (30), intrauterine death (12), preeclampsia (3) and HELLP (3). The median 
TFPI sensitivity index was significantly lower in previous pregnancy morbidity than in 
the control group (0.958 v 0.987; p = 0.007) with low values in 20/33 (61%) women. 
aPA status (Figure 76) and time o f morbidity (Figure 77) had no significant effect. As
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with a previous study (Dahm et al 2005), the correlation between TFPI activity and 
antigen levels was poor.
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Figure 76: The effect o f aPA status on TFPI activity
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Figure 77: The effect o f time of pregnancy m orbidity on TFPI activity
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A significant inverse correlation was observed between TFPI sensitivity index and
i a n p
ETP (Figure 78, but there was no correlation between TFPI sensitivity index and 
ETP (Figure 79).
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Figure 78: The effect of TFPI index on thrombin generation in the presence of APC
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Figure 79: The effect of TFPI index on thrombin generation without APC
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7.3.3 The prevalence of anti-TFPI antibodies
I investigated the presence o f  anti-TFPI antibodies in 48 women with previous 
pregnancy morbidity and twelve patients with a history o f thrombosis and potent aPA. 
Normality was defined by the 99th percentile o f 24 normal healthy women. Six women 
with previous pregnancy morbidity and two APS thrombosis patients had low titre IgG 
anti-TFPI (Figure 80). No IgM anti-TFPI antibodies were detected (Figure 81). Three of 
the women with anti-TFPI were aPA positive and three were aPA negative. All had high 
E T P +apc (median 1.57; range 1.10 -  2.41), while four had raised ETP (median 1.34; 
range 1.23 -  1.41). Low TFPI activity or antigen was found in 4/6women.
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Figure 80: IgG anti-TFPI antibodies in pregnancy morbidity and thrombosis. 
The broken line indicates the 99th percentile of normal
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Figure 81: IgM anti-TFPI antibodies in pregnancy morbidity and thrombosis 
The broken line indicates the 99th percentile of normal
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7.3.4 The effect of low molecular weight heparin in a high risk pregnancy
A 32-year-old woman (not previously studied) with a family history o f  VTE and 
homozygous for factor V Leiden, was seen in our miscarriage clinic in the 11th week o f 
pregnancy. All tests for aPA were negative, protein C and antithrombin were within 
normal limits, free protein S was borderline (0.55 IU/ml, normal 0.55 -1.30 IU/ml) and 
TFPI antigen was low (57.1 ng/ml). At this time she was not receiving anticoagulants, 
so in accordance with local practice for high-risk pregnancies, daily LMW H (5000 iu 
Dalteparin) and aspirin were commenced. Anti-Xa levels, TFPI antigen, ETP and 
ETP+apc were studied serially in an effort to elucidate the relationship between these 
parameters. She was unusually resistant to LMW H treatment and two dose escalations 
(7500 then 10000 iu daily) were required to achieve the desired anti-Xa level (Figure 
82). The 10000 iu dose achieved an anti-Xa level o f  0.44 and brought the ETP value to 
within the normal range (0.67-1.19) (Figures 83 and 84). The ETP+APC, although 
reduced was still above normal (<1.14) due to the homozygous factor V Leiden 
mutation. TFPI antigen rose from 57 ng/ml at 11 weeks to 115 ng/ml at 22 weeks, with 
concomitant decreases in ETP+Apc from 2.76 to 1.80 and ETP from 1.29 to 1.00.
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Figure 82 Anti-Xa, TFPI and thrombin generation values in a single high-risk pregnancy.
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Figure 83 Thrombin generation in a factor V Leiden patient, pre-treatment
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Figure 84 Thrombin generation in a factor V Leiden patient, showing partial normalisation with 
0.44IU/ml LMWH
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7.4 Discussion
Markers o f  coagulation activation (D-dimer and fibrinopeptide A) are known to increase 
preceding spontaneous abortion (W oodhams et al 1989), but little is known about in 
vitro throm bin generation in wom en with pregnancy morbidity. In chapter 6  I showed 
that women with previous pregnancy morbidity had higher ETP and ETP+apc than other 
patient groups and that this was independent o f  aPA status. In order to study this further, 
I studied an extended group o f  52 w om en with previous pregnancy m orbidity and found 
increased thrombin generation by ETP and/or ETP+apc in 85% o f these women. While 
the prothrombin gene and factor V Leiden mutations may be associated with pregnancy 
loss (Martinelli et al. 2000; Robertson et al 2006), none o f  the women in this group 
carried the factor V Leiden m utation and, while prothrombin gene analysis was not 
performed on most o f these women, my data from chapter 4 suggested that increased 
plasma prothrombin alone was unlikely to cause the degree o f increase in ETP and 
ETP+apc values observed in this group.
The in vitro anti-TFPI spiking experiments, suggested that reduced plasm a TFPI could 
be responsible and, as it has been reported that the APC resistant phenotype observed 
during hormone replacement therapy is associated with a decrease in both TFPI and 
protein S levels (Hoibraaten et al. 2001a), I decided to measure TFPI antigen and TFPI 
activity in the women with previous pregnancy m orbidity to test this hypothesis. I found 
low TFPI antigen in 59% and low TFPI activity levels in 61% o f the women tested. 
Furthermore, significant negative correlations were observed between ETP+apc and both 
TFPI activity and TFPI antigen, although no significant relationship between ETP and 
TFPI was observed.
LMWH has been the mainstay o f antithrombotic therapy in women with aPA or 
hereditary throm bophilia for many years and, although it has is reported to be “the 
superior choice”, on the grounds o f safety and effectiveness, in improving pregnancy
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outcome (Robertson, Wu, & Greer 2004), the use o f LM W H in this setting is still highly 
controversial (W alker et al. 2005). It has been shown that in a purified system, TFPI and 
APC act synergistically in the regulation o f throm bin generation, and that reduced levels 
o f TFPI exacerbated the APC resistance produced by the factor V Leiden m utation (van 
't Veer et al 1997a). However, this work was performed in the presence o f saturating 
concentrations o f phospholipid, and the absence o f protein S. As protein S is now 
known to be a cofactor for TFPI in the inactivation o f factor Xa (Hackeng et al 2006), 
and saturating levels o f phospholipid are seldom seen in vivo, I was unsure if  these 
mechanisms would apply to patient plasm a in the presence o f limited quantities o f 
phospholipid.
My data show how combined throm bophilic defects (homozygous FVL, low TFPI and 
protein S) act synergistically to produce almost complete resistance to APC, as 
demonstrated by increased in vitro throm bin generation. The adm inistration o f 
subcutaneous LMWH produced the following effects:
• An increase in plasm a TFPI
• A 25% reduction in ETP to the same level as that o f  pooled normal plasma.
• A 36% decrease in ETP+apc
This is in keeping with my findings in chapter 4, in which I dem onstrated that the 
addition o f increasing am ounts o f a polyclonal antibody, that blocked TFPI function, 
caused a dose dependent increase in ETP+apc o f up to 50% and but only a modest 
increase in ETP (<10%). Furthermore, I have demonstrated a negative association 
between plasma TFPI concentration and APC resistance in a range o f patients. I have 
also demonstrated that the restoration o f TFPI levels by treatment with LMWH, 
overcomes APC resistance. These data strongly suggest that deficiency o f  TFPI 
produces an APC resistant phenotype, most probably due a failure o f TFPI to limit the
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initial rate o f  throm bin production through FXa and hence FVa and FVIIIa production. 
Unfortunately, due to plasm a sample volume constraints, it was not possible to 
determine the relative im portance o f TFPI and the anti-Xa/antithrombin effects o f 
LMWH.
It has previously reported that the majority o f known thrombophilic defects in women 
with pregnancy loss are in the protein C pathway. In one study, resistance to APC was 
been demonstrated in 70% o f  all women with recurrent pregnancy loss using the Pro-C 
Global test (Dade-Behring), 52% without a known thrombophilic risk factor (Sarig et al 
2002). However, the antiphospholipid status o f  these patients was not investigated in 
this study and, as discussed in chapter 3, I have shown this test to be susceptible to 
interference by lupus anticoagulant (Gardiner et al. 2002).
The relationship between APC resistance and pregnancy morbidity is disputed. This 
may be in part because the ETP based assay and the two types o f APTT-based APC 
sensitivity tests (with and w ithout predilution in factor V deficient plasma) have 
different determinants (de V isser et al 2005). M any cases o f unexplained pregnancy 
loss occur in the absence o f  aPA or known thrombophilic defects, but is known that 
many pregnant women develop a physiological resistance to APC during pregnancy 
(Cumming et al. 1995) and that acquired APC resistance (measured by the APTT based 
method), independent o f  the factor V Leiden mutation (FVL), is a risk factor for 
pregnancy loss (Rai et al. 2001; Robertson et al 2006), preeclampsia (Paternoster et al. 
2002) and low birth w eight (Clark et al. 2001).
Mercier et al (1998) reported that a n t i^ G P I  from women suffering recurrent
miscarriages caused APC resistance. It has also been reported that anti-p 2 GPI interfere
with the phospholipid-dependent inhibition o f TF-induced coagulation by TFPI
(Salemink et al. 2000). However, although six o f the TFPI deficient women in my study
had anti-p 2 GPI, the majority did not. Anti-TFPI antibodies have also been reported in
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women with aPA and recurrent miscarriage (Martinuzzo et al. 2005), but I found anti- 
TFPI in only 6/48 women studied with previous pregnancy loss. I concluded that, in the 
majority o f  cases, there is little evidence for an antibody dependent mechanism for TFPI 
deficiency in women with previous pregnancy morbidity.
It is clear that many haem ostatic mechanisms may contribute towards recurrent 
pregnancy loss and preeclampsia. M any o f  these may be antibody mediated: aPA 
binding to normal term placenta (Donohoe, Kingdom, & Mackie 1999); antibodies to 
annexin V (Gris et al. 2000; Rand et al 1997); antibodies to EPCR (Hurtado et al 
2004); and antibodies directed against factor XII (Jones et al 2001). In addition to APC 
resistance, other antibody-independent haemostatic defects have been implicated in 
pregnancy morbidity (Preston et al 1996): hyperfibrinolysis and low factor XII (Gris et 
al. 1997), increased factor VIII:c levels (Dossenbach-Glaninger et al. 2004; M arietta et 
al. 2003) although this had been disputed (M iddeldorp et al. 2004); the prothrombin 
gene and factor V Leiden mutations (M artinelli et al 2000); reduced placental TFPI 
(Aharon et al. 2005; Sarig et al 2005); and protein S deficiency(Sarig et al 2002)
Treatment o f pregnant women who have aPA and recurrent pregnancy loss with 
unfractionated heparin and aspirin (Rai et al 1997) aspirin (Farquharson et al 2002) 
and/or low molecular weight heparin is reported to improve the live birth rate (Backos 
et al 1999; Brenner et al 2005; Gris et al. 2004) although the precise mechanisms for 
the protective effect o f heparin in this setting are unclear. Although it was often 
assumed that it was the anticoagulant effect o f LMWH that afforded this protection, 
significant activation o f the coagulation system still occurs during LM W H treatment 
(Hoke et al. 2004)and several other mechanisms have been proposed. Heparin has been 
shown to attenuate placental apoptosis (Bose et al. 2005), prevent complement 
activation on decidual cells (Girardi, Redecha, & Salmon 2004) and prevent binding o f 
aPA (McIntyre et al. 1993).
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Treatment o f recurrent pregnancy loss associated with other thrombophilic defects is a 
hotly debated topic, which is unlikely to be resolved until further randomised controlled 
trials are performed (W alker et al 2005). Despite this treatment with low molecular 
weight heparin has been used in the treatment o f recurrent pregnancy loss associated 
with thrombophilia for several years. It is known that placental TFPI, which may be 
decreased in gestational vascular complications, can be restored by maternal LMW H 
treatment (Aharon et al 2005; Sarig et al 2005).
My data suggest that TFPI deficiency associated with ETP dependent APC resistance 
could be a risk factor for pregnancy loss, and imply a potential role for heparin in the 
treatment o f this condition.
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Chapter 8. Discussion
There is a great deal o f  heterogeneity in the specificity, concentration and avidity o f 
aPA and not all o f  the target antigens are represented by the antibodies detected by the 
typical clinical laboratory. Furthermore, there is poor standardisation o f assays for aPA 
and a lack o f agreement over their pathological mechanisms. It was against this 
background o f that I hypothesised that a global measurement o f the coagulation and 
protein C anticoagulant pathways might be more informative than the traditional 
immunological markers. In this thesis I have studied the phenomenon o f acquired 
resistance to protein C and its association with the antiphospholipid syndrome.
In chapter 3 I showed that plasm a from some patients with APS interfere with the 
protein C pathway and that this may m anifest as APC resistance in the absence o f the 
factor V Leiden mutation. These prelim inary results suggested that the antibodies which 
caused LA activity, and those that interfered with the protein C pathway, were not 
always found in the same patients, and that their detection was highly dependent upon 
the reagents/method used.
In the fourth chapter I described how I developed method for measuring the 
anticoagulant response to APC, w hich was more sensitive to aPA, so that I could 
investigate my initial findings further. I confirmed the importance o f  zwitterionic 
phospholipids for APC function. Using this method, I found resistance to APC in the 
majority o f the patients w ith APS studied and I also showed that this occurred in an 
antibody dependent manner. The data also suggested that while most patients with anti- 
P2 GPI demonstrated resistance to APC as previously reported (Martinuzzo et al 1996), 
the converse was not true, in that most patients with APC resistance did not have anti- 
P2 GPI.
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In chapter 5, I described the development and characterisation o f a throm bin generation 
based method to measure sensitivity to APC. The preliminary data suggested that in the 
majority o f  patients with aPA, thrombin generation was abnormal, with a variable 
anticoagulant response to APC. In demonstrating a delay in thrombin generation 
coupled with a failure o f  APC to inhibit thrombin generation, I have established a 
potential mode o f  action for lupus anticoagulants, which could explain both the 
observed prolonged in vitro clotting time and the paradoxical increase in markers o f  in 
vivo thrombin generation and throm botic risk.
I developed these ideas further in Chapter 6 . Using automated thrombin generation to 
study a much larger cohort o f  patients, I found that the thrombin generation and 
sensitivity to APC were highly heterogeneous. While aPA status had no significant 
effect o f ETP (in the absence o f  APC), ETP+apc was significantly higher in aPA patients 
with thrombosis than in aPA negative thrombosis patients. However, women with 
previous pregnancy m orbidity significantly higher ETP and ETP+apc values than any 
other group o f patients studied, and this was independent o f aPA status. I demonstrated 
that a failure o f APC to effectively downregulate thrombin generation is associated with 
LA and, while this may be due in part to anti-p 2 GPI antibodies, P2 GPI independent 
mechanisms also exist.
In chapter 7, I went on to study the excess thrombin generation in a larger group o f 
women with a history o f pregnancy morbidity. Increased thrombin generation with and 
without APC were found in the majority o f women with a history o f pregnancy 
morbidity and approxim ately half o f  the women with previous pregnancy morbidity had 
low TFPI antigen and/or low TFPI activity. Low titre anti-TFPI antibodies were found 
in only a few o f these women and aPA status had no significant effect on throm bin 
generation, or TFPI levels. These findings occurred in the non-pregnant state, indicating 
an underlying prothrombotic condition. I demonstrated in one woman that treatment
182
with LMW H restored TFPI antigen levels to normal with a concomitant decrease in 
ETP+apc. My data suggested that TFPI deficiency associated with ETP dependent APC 
resistance could be a risk factor for pregnancy loss, and implied a potential role for 
heparin in the treatment o f  this condition.
In developing the methods used in this thesis, I have been mindful o f the necessity o f 
achieving the correct balance in term s o f  sensitivity to the different coagulant and 
anticoagulant pathways. At very low tissue factor concentrations, throm bin generation 
is exquisitely sensitive to TFPI and procoagulant pathways, but less sensitive changes in 
the protein C pathway (Baglin 2005). I wanted to assess the response to APC while 
retaining sensitivity to TFPI and factor VIIIc levels. This will always be a compromise 
and I am fully aware no single throm bin generation method will be suitable for studying 
all bleeding and thrombotic conditions. The method that I have used, does not take into 
account the important roles that platelets and fibrinogen/fibrin play in thrombin 
generation (Baglin 2005) and I realise that this is a serious limitation o f  this work. 
However, I believe that I have achieved an acceptable compromise through which I 
have been able to simultaneously assess TFPI, the response to APC, and prothrombotic 
conditions such as the acute phase response.
8.1 Can activated protein C resistance be used to diagnose 
antiphospholipid syndrome
I have demonstrated APC resistance by different methods in a significant proportion o f 
patients with APS. However, the APC resistance phenotype is far from specific for the 
presence o f aPA, with factor VIII, protein S, prothrombin and TFPI all acting as 
confounding variables. A lthough this study was not sufficiently powered to test for an 
association between APC resistance and the severity o f disease, many o f  the patients 
with the most severe forms o f APS had very high ETP+apc values. This work was
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performed on retrospective cohorts, rather than in a prospective fashion on consecutive 
patients and this is a limitation o f  this study.
However, I have found significant associations between increased thrombin 
generation/APC resistance and the presence o f aPA in patients with thrombosis. I 
believe that prospective studies are now warranted to determine whether APC resistance 
could be clinically useful in the diagnosis and management o f APS.
8.2 Can interference in the protein C pathway explain the thrombogenicity 
of antiphospholipid antibodies
Since the inception o f this work there have been some significant advances in our 
knowledge o f the protein C system. At that time, the prevailing view  was that only 
P2 GP-I dependent antibodies were responsible for aPA associated APC resistance (Galli 
et al 1998; Martinuzzo et al 1996; M ercier et al 1998; Viveros et al 2005). M uch o f 
this work was based on differentiation o f  anti-prothrombin from P2 GPI dependent 
antibodies by means o f the KCT and dRVVT tests. However, this was based on the 
ability o f cardiolipin vesicles to adsorb aPA, rather than a genuine dem onstration o f  anti 
prothrombin and or a n t i^ G P I  activity and the conclusions were drawn from results 
from relatively few patients. These data were extrapolated to support the claim that only 
P2GPI dependent aPA were responsible for the inhibition o f APC (Galli et al 1998), a 
view that this group now concede was incorrect (Galli et al 2005). Other publications 
relied on the use o f monoclonal antibodies (Hwang et al 2001; Hwang et al 2003) 
which do not necessarily act as one would expect in biological systems.
I have demonstrated in several systems that aPA associated resistance to APC may be 
antibody mediated. Furthermore I have shown that this may occur through both P2 GPI 
dependent and P2 GPI independent mechanisms. However, not all o f the 
immunoglobulin fractions that I purified from aPA patients caused resistance to APC
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when added to normal plasma. It is likely that aPA dependent resistance to APC is only 
one o f the many thrombogenic mechanisms present in APS.
I have confirmed the presence o f  antibodies to TFPI in a small number o f patients and 
although I cannot discount an autoimmune mechanism for TFPI deficiency, it is 
unlikely that this alone can explain the high incidence o f APC resistance and increased 
throm bin generation that I have described in women with a history o f  pregnancy 
morbidity. It is clear that the causes o f  acquired APC resistance are complex. The APC 
resistant phenotype observed during hormone replacement therapy is associated with a 
decrease in both TFPI and protein S levels (Hoibraaten et al. 2001b). Furthermore, it has 
recently been reported that protein S may act as a cofactor for the TFPI dependent 
inactivation o f factor Xa (Hackeng et al 2006), and it was not until then that I fully 
understood the complex relationship between TFPI and the protein C system. This 
supports the “threshold limited” hypothesis o f throm bin generation (v a n 't  Veer et al 
1997b), in which TFPI limits the rate o f  factor V activation, thus allowing the regulation 
o f prothrombinase activity by APC. W hen TFPI concentration is low, the rapid rate o f 
FVa formation swamps APC, whereas when TFPI levels are sufficiently high, even the 
limited proteolysis o f activated factor V Leiden by APC has an appreciable effect on 
thrombin generation. I have demonstrated, albeit in one patient, that LM W H can 
partially attenuate the factor V Leiden phenotype through increasing TFPI levels. I 
believe that this may explain the reported efficacy o f LMWH treatment in patients with 
the factor V Leiden mutation in high-risk situations.
8.3 Future directions
It has been known for some time that platelet microparticles have procoagulant activity 
(Berckmans et al. 2001; N ieuwland et al. 1997; Tans et al. 1991) and may produce an 
APC resistant phenotype (Taube et al 1999). Microparticle shedding from the placenta 
into the maternal circulation has also been implicated in the pathology o f preeclampsia
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(Goswami et al. 2006), and this in association with APC resistance combined has been 
suggested as a possible mechanism for coagulation activation in this disease (VanW ijk 
et al. 2002). Recently, an association between circulating platelet-derived 
microparticles, thrombin generation and a procoagulant state has been reported in 
systemic lupus erythematosus (Pereira et al. 2006).
Against this background, it is not surprising that microparticles have been implicated in 
the antiphospholipid syndrome (Ambrozic et al. 2005; Dignat-George et al. 2004; Morel 
et al. 2005). While I was not wholly unaware o f this during the course o f  my work, the 
technology to measure, identify, purify and remove microparticles was not easily 
obtainable. With hindsight, I would liked to have studied the role o f microparticles from 
various cell types on the pathology o f  APS, their role in throm bin generation and 
resistance to APC resistance and I hope to study these areas in the near future.
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